Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# DANISH BIO – DANSK BIOTEK

Bioteknologi anvendt inden for lægemiddeludvikling og industriel bioteknologi

## Sitemaps

- [XML Sitemap](http://danskbiotek.dk/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Denmark’s most comprehensive biotech salary survey](http://danskbiotek.dk/news/denmarks-most-comprehensive-biotech-salary-survey/) - Make better pay decisions with industry salary insights: Denmark’s most comprehensive biotech salary survey. The Danish Biotech Salary Survey gives you hard-to-find data on key roles across the biotech industry. At a glance: A salary survey developed specifically for the biotech industry A tailor-made job catalogue covering both management and specialist roles within: Research Clinical
- [Cessatech announces positive top-line results from  its final CT001 Study 0202](http://danskbiotek.dk/news/cessatech-announces-positive-top-line-results-from-its-final-ct001-study-0202/) - 28 May 2025 – 17.15 Cessatech announces positive top-line results from its final CT001 Study 0202 The primary endpoint of responder analysis, of pain relief (pain score ≤4/10), was met and reported by 54% of patients after 15 minutes and by 88% after 30 minutes. Overall pain reduction was 75% after 30 minutes, and 86%
- [Minutes of AGM 2025](http://danskbiotek.dk/news/minutes-of-agm-2025/) - Please find here the minutes of our AGM 2025. DANISH BIO - DANSK BIOTEK - Minutes of annual general meeting - 27 May 2025
- [Biotech Salary Survey](http://danskbiotek.dk/news/biotech-salary-survey/) - Get exclusive insights into Biotech pay: The most complete salary survey in Denmark. The Danish Biotech Salary Survey gives you hard-to-find data on all the most important biotech specific jobs. Danish Biotech Salary Survey in short: A salary survey specifically developed for the conditions in the biotech industry Tailor-made job catalogue for management and specialist
- [New CEO at LINK Medical](http://danskbiotek.dk/news/new-ceo-at-link-medical/) - Oslo Norway, January 24, 2025. The LINK Medical Board is pleased to announce the appointment of Anders Göransson as the new CEO of LINK Medical. Anders has over 20 years of diverse experience in the life science industry, he has established an impressive track record of success. Anders has held prominent positions at leading biotech
- [Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer](http://danskbiotek.dk/news/scandion-oncology-announces-final-data-from-the-corist-trial-and-is-ready-to-move-into-a-randomized-phase-ii-proof-of-concept-trial-in-colorectal-cancer/) - Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II trial heavily pretreated patients with advanced colorectal cancer were treated with different doses of FOLFIRI (folinic acid, 5-FU and Irinotecan) in combination with different
- [ExpreS2ion to Present in Upcoming Investor and Scientific Events](http://danskbiotek.dk/news/expres2ion-to-present-in-upcoming-investor-and-scientific-events/) - ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming events: PepTalk – the Annual Protein Science and Production Week in San Diego, USA, and an Institutional Investor Seminar hosted by HC Andersen Capital in Copenhagen, Denmark. These events represent important opportunities to showcase ExpreS2ion’s innovative
- [Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th](http://danskbiotek.dk/news/zealand-pharma-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-january-13th/) - Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th Copenhagen, Denmark, January 6, 2025 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will present an overview of the company at the 43rd Annual J.P.
- [Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline](http://danskbiotek.dk/news/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/) - Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept Copenhagen, Denmark – November 25th,
- [Lasse Nørregaard as new board observer in DANISH BIO-DANSK BIOTEK](http://danskbiotek.dk/news/lasse-norregaard-as-new-board-observer-in-danish-bio-dansk-biotek/) - We are very excited to announce that Lasse Nørregaard has joined DANISH BIO’s board as an observer! Lasse has in just a few years created an impressive track record in the early-stage life science space, and has across six different start-ups successfully been part of raising over €35 million in several fundraising rounds. Beyond
- [LOPHORA RECEIVES APPROVAL FROM EMA TO INITIATE PHASE I CLINICAL TRIAL FOR LPH-5, A PROMISING TREATMENT FOR DEPRESSION](http://danskbiotek.dk/news/lophora-receives-approval-from-ema-to-initiate-phase-i-clinical-trial-for-lph-5-a-promising-treatment-for-depression/) - Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA therapeutics to treat psychiatric disorders, is thrilled to announce that it has received approval from the European Medicines Agency (EMA) to commence a Phase I, first-in-man, randomized, placebocontrolled, single-dose escalation study for LPH-5. This study will investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic
- [TECHBBQ - get a discount of 25%](http://danskbiotek.dk/news/techbbq-get-a-discount-of-25/) - We're partnering with TECHBBQ for a disount of 25%. TECHBBQ takes place in Copenhagen on 11-12 September 2024. Read more here: About TechBBQ2024 - TechBBQ You can get the discount code by emailing ps@danskbiotek.dk
- [NLSDays 2024 - 15% discount](http://danskbiotek.dk/news/nlsdays-2024-15-discount/) - We are partnering with NLSDays 2024 for a good discount on the registration fees! NLSDays 2024 is in Malmö, Sweden, on 18-19 September. Read more here: Registration Info - NLSDays - NLSDays You can get the dicount code by emailing ps@danskbiotek.dk.
- [World Drug Safety Congress Europe 2024 - discount of 50%](http://danskbiotek.dk/news/world-drug-safety-congress-europe-2024-discount-of-50/) - It is a great pleasure to announce another partnership: World Drug Safety Congress Europe 2024, 9-10 October 2024, Amsterdam, The Netherlands: World Drug Safety Congress Europe 2024 | Amsterdam (terrapinn.com) The discount rate is 50%, and you can get the code by emailing ps@danskbiotek.dk
- [BioEurope - get a 10% discount on registration fees!](http://danskbiotek.dk/news/bioeurope-get-a-10-discount-on-registration-fees/) - We're delighted to share that we have partnered with BioEurope which will take place in Stockholm, Sweden, on 4-6 November 2024. Members of Danish Bio-Dansk Biotek will get a 10% discount on registration fees by use of a code that you will receive by contacting ps@danskbiotek.dk. Please see the following goodies for the early birds:
- [Get a 15% discount for the LSX Nordic Congress 2024!](http://danskbiotek.dk/news/get-a-15-discount-for-the-lsx-nordic-congress-2024/) - Here we go again! Another great offer for you. DANISH BIO-DANSK BIOTEK has partnered with LSX Nordic Congress 2024 to get you a great discount when registering for the congress. Please ask for your discount code by emailing ps@danskbiotek.dk.
- [Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.](http://danskbiotek.dk/news/cessatech-announces-superior-simulated-pain-efficacy-in-children-favouring-its-lead-candidate-ct001-relative-to-its-active-comparators/) - The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively. Estimates for the opioid sparing effect of ketamine showed a need for more than double the sufentanil exposure to get the same overall effect seen with the treatment of CT001. The
- [Nykode Therapeutics ASA: Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy](http://danskbiotek.dk/news/nykode-therapeutics-asa-nykode-therapeutics-announces-mrna-lnp-cancer-vaccine-demonstrates-superior-efficacy/) - Oslo, Norway, June 11, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle
- [NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients](http://danskbiotek.dk/news/nmd-pharma-initiates-phase-2b-trial-of-nmd670-in-generalized-myasthenia-gravis-patients/) - Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces today that it has dosed the first generalized myasthenia gravis (gMG) patient in a Phase 2b clinical trial of NMD670, after receiving FDA IND clearance in March 2024
- [LOPHORA SUBMITS CLINICAL TRIAL AUTHORISATION (CTA) APPLICATION TO THE FRENCH MEDICINES AGENCY (ANSM) FOR LEAD CNS DRUG LPH-5.](http://danskbiotek.dk/news/lophora-submits-clinical-trial-authorisation-cta-application-to-the-french-medicines-agency-ansm-for-lead-cns-drug-lph-5/) - Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders, announced today that it has submitted a Clinical Trial Application (CTA) for its lead drug program LPH-5. The CTA is directed towards a Phase I first-in-human study to assess the safety, tolerability, pharmacokinetics and potential
- [NLSDays Nordic Star Pitch Competition is NOW OPEN for applications](http://danskbiotek.dk/news/nlsdays-nordic-star-pitch-competition-is-now-open-for-applications/) - As Dansk Biotek has been a supporter for NLSDays 2024 in Malmö, I’m happily sharing with you that the application for NLSDays Nordic Star Pitch Competition is NOW OPEN. Through Nordic Star Pitch Competition 2024, Dansk Biotek’s community members can showcase their ground-breaking ideas, impress a jury of pharmaceutical giants and savvy investors during NLSDays.
- [Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer](http://danskbiotek.dk/news/nykode-therapeutics-announces-clinical-collaboration-with-msd-to-evaluate-vb10-16-in-combination-with-keytruda-pembrolizumab-in-patients-with-hpv16-positive-high-risk-locally-advanced-cervical/) - Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial
- [Scandion confirms positive final Phase Ib data from  PANTAX trial with SCO-101](http://danskbiotek.dk/news/scandion-confirms-positive-final-phase-ib-data-from-pantax-trial-with-sco-101/) - Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX phase Ib trial confirming the good safety profile of SCO-101 and showing good signs of efficacy in hard-to-treat pancreatic cancer. The open-label PANTAX phase Ib international multi-center trial
- [Data from the first human study demonstrate excellent  performance of Zerion Pharma’s Dispersome® technology](http://danskbiotek.dk/news/data-from-the-first-human-study-demonstrate-excellent-performance-of-zerion-pharmas-dispersome-technology/) - May 13, 2024 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces positive results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a pharmaceutical used to treat cystic fibrosis. The study was conducted by ZERION’s Spanish partner Insud Pharma, a global leader in generic and branded pharmaceuticals. The clinical study
- [BioFIT and MedFIT - 3-4 December 2024 - discount rate of 20%](http://danskbiotek.dk/news/biofit-and-medfit-3-4-december-2024-discount-rate-of-20/) - We are happy to tell you that we have entered cooperation with BioFIT and MedFIT for the 2024 conference which is held in Lille, France. As a member of DANISH BIO-DANSK BIOTEK, you will obtain a discount of 20% on the regular rates. All you need to do is apply a discount code which you
- [Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer](http://danskbiotek.dk/news/allarity-therapeutics-stenoparib-shows-clear-clinical-benefit-and-achieves-significant-milestone-with-early-conclusion-of-phase-2-trial-in-advanced-ovarian-cancer/) - Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been
- [What is the right pay for biotech jobs?](http://danskbiotek.dk/news/what-is-the-right-pay-for-biotech-jobs/) - Participate now in The Danish Biotech Salary Survey 2024 to find out. The Danish Biotech Salary Survey gives you hard-to-find data on all the most important biotech specific jobs. Danish Biotech Salary Survey in short: A salary survey specifically developed for the conditions in the biotech industry Tailor-made job catalogue for management and specialist roles
- [Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer](http://danskbiotek.dk/news/nykode-therapeutics-initiates-phase-2-trial-of-vb10-16-in-second-line-hpv16-positive-cervical-cancer/) - Oslo, Norway, April 19, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s
- [Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol As A Treatment For Niemann-Pick Disease Type C At The SIMD 45th Annual Meeting](http://danskbiotek.dk/news/zevra-therapeutics-presents-new-data-on-the-long-term-safety-and-efficacy-of-arimoclomol-as-a-treatment-for-niemann-pick-disease-type-c-at-the-simd-45th-annual-meeting/) - ELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that new long-term real-world data from the arimoclomol expanded access program (EAP: NCT04316637) for the treatment of Niemann-Pick disease type C (NPC) was featured in an oral presentation during the Society for Inherited Metabolic Disorders (SIMD) 45th Annual Meeting
- [Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)](http://danskbiotek.dk/news/allarity-therapeutics-receives-nasdaq-approved-extension-to-regain-compliance-with-nasdaq-listing-rule-5550b1/) - Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1). On February 1, 2024, Allarity Therapeutics presented a strategic plan to the
- [Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss](http://danskbiotek.dk/news/gubra-unveils-ucn2-as-novel-anti-obesity-drug-candidate-for-healthy-weight-loss/) - Gubra announces the selection of a development candidate and unveils urocortin-2 (UCN2) as a novel anti-obesity drug candidate for healthy weight loss. This once weekly peptide will be developed as a healthy weight loss drug with a favourable cardiac profile. This marks the start of the preclinical toxicology programme. Niels Vrang, Chief Scientific Officer at
- [ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate](http://danskbiotek.dk/news/expres2ion-announces-completion-of-glp-safety-study-for-es2b-c001-her2-vlp-breast-cancer-vaccine-candidate/) - Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This significant milestone marks an important step towards enabling a clinical
- [Great news from NMD Pharma!](http://danskbiotek.dk/news/great-news-from-nmd-pharma/) - On 21 March 2024, the company released the great news about the peer-reviewed publication in the journal Science Translational Medicine of data-sets that demonstrate the ability of CIC-1 inhibition to restore muscle function in patients suffering from myasthenia gravis (MG) and in animal models of MG. And today, 22 March 2024, NMD Pharma A/S releases
- [GOOD NEWS: The EU Commission promotes investments in infrastructure and know-how](http://danskbiotek.dk/news/good-news-the-eu-commission-promotes-investments-in-infrastructure-and-know-how/) - The EU Commision has published the initiative: ”Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU” Conclusion "The extraordinary advances in life sciences, supported by digitalisation and AI, and the potential of solutions based on biology for solving societal issues make biotechnology and biomanufacturing one of the most promising technological areas of
- [Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy](http://danskbiotek.dk/news/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/) - Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"). The proceeds are intended to be used to strengthen the Company’s
- [Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company](http://danskbiotek.dk/news/curasight-announces-acceleration-of-therapeutic-strategy-to-strengthen-position-as-a-radiopharmaceutical-theranostic-company/) - Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025. Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the
- [dsm-firmenich and Zerion Pharma form a partnership to develop improved cannabinoids](http://danskbiotek.dk/news/dsm-firmenich-and-zerion-pharma-form-a-partnership-to-develop-improved-cannabinoids/) - First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces an exclusive partnership with dsm-firmenich to take advantage of ZERION’s expertise and its Dispersome® technology for improving the bioavailability of cannabinoids. Improvements in bioavailability of cannabinoids can open the way for broadly
- [ExpreS2ion announces financial results for the fourth quarter and full-year 2023](http://danskbiotek.dk/news/expres2ion-announces-financial-results-for-the-fourth-quarter-and-full-year-2023/) - Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report. CEO Bent U. Frandsen comments: “2023 unfolded in ways we had not anticipated, primarily
- [https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-present-oppenheimer-34th-annual-healthcare](http://danskbiotek.dk/news/https-investors-zevra-com-news-releases-news-release-details-zevra-therapeutics-present-oppenheimer-34th-annual-healthcare/) - CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually on Tuesday, February 13, 2024, at 9:20 a.m. ET. Additionally, members of Zevra’s management team will be available for one-on-one investor meetings with registered attendees
- [ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit](http://danskbiotek.dk/news/expres2ion-to-present-in-redeye-fight-cancer-event-and-the-bio-innovation-leaders-summit/) - Hørsholm, Denmark, 22 January 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events in the coming weeks. This Wednesday, January 24th, CEO Bent Frandsen will present at the Redeye thematic event, Fight Cancer. Furthermore, Senior VP of R&D and Technology Dr. Max Søgaard will present at
- [Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, To The Board Of Directors](http://danskbiotek.dk/news/zevra-therapeutics-appoints-experienced-biopharma-executive-alvin-shih-md-mba-to-the-board-of-directors/) - CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shih, MD, MBA, to the Company’s Board of Directors (Board) effective as of January 20, 2024. Dr. Shih has extensive experience in biotechnology leadership and rare disease therapeutics development and currently serves as President and CEO of
- [Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021](http://danskbiotek.dk/news/issuance-of-new-shares-and-directed-share-buyback-as-well-as-the-sale-of-shares-in-connection-with-the-long-term-incentive-program-for-2021/) - The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to
- [Curasight A/S Achieves First Milestone under collaboration with Curium Inc.](http://danskbiotek.dk/news/curasight-a-s-achieves-first-milestone-under-collaboration-with-curium-inc/) - Copenhagen, January 22, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight’s uTRACE® PET imaging technology for the improved diagnosis of prostate cancer. The milestone relates to the validation of GMP manufacturing of finished product. USD
- [PILA PHARMA HAS BEEN SELECTED TO PARTICIPATE IN THE REGIONAL SCALE-UP PROGRAM "10 X HEALTH"](http://danskbiotek.dk/news/pila-pharma-has-been-selected-to-participate-in-the-regional-scale-up-program-10-x-health/) - Pila Pharma and its CEO, Dorte X. Gram, has been selected to participate cost-free in a scale-up program "10 X Health" partially sponsored by the European Regional Development Fund and organised by the SmiLe Incubator and Medicon Village in Lund, Sweden. Medicon Village and the SmiLe Incubator in Southern Sweden have - with the support
- [AGC Biologics Building New ATMP and Mammalian Facility in Japan](http://danskbiotek.dk/news/agc-biologics-building-new-atmp-and-mammalian-facility-in-japan/) - Today we are pleased to share construction plans for a new manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan. Our large-scale facility will be centrally located in this important APAC market, and will support global developers seeking biopharmaceutical product development and manufacturing. AGC Biologics Yokohama will offer services from pre-clinical to commercial stages,
- [Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference](http://danskbiotek.dk/news/hemab-therapeutics-appoints-dr-akshay-vaishnaw-to-board-of-directors-and-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-conference/) - COPENHAGEN, DENMARK AND CAMBRIDGE, MASS., US – January 4, 2024 – Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of Akshay Vaishnaw, MD, PhD, to its Board of Directors. The company also announced CEO Benny Sorensen, MD, PhD, will present an update on
- [Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts](http://danskbiotek.dk/news/initiator-pharma-expands-its-position-to-a-broader-sexual-health-franchise-and-intensifies-its-business-development-efforts/) - Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the company will expand the position of the company to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications. Initiator Pharma will
- [Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference](http://danskbiotek.dk/news/y-mabs-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference/) - NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January
- [Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index](http://danskbiotek.dk/news/y-mabs-therapeutics-added-to-the-nasdaq-biotechnology-index/) - NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18,
- [Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration](http://danskbiotek.dk/news/gubra-and-boehringer-ingelheim-sign-4th-partnership-expanding-their-successful-obesity-treatment-discovery-collaboration/) - Today, Gubra announces the signing of a new research and license agreement with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. The new research collaboration builds on the successfully progressing joint research projects between the companies. It takes on a new approach to identify, validate and develop innovative treatments with the aim
- [Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-reports-third-quarter-2023-financial-results-and-recent-corporate-developments/) - Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59% U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin Lymphoma Cash and cash equivalents of $86.6 million as of September 30, 2023, with anticipated cash runway extended into 2027 Management updates FY 2023 financial guidance by lowering anticipated operating expenses and use of cash
- [Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023](http://danskbiotek.dk/news/y-mabs-to-announce-third-quarter-2023-financial-and-operating-results-on-november-13-2023/) - NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday,
- [Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director](http://danskbiotek.dk/news/y-mabs-names-michael-rossi-as-president-and-chief-executive-officer-and-director/) - NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today that its Board of Directors has appointed Michael Rossi as President and Chief Executive Officer (“CEO”) and a member of the Board
- [MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus](http://danskbiotek.dk/news/minervax-raises-eur-54m-in-upsized-financing-to-advance-the-development-of-its-maternal-vaccine-against-group-b-streptococcus/) - Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of EUR 54 million upsized financing. The financing includes investment from new investors EQT Life Sciences and OrbiMed, with participation from existing investors Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill
- [Y-mAbs Announces Publication in Cancers](http://danskbiotek.dk/news/y-mabs-announces-publication-in-cancers/) - Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatmentNEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the publication of naxitamab-based chemoimmunotherapy in patients
- [Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA](http://danskbiotek.dk/news/y-mabs-therapeutics-announces-u-s-fda-clearance-of-investigational-new-drug-application-for-cd38-sada/) - Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food
- [Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology](http://danskbiotek.dk/news/y-mabs-announces-data-to-be-presented-at-the-55th-congress-of-the-international-society-of-pediatric-oncology/) - NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 55th Congress of the International Society of Pediatric Oncology ("SIOP") to be held October 11-14, 2023 in Ottawa, Canada. The
- [MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults](http://danskbiotek.dk/news/minervax-announces-completion-of-enrolment-in-phase-1-clinical-vaccine-trial-as-it-addresses-the-global-burden-of-group-b-streptococcus-in-older-adults/) - Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated in Q4, 2023 Copenhagen, Denmark, 27 June 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today
- [Minutes from Annual General Meeting](http://danskbiotek.dk/news/minutes-from-annual-general-meeting/) - The Annual General Meeting in DANISH BIO-DANSK BIOTEK was held on 11 May 2023 at Børsen. The Minutes from the Meeting have been attached.
- [Y-mAbs Announces Presentation of GD2-SADA Study at ASCO](http://danskbiotek.dk/news/y-mabs-announces-presentation-of-gd2-sada-study-at-asco/) - NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring the design of its Phase 1 clinical trial, evaluating the Company’s Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy
- [Y-mAbs Announces Presentation of Naxitamab Data at ASCO](http://danskbiotek.dk/news/y-mabs-announces-presentation-of-naxitamab-data-at-asco/) - NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring interim clinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody, in combination with granulocyte-macrophage colony-stimulating
- [Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil](http://danskbiotek.dk/news/y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-high-risk-neuroblastoma-approved-in-brazil/) - May 23, 2023 PDF Version NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (“Anvisa”) has granted marketing authorization
- [Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis](http://danskbiotek.dk/news/galecto-completes-dosing-in-52-week-phase-2b-galactic-1-trial-of-gb0139-in-idiopathic-pulmonary-fibrosis/) - BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced the last dosing of the last patient in the GALACTIC-1 Phase 2b trial of its most advanced product candidate, GB0139, for the treatment of idiopathic
- [Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance](http://danskbiotek.dk/news/y-mabs-reports-first-quarter-2023-financial-results-and-recent-corporate-developments-and-updates-2023-financial-guidance/) - Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 million for FY 2023 Ongoing patient recruitment in the Phase I SADA trial Cash and cash
- [Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023](http://danskbiotek.dk/news/y-mabs-to-announce-first-quarter-2023-financial-and-operating-results-on-may-8-2023/) - Apr 28, 2023 PDF Version NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with
- [Y-mAbs Announces Presentation of Naxitamab data at AACR](http://danskbiotek.dk/news/y-mabs-announces-presentation-of-naxitamab-data-at-aacr/) - NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring preclinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody will be presented at the
- [What is the right pay for your researchers?](http://danskbiotek.dk/news/what-is-the-right-pay-for-your-researchers/) - Participate now in The Danish Biotech Salary Survey to find out. Finding the right balance between salary costs and the ability to attract and retain key talent is crucial to company performance in our industry. For this you need market data. The Danish Biotech Salary Survey 2023 will give you hard-to-find data on all the
- [Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA](http://danskbiotek.dk/news/y-mabs-announces-first-patient-dosed-in-phase-1-clinical-trial-of-gd2-sada/) - NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been dosed with both the protein dose and the 177Lu-DOTA imaging dose in its Phase
- [Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-developments/) - Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidance First ever SADA Phase I trial opened Cash and cash equivalents of $105.8 million as of December 31, 2022, anticipated runway into the first quarter
- [Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe](http://danskbiotek.dk/news/pharm-assist-is-now-part-of-link-medical-making-the-regulatory-team-one-of-the-largest-and-unique-in-northern-europe/) - Oslo Norway, March 23, 2023 Today LINK Medical has announced the integration of Pharm Assist into the LINK Medical family. Pharm Assist is a consultant and service company based in Uppsala Sweden offering regulatory solutions for Medicinal and MedTech products since 1996. The Pharm Assist team is a highly qualified group of specialists with a
- [Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023](http://danskbiotek.dk/news/y-mabs-to-announce-2022-financial-and-operating-results-on-march-30-2023/) - NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 31,
- [How much is a Senior Research Scientist paid?  Find the answer in The Danish Biotech Salary Survey 2023.](http://danskbiotek.dk/news/how-much-is-a-senior-research-scientist-paid-find-the-answer-in-the-danish-biotech-salary-survey-2023/) - Finding the right balance between salary costs and the ability to attract and retain key talent is crucial to company performance in our industry. For this you need market data. The upcoming Danish Biotech Salary Survey will give you unique insights in 20 biotech specific jobs such as Research Scientist, Laboratory Technician, Project Manager, Patent
- [Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab](http://danskbiotek.dk/news/y-mabs-and-the-european-medicines-agency-reach-agreement-on-the-pediatric-investigation-plan-for-naxitamab/) - NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Medicines Agency (“EMA”) has agreed to the Company’s proposed Pediatric Investigation Plan (“PIP”) for naxitamab. The decision follows a
- [Unilabs og Siemens Healthineers lancerer strategisk partnerskab, for at den nyeste diagnostiske testinfrastruktur kan medvirke til at forbedre patienters pleje](http://danskbiotek.dk/news/unilabs-og-siemens-healthineers-lancerer-strategisk-partnerskab-for-at-den-nyeste-diagnostiske-testinfrastruktur-kan-medvirke-til-at-forbedre-patienters-pleje/) - Genève og Erlangen – 2. februar 2023: Unilabs, en førende udbyder af diagnostiske services, og Siemens Healthineers, en førende medicinsk teknologivirksomhed, annoncerede i dag en flerårig aftale til en værdi af over €200 millioner. Unilabs har investeret i Siemens Healthineers’ førsteklasses teknologi og vil erhverve mere end 400 laboratorieanalysatorer for yderligere at forbedre sin laboratorieinfrastruktur
- [Dansk Erhverv har lavet en ny life science-politik: Vi kan nå endnu længere, hvis vi justerer rammevilkårerne](http://danskbiotek.dk/news/dansk-erhverv-har-lavet-en-ny-life-science-politik-vi-kan-na-endnu-laengere-hvis-vi-justerer-rammevilkarerne/) - Efter et solidt politisk fokus på life science-området, mener Dansk Erhverv ikke, at foden skal slippes fra speederen. Derfor har interesseorganisationen lavet en politisk plan på 18 sider, der skal styrke rammevilkårerne i branchen. Med overskriften ”Verdens bedste life science-nation”, er Dansk Erhverv klar med en ny politisk plan for, hvordan interesseorganisationen mener dansk life science skal bringes fremad.
- [IO Biotech får lovende fase 2-data](http://danskbiotek.dk/news/io-biotech-far-lovende-fase-2-data/) - Biotekselskabet IO Biotech har fået opløftende foreløbige resultater fra et fase 2-forsøg mod lungekræft. Mens IO Biotech stadig er ved at rekruttere patienter til sit fase 2-studie mod lungekræft, så har selskabet samtidig fået de første tilbagemeldinger fra ni deltagere, og de er lovende. Det fortæller IO Biotech i en meddelelse fra sidste uge, hvor
- [Nyt netværk for kvinder i life science får støtte fra Novo Nordisk Fonden](http://danskbiotek.dk/news/nyt-netvaerk-for-kvinder-i-life-science-far-stotte-fra-novo-nordisk-fonden/) - Et nyt fagligt netværk for kvindelige topledere og specialister med prominente life science-kapaciteter bag og Novo Nordisk Fonden i ryggen har set dagens lys. Målet er at få flere kvinder på topposter i dansk life science. Selvom det går fremad, er der stadig for få kvinder og for lidt diversitet i toppen af den danske
- [Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA](http://danskbiotek.dk/news/y-mabs-announces-restructuring-plan-and-provides-financial-outlook-following-complete-response-letter-from-fda/) - Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million; Estimated total cash burn for 2023, including restructuring expenses, expected to be $50-55 million, expected to extend cash runway into Q1 2026 based on revised business plan; Estimated 2023 DANYELZA net product revenues expected to be $60-65 million; Focusing
- [MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine](http://danskbiotek.dk/news/minervax-appoints-lidia-oostvogels-as-chief-medical-officer-and-provides-clinical-and-regulatory-update-on-its-novel-gbs-vaccine/) - Newly appointed CMO with more than 25 years’ experience in vaccine development Fast Track status granted by US Food and Drug Administration Completion of enrolment of its 2nd phase II clinical trial in pregnant women Copenhagen, Denmark, 5 January 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B
- [Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe](http://danskbiotek.dk/news/y-mabs-announces-partnership-regarding-early-access-program-for-danyelza-naxitamab-gqgk-in-europe/) - NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA
- [The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe](http://danskbiotek.dk/news/the-chmp-has-adopted-a-negative-opinion-for-omburtamab-for-the-treatment-of-cns-lm-metastasis-from-neuroblastoma-in-europe/) - NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Committee for Medicinal Products for Human use (“CHMP”) has adopted a negative opinion recommending a refusal of the marketing
- [Trial Nation-formand: Ny life science-strategi skal fokusere på biotekvirksomheder](http://danskbiotek.dk/news/trial-nation-formand-ny-life-science-strategi-skal-fokusere-pa-biotekvirksomheder/) - Formand for Trial Nation Thomas Kongstad Petersen havde gerne set, at SVM-regeringen havde finansieringen på plads til det forhøjede forsknings- og udviklingsfradrag, men han glæder sig over udsigten til en ny life science-strategi og den nye regerings fokus på klinisk forskning. AF ANDREAS LØNSTRUP Offentliggjort: 15.12.22 kl. 10:46 Den nye SVM-regering vil i denne valgperiode lancere
- [MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus](http://danskbiotek.dk/news/minervax-announces-72m-eur-financing-to-advance-development-of-novel-vaccine-against-group-b-streptococcus/) - Copenhagen, Denmark, 15 December 2022 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing
- [Y-mAbs Announces Pipeline Update](http://danskbiotek.dk/news/y-mabs-announces-pipeline-update/) - NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update for naxitamab and the Company’s SADA technology programs will be presented at the Company’s R&D event,
- [Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China](http://danskbiotek.dk/news/y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-high-risk-neuroblastoma-approved-in-china/) - NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the National Medical Products Administration (“NMPA”) in China has granted DANYELZA (naxitamab-gqgk) 40mg/10ml conditional approval. DANYELZA will be marketed in China by Y-mAbs’ partner SciClone
- [Y-mAbs to Host Annual Research and Development Day in New York](http://danskbiotek.dk/news/y-mabs-to-host-annual-research-and-development-day-in-new-york/) - NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company today announced that it will host its annual Research and Development Day in New York, NY on December 14, 2022, at 9:00 am ET. The event will feature presentations of the Company, its clinical development, and advanced product pipeline. Company Presenters: Thomas
- [Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application](http://danskbiotek.dk/news/y-mabs-announces-complete-response-letter-for-omburtamab-biologics-license-application/) - NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”) for
- [Development of suPAR tests for commercial use in the US is a post-authorisation reqirement in new EUA of Kineret for COVID-19](http://danskbiotek.dk/news/development-of-supar-tests-for-commercial-use-in-the-us-is-a-post-authorisation-reqirement-in-new-eua-of-kineret-for-covid-19/) - ViroGates announces the emergency use authorisation of Kineret treatment for COVID-19 related pneumonia with a post-authorisation requirement on developing suPAR tests for commercial use in the US ViroGates announces that the United States Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) for the use of Sobi®’s medicine Kineret (anakinra) for the treatment
- [New CEO at LINK Medical, the Northern European CRO](http://danskbiotek.dk/news/new-ceo-at-link-medical-the-northern-european-cro/) - Oslo Norway, November 18, 2022. The LINK Medical Board is pleased to announce the appointment of Sissel Lønning Andresen as the new CEO of LINK Medical. Sissel will assume the position as the CEO of the company as of January 1st, 2023. Sissel has a Master of Science in pharmacy and brings nearly 25 years
- [Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases](http://danskbiotek.dk/news/novo-holdings-and-sound-bioventures-launch-breye-therapeutics-to-develop-novel-oral-therapies-for-ophthalmologic-diseases/) - COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR 4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and
- [Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab](http://danskbiotek.dk/news/y-mabs-announces-outcome-of-fda-advisory-committee-meeting-on-omburtamab/) - NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the outcome of the meeting of the U.S. Food and Drug Administration (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”), which reviewed investigational 131I-omburtamab (“omburtamab”) for the
- [Biotekvirksomhed er årets vækstskaber på Sjælland](http://danskbiotek.dk/news/biotekvirksomhed-er-arets-vaekstskaber-pa-sjaelland/) - Copenhagen, 25th October 2022 Gubra i Hørsholm vinder EY Entrepreneur Of The Year 2022 i region Sjælland efter et år med 400 % vækst. De blev hyldet ved den regionale finale, der også bød på ’ølkasse’-pitch blandt finalisterne i startup-kategorien samt uddelingen af den første inspirationspris i regionen. Gubra ved Jacob Jelsing og Niels Vrang
- [Pila Pharma completes 13-week safety studies in rats with no adverse signals during the dosing phase](http://danskbiotek.dk/news/pila-pharma-completes-13-week-safety-studies-in-rats-with-no-adverse-signals-during-the-dosing-phase/) - Malmö, October 11, 2022 PILA PHARMA AB (publ) (FN STO: PILA) today publishes that a 13-week oral safety study in rats has completed the in-life phase with no adverse signals during the dosing phase. Outstanding investigations still to be completed include the pathology, and the bioanalysis and toxicokinetic analyses which are necessary to determine the
- [Y-mAbs Announces Pivotal Data for Omburtamab](http://danskbiotek.dk/news/y-mabs-announces-pivotal-data-for-omburtamab/) - NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company’s product candidate OMBLASTYS® (131I-omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. Data was presented
- [Survey of clinical research activities in Denmark 2021 (Danish only)](http://danskbiotek.dk/news/survey-of-clinical-research-activities-in-denmark-2021-danish-only/) - As part of being able to document and communicate the importance of the pharmaceutical and biotech industry to health science research in Denmark, DANISH BIO – DANSK BIOTEK and Lif's Committee on Clinical Trials each year obtain information on the activities of their member companies and use of resources for clinical drug research in this
- [Barriers to success in biotech - a survey by Newlab and Watch Medier](http://danskbiotek.dk/news/barriers-to-success-in-biotech-a-survey-by-newlab-and-watch-medier/) - Newlab in collaboration with Watch Medier has conducted a new survey setting out to understand the current health of the Danish biotech industry. The survey sheds a light on how decision makers in the Danish biotech companies assess their own business performance across a range of parameters including funding, research, employees, business economics, branding and
- [2022 EU/UK Biotech Board & Executive Remuneration Study](http://danskbiotek.dk/news/2022-eu-uk-biotech-board-executive-remuneration-study/) - PIR welcomes you to the International 2022 Biotech Board & Executive Remuneration Study. An independent and exclusive study which focuses directly on growth stage Biotech board members and executives to help bridge a clear gap in available data on key aspects of compensation, equity distribution, participation and diversity amongst leading European and UK Biotechs. By
- [Y-mAbs’ Announces Clearance of IND for GD2-SADA](http://danskbiotek.dk/news/y-mabs-announces-clearance-of-ind-for-gd2-sada/) - NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced initiation of its first clinical trial with a SADA construct. This Phase 1 multicenter basket trial targets malignant melanoma, sarcoma and
- [Pila Pharma AB initiates toxicological studies](http://danskbiotek.dk/news/pila-pharma-ab-initiates-toxicological-studies/) - Pila Pharma AB (publ) announces that the preclinical toxicological three-month studies of the active substance XEN-D0501 has begun. Pila Pharma is, as previously announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a
- [Fujifilm to invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing service](http://danskbiotek.dk/news/33626/) - TOKYO, June 29, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and world-leading contract development and manufacturing organization (CDMO). This investment will enhance FUJIFILM Diosynth Biotechnologies’
- [Another milestone reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440](http://danskbiotek.dk/news/another-milestone-reached-for-alzecures-phase-ii-clinical-trial-in-neuropathic-pain-with-non-opioid-acd440/) - Uppsala Sweden, June 22st LINK Medical, the Northern European clinical research organization (CRO), and AlzeCure Pharma AB (publ) (FN STO: ALZCUR), announced today that the first patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440. Alzecure is a pharmaceutical company that develops a broad portfolio of drug candidates for diseases
- [Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint](http://danskbiotek.dk/news/y-mabs-announces-naxitamab-chemoimmunotherapy-investigational-trial-for-high-risk-neuroblastoma-meets-primary-endpoint/) - NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Shakeel Modak, MD from Memorial Sloan Kettering (“MSK”) will present results from the naxitamab-based chemoimmunotherapy trial in patients with
- [Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review](http://danskbiotek.dk/news/y-mabs-announces-fda-acceptance-of-biologics-license-application-for-omblastys-omburtamab-for-the-treatment-of-neuroblastoma-for-priority-review/) - NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Biologics License Application (“BLA”) for OMBLASTYS® (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma
- [DANISH BIO – DANSK BIOTEK celebrates the industry at the first ever Biotech Spring Gala](http://danskbiotek.dk/news/dansk-biotek-celebrates-the-industry-at-the-first-ever-biotech-spring-gala/) - On Friday 6th May 2022 DANISH BIO – DANSK BIOTEK held its first Biotech Spring Gala; an amazing evening with the top echelon of the Danish biotech scene at the beautiful Børssalen. During the gala, we also celebrated the persons and companies that made an extraordinary effort in 2021. The awards went to: Jan Møller
- [Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-announces-first-quarter-financial-results-and-recent-corporate-developments/) - NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter 2022. "Y-mAbs had a successful first quarter. We resubmitted the
- [LINK Medical, the Northern European CRO has raised capital to fund further growth](http://danskbiotek.dk/news/link-medical-the-northern-european-cro-has-raised-capital-to-fund-further-growth/) - May 2, 2022, LINK Medical and Serendipity Partners announce a new partnership. Serendipity Partners (Serendipity) has been invited as part owner of LINK Medical. Serendipity now owns 49% of the shares, however Dr. Ola Gudmundsen will stills hold the majority of the shares. The transaction is mainly structured as a share issue, where Serendipity provides
- [SDG Business Accelerator - Strengthening Sustainable Export](http://danskbiotek.dk/news/sdg-business-accelerator-strengthening-sustainable-export/) - The SDG Business Accelerator is driven by the Ministry of Foreign affairs in partnership with a number of partners who all share a common goal to strengthen sustainable export for Danish SMEs and reinforce Denmark’s progress on sustainable development. Please find a limited offer to SMEs to participate in the SDG Accelerator in the briefing
- [Y-mAbs Announces Presentation of SADA Technology at AACR](http://danskbiotek.dk/news/y-mabs-announces-presentation-of-sada-technology-at-aacr/) - NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring preclinical data from its GD2 SADA construct will be presented at
- [DANEMO Fellowships for Collaborative Work](http://danskbiotek.dk/news/danemo-fellowships-for-collaborative-work/) - Available to researchers and students at Danish research institutions for exploring opportunities for collaborations with EMBL Focusing on research within the framework of the new EMBL Programme “Molecules to Ecosystems”. Download and read more through the links below.
- [Danish biotech company to create more sustainable shipping](http://danskbiotek.dk/news/danish-biotech-company-to-create-more-sustainable-shipping/) - The Danish biotech company Cysbio may have broken the code on how to eliminate copper in ship’s paint. The copper is replaced with sustainable and biodegradable eelgrass acid. Shipping is one of the biggest logistical industries in global trade. Almost all the thousands of container ships and other boats that sail the world ocean daily
- [Report - Danish biotech: VC trends and insights](http://danskbiotek.dk/news/report-danish-biotech-vc-trends-and-insights/) - Biotech – a rapid growth journey While accelerated by the pandemic, biotech was already on a rapid growth journey. Global VC investment in biotech reached an all-time high in 2021 of $41B, a 3.4x increase in five years. By the end of 2021, the combined value of biotech companies globally passed $2.0T, up 5.3x on
- [PILA PHARMA publishes year-end report January 1 – December 31, 2021](http://danskbiotek.dk/news/pila-pharma-publishes-year-end-report-january-1-december-31-2021/) - Press Release PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January – December 2021. The report can be found on the Company´s website: https://pilapharma.com/investors/finansiell-information/
- [Fodaftryksanalyse for life science-industrien 2021](http://danskbiotek.dk/news/fodaftryksanalyse-for-life-science-industrien-2021/) - Der har været stor efterspørgsel på at se årets fodaftryksanalyse for life science-industrien 2021, men nu er den her. Og Erhvervsministeriets analyse viser endnu engang en industri i topform!
- [VIGTIGT: Adgang til forskningslitteratur](http://danskbiotek.dk/news/vigtigt-adgang-til-forskningslitteratur/) - I forbindelse med life science-strategien er det besluttet, at der skal foretages en analyse af forskningsbaserede life science start ups og SMV’ers adgang til forskningslitteratur. Analysen indgår som et centralt element i arbejdet med at give nemmere og måske gratis adgang til videnskabelig litteratur, og det er derfor meget vigtigt, at så mange som muligt
- [UPDATE - Y-mAbs Announces Pipeline Update](http://danskbiotek.dk/news/update-y-mabs-announces-pipeline-update/) - Press Release NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will
- [Y-mAbs Hosting Virtual Research and Development Day](http://danskbiotek.dk/news/y-mabs-hosting-virtual-research-and-development-day/) - NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time. The Y-mAbs research and
- [Become an Industry Mentor](http://danskbiotek.dk/news/become-an-industry-mentor/) - Hereby an invitation to partake the BRIDGE – Translational Excellence Programme as an industry mentor, enabling you, your colleague and/or your company to Tap into curiosity-driven research in academia Network and establish new collaborations with outstanding basic researchers at the University of Copenhagen and clinical researchers at the regional hospitals (Capital Region and Region Zealand)
- [Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021](http://danskbiotek.dk/news/y-mabs-to-announce-third-2021-financial-and-operating-results-on-november-4-2021/) - Press Release NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday,
- [CPHLabs: The perfect cure for lack of wet-labs available for Life Science entrepreneurs](http://danskbiotek.dk/news/cphlabs-the-perfect-cure-for-lack-of-wet-labs-available-for-life-science-entrepreneurs/) - Press Release Copenhagen October 15th 2021 A new collaboration between Symbion Community, REBBLS and Københavns Universitet - University of Copenhagen: CPHLabs – an infrastructure targeting early stage life science entrepreneurs that includes easy access to shared wet-labs has been announced. The collaboration is financed by Industriens Fond and includes 15 labspaces, networking events and workshops
- [Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA](http://danskbiotek.dk/news/y-mabs-177lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-granted-rare-pediatric-disease-designation-by-fda/) - Press Release NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation
- [Danish 'NoStressTrial' winner of the Data 4 Healthy Recovery Hackathon](http://danskbiotek.dk/news/the-winner-of-the-data-4-healthy-recovery-hackathon-is-a-danish-company/) - We have a winner ! As part of the European Commission’s Data 4 Healthy Recovery Hackathon EuropaBio sponsored an exciting challenge. The winning team - not only of the challenge but indeed of the entire Hackathon - is Danish company Healthy Mind Tech with their NoStressTrial platform used for planning, running and reporting of clinical
- [PILA PHARMA presents at Aktiespararna September 28th 2021 at CET 16:30](http://danskbiotek.dk/news/pila-pharma-presents-at-aktiespararna-september-28th-2021-at-cet-1630/) - PILA PHARMA was listed on Nasdaq First North on July 15. After just over two months, it is time for CEO Dorte X. Gram to make a status update and present how the company is doing with the exciting development of a new drug for type 2 diabetes. PILA PHARMA therefore participates in Aktiespararna's event
- [Publication of Prior Information Notice EU FAB](http://danskbiotek.dk/news/publication-of-prior-information-notice-eu-fab/) - From Ministry of Industry, Business and Financial Affairs (Erhvervsministeriet) we received the following: The Commission published last week, on 17 September, a “Prior Information Notice” where we announce our plans to launch a call for the EU Fab project beginning 2022. The Commission is setting up the EU FAB flexible manufacturing project, a network of
- [PILA PHARMA recieves GMP certification of placebo tablets](http://danskbiotek.dk/news/pila-pharma-recieves-gmp-certification-of-placebo-tablets/) - Press Release PILA PHARMA AB (publ) ("PILA PHARMA" or "the Company") announces that the placebo tablets to be used in coming clinical studies have now been manufactured, and GMP (Good Manufacturing Practice) certified. Placebo tablets are a key component of most clinical trials, in order to ensure a high degree of outcome reliability. Already in
- [Strategic collaboration between Bioneer A/S and National Biologics Facility](http://danskbiotek.dk/news/strategic-collaboration-between-bioneer-a-s-and-national-biologics-facility/) - Press Release Bioneer A/S announces a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins. Copenhagen, September 16th, 2021. Bioneer A/S, a globally operating Danish specialty-CRO creating and commercializing innovative research service solutions for early stage drug development and in vitro modelling, announced today
- [Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma](http://danskbiotek.dk/news/y-mabs-to-host-key-opinion-leader-webinar-on-danyelza-naxitamab-gqgk-frontline-and-hits-data-in-high-risk-neuroblastoma/) - Press Release NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a key opinion leader ("KOL") webinar on DANYELZA frontline and
- [LINK Medical strengthens its stand-out Real World Evidence (RWE) department with a uniquely qualified expert, Maria Hortlund](http://danskbiotek.dk/news/link-medical-strengthens-its-stand-out-real-world-evidence-rwe-department-with-a-uniquely-qualified-expert-maria-hortlund/) - Press Release LINK Medical is pleased to announce that Maria Hortlund joins the Market Access team as a RWE Manager. Maria has over 15 years’ experience within RWE in the Nordics. She holds a PhD in Epidemiology and brings extensive knowledge of RWE-studies, from study concept to final report. She joins LINK Medical from the
- [Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-announces-second-quarter-financial-results-and-recent-corporate-developments/) - Press Release NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter of 2021. “We are very pleased with our
- [Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021](http://danskbiotek.dk/news/y-mabs-to-announce-second-quarter-2021-financial-and-operating-results-on-august-5-2021/) - Press Release NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets. The announcement will be followed by a
- [Y-mAbs Announces Update on Omburtamab for DIPG](http://danskbiotek.dk/news/y-mabs-announces-update-on-omburtamab-for-dipg/) - Press Release NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center (“MSK”) and Weill Cornell Medicine
- [Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting](http://danskbiotek.dk/news/y-mabs-announces-data-to-be-presented-at-2021-asco-annual-meeting/) - Press Release NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer is pleased to announce the acceptance of two poster presentations for DANYELZA and an oral presentation for omburtamab at the American Society of
- [Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma](http://danskbiotek.dk/news/y-mabs-announces-frontline-data-for-danyelza-naxitamab-gqgk-in-high-risk-neuroblastoma/) - Press Release NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline
- [LINK Medical Research has been appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer](http://danskbiotek.dk/news/link-medical-research-has-been-appointed-by-ectin-research-ab-as-cro-for-its-landmark-phase-i-ii-study-of-a-new-treatment-for-metastatic-bladder-cancer/) - Press Release June 24th LINK Medical and Ectin Research AB have signed an agreement appointing LINK Medical Research AB to run the Phase I/II clinical study of the treatment of metastatic bladder cancer patients with the drug candidate MFA-370. Ectin Research aims to submit its clinical trial application (CTA) to the Swedish Medical Products Agency, in collaboration
- [LINK Medical and Insife partnership combines full CRO services with powerful safety and pharmacovigilance tools](http://danskbiotek.dk/news/link-medical-and-insife-partnership-combines-full-cro-services-with-powerful-safety-and-pharmacovigilance-tools/) - Press Release Uppsala, Sweden June 7th 2021, - LINK Medical, a full-service contract research organization (CRO) providing product development and post-marketing services for the pharmaceutical and medical device industries, has signed a contract to join forces with Insife, an expert consulting and technology service provider for safety and pharmacovigilance organizations. This partnership combines extensive experience and
- [Scandion Oncology reports positive interim results from the CORIST Phase II study](http://danskbiotek.dk/news/scandion-oncology-reports-positive-interim-results-from-the-corist-phase-ii-study/) - Press Release THU, JUN 24, 2021 08:00 CET Scandion Oncology A/S today reports positive results from the dose-finding part 1 of the CORIST Phase II study. A well tolerated dose of SCO-101 in combination with the chemotherapy regimen FOLFIRI has been determined and the SCO-101 treatment in the optimized combination resulted in notable potentiation of
- [Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA](http://danskbiotek.dk/news/y-mabs-177lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-receives-positive-opinion-on-orphan-medicinal-product-designation-by-ema/) - Press Release NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan
- [Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma](http://danskbiotek.dk/news/y-mabs-provides-regulatory-update-on-omburtamab-for-the-treatment-of-patients-with-neuroblastoma-2/) - Press Release NEW YORK, June 23, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has recently concluded a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding omburtamab for
- [Ask the experts #1/6: What's the focus in a GCP inspection?](http://danskbiotek.dk/news/ask-the-experts-1-6-whats-the-focus-in-a-gcp-inspection/) - Over the next 3 weeks LINK Medical will release 6 video's called 'Ask the experts'. Have a look at this first video on LinkedIn where Gunnar Danielsson, former GCP inspector, and Senior Regulatory Advisor at LINK Medical Research talks to Maria Lundius Kastenfalk, about his experience. For more LINK Medical video's follow this Youtube channel
- [Ask the experts #2/6: What is Risk Based Quality Management?](http://danskbiotek.dk/news/ask-the-experts-2-6-what-is-risk-based-quality-management/) - On the second video of LINK Medical's 'Ask the expert' series, Gunnar Danielsson former GCP inspector and Senior Regulatory Advisor talks to Maria Lundius Kastenfalk about RBQM. Subscribe to LINK Medical's Youtube channel to get the full series. https://lnkd.in/gBvAuDV Click the 'Read more' link below to see the video on LinkedIn
- [LINK Medical and Medaffcon join forces in Real World Evidence (RWE) and Market Access to offer customers full support across the Nordics](http://danskbiotek.dk/news/link-medical-and-medaffcon-join-forces-in-real-world-evidence-rwe-and-market-access-to-offer-customers-full-support-across-the-nordics/) - Press Release OSLO, Norway/ESPOO, Finland May 24, 2021 – LINK Medical, the Northern European clinical research organization (CRO), and Medaffcon Oy, the expert service and research consultancy company based in Finland, announce their collaboration to provide customers with integrated, full-service Real World Evidence (RWE) and Market Access support across all Nordic countries. Read the full
- [Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America](http://danskbiotek.dk/news/y-mabs-enters-into-exclusive-distribution-agreement-with-adium-pharma-s-a-for-danyelza-naxitamab-gqgk-and-omburtamab-in-latin-america/) - Press Release NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into an exclusive distribution agreement with Adium Pharma S.A. (“Adium”) to be the exclusive distributor in Latin
- [Nomination call: 2022 Novo Nordisk Prize - Advances in Medical Sciences](http://danskbiotek.dk/news/nomination-call-2022-novo-nordisk-prize-advances-in-medical-sciences/) - 2022 Novo Nordisk Prize - Advances in Medical Sciences The 2022 Novo Nordisk Prize will recognize an active scientist for her/his excellent research, inspirational leadership and mentoring, leading to a major discovery or breakthrough in biomedical science. Since 2020, the Prize is awarded to excellent scientists based in academic institutions or companies conducting research in
- [LINK Medical expands its regulatory services team, strengthening its IMPD & CMC capabilities](http://danskbiotek.dk/news/link-medical-expands-its-regulatory-services-team-strengthening-its-impd-cmc-capabilities/) - Press Release OSLO, Norway, May 03 2021 – LINK Medical, the Northern European clinical research organization (CRO), today announced the expansion of its regulatory team with the recent appointment of new regulatory directors in Norway, Sweden and Denmark. This growth further builds upon the company’s existing capabilities in early development regulatory strategies including Investigational Medicinal
- [Y-mAbs Provides Regulatory Update on Omburtamab](http://danskbiotek.dk/news/y-mabs-provides-regulatory-update-on-omburtamab/) - Press Release NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a regulatory update for omburtamab, which is an investigational, monoclonal antibody that targets B7-H3 and has been radiolabeled before intraventricular
- [LINK Medical strengthens its position in Germany as a strategic gateway between Europe and the Nordics](http://danskbiotek.dk/news/link-medical-strengthens-its-position-in-germany-as-a-strategic-gateway-between-europe-and-the-nordics/) - Press Release BERLIN, Germany, April 14, 2021 – LINK Medical, the Northern European clinical research organization (CRO), is continuing the expansion of its German presence. This further strengthens their position as a gateway between the Nordics and one of the largest medical device and pharmaceutical markets in Europe. By establishing a stronger position in Germany,
- [Y-mAbs Announces GPA33-SADA Data Presented at AACR](http://danskbiotek.dk/news/y-mabs-announces-gpa33-sada-data-presented-at-aacr/) - Press Release NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Sebastian Chung from Memorial Sloan Kettering Cancer Center (“MSK”) presented a virtual poster discussing the SADA technology platform for pre-targeted radioimmunotherapy against
- [Introducing New Products and Initiatives by EBD Group](http://danskbiotek.dk/news/introducing-new-products-and-initiatives-by-ebd-group/) - We are excited to share with you EBD’ new products and initiatives that are being launched this month. Startup Springboard, March 18, 2021 The Startup Springboard is a one-day virtual event taking place the week before BIO-Europe Spring®. Providing biopharma companies new opportunities to engage with a pool of curated pipeline companies. Read more here
- [Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-announces-2020-financial-results-and-recent-corporate-developments/) - Press Release NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for 2020. Read the full press release here
- [2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint](http://danskbiotek.dk/news/2curex-announces-that-the-clinical-trial-of-inditreat-guided-treatment-of-metastatic-colorectal-cancer-has-met-the-primary-endpoint/) - Press Release 2cureX announced today that its prospective interventional clinical trial investigating the benefit of IndiTreat®-guided treatment achieved its primary endpoint by improving Progression Free Survival (PFS) after eight weeks of treatment beyond the primary endpoint. Full data has been submitted to the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. “These results show
- [Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](http://danskbiotek.dk/news/y-mabs-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares/) - Press Release NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 2,804,878 shares of its common stock, at a public offering price of $41.00 per share,
- [Y-mAbs Announces Proposed Public Offering of Common Stock](http://danskbiotek.dk/news/y-mabs-announces-proposed-public-offering-of-common-stock-2/) - PRESS RELEASE NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the commencement of a registered underwritten public offering of up to $100 million
- [Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for Treatment of Plaque Psoriasis](http://danskbiotek.dk/news/almirall-and-mc2-therapeutics-enter-a-license-collaboration-and-commercialization-agreement-for-european-rights-to-wynzora-cream-for-treatment-of-plaque-psoriasis/) - PRESS RELEASE In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply. MC2 Therapeutics and Almirall partner to make Wynzora® Cream a leading topical product for Plaque Psoriasis in Europe In a large European based Phase 3 clinical trial (n=490),
- [A great milestone reached in the Gedea Biotech’s NEFERTITI Clinical Trial of pHyph for antibiotic-free treatment of women with bacterial vaginosis](http://danskbiotek.dk/news/a-great-milestone-reached-in-the-gedea-biotechs-nefertiti-clinical-trial-of-phyph-for-antibiotic-free-treatment-of-women-with-bacterial-vaginosis/) - LINK Medical, the Northern European clinical research organization (CRO), and the Swedish women’s health company Gedea Biotech announced today that it has enrolled the first patient in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed to confirm
- [2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO](http://danskbiotek.dk/news/2curex-appoints-fernando-andreu-an-international-biotech-executive-as-new-ceo/) - 2cureX is pleased to announce that Fernando Andreu has been appointed new CEO and will start latest on 1 April 2021. Ole Thastrup, the present CEO and Founder of 2cureX, will continue as CSO, being responsible for 2cureX’s clinical and scientific activities. 2cureX has recently launched the world’s first CE-marked and ISO13485 compliant Functional Precision Medicine
- [2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO](http://danskbiotek.dk/news/2curex-appoints-kenneth-graabek-johansen-an-experienced-business-and-financial-executive-as-new-cfo/) - 2cureX is pleased to announce that Kenneth Graabek Johansen has been appointed new CFO and will start on 1 February 2021. Kenneth has a strong track record in business administration at executive level in the biomedical area. Today, 2cureX is pleased to announce, that Kenneth Graabek Johansen also will be joining the company as CFO.
- [Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference](http://danskbiotek.dk/news/y-mabs-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference/) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Claus Møller, MD, Ph.D., Chief Executive Officer of Y-mAbs Therapeutics will provide an overview and update on the company's business at the virtual 39th Annual J.P. Morgan
- [Recording from Virtual Members' Meeting on Vaccines December 11, 2020](http://danskbiotek.dk/news/recording-from-virtual-members-meeting-on-vaccines-december-11-2020/) - DANISH BIO – DANSK BIOTEK conducted its first virtual members’ meeting ever on December 11 on the topic 'Covid-19 – A Biotech Perspective'. We had invited two experts from the field to present their take on the current situation and the future perspectives. As we have received several requests for a recording of the Zoom
- [Lif og DANISH BIO – DANSK BIOTEKs undersøgelse af de kliniske forskningsaktiviteter i Danmark 2019](http://danskbiotek.dk/news/lif-og-dansk-bioteks-undersogelse-af-de-kliniske-forskningsaktiviteter-i-danmark-2019/) - ARTIKEL Antallet af private kliniske forsøg i Danmark står stille Trods flere års offentlig-privat indsats med bl.a. Next og Trial Nation for at tiltrække flere forsøg med nye lægemidler til de danske sygehuse, er der ikke en positiv udvikling at spore. Det viser Lif og DANISH BIO – DANSK BIOTEKs undersøgelse af de kliniske forskningsaktiviteter
- [The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma](http://danskbiotek.dk/news/the-food-and-drug-administration-fda-grants-io-biotech-breakthrough-therapy-designation-for-io102-and-io103-in-combination-with-anti-pd-1-in-unresectable-metastatic-melanoma/) - IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on IO Biotech’s proprietary T-win® technology
- [Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel](http://danskbiotek.dk/news/y-mabs-and-takeda-announce-exclusive-license-and-distribution-agreement-for-danyelza-naxitamab-gqgk-and-omburtamab-in-israel/) - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced today that they have entered into an exclusive license and distribution agreement for the registration
- [Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO](http://danskbiotek.dk/news/y-mabs-announces-update-on-danyelza-naxitamab-gqgk-at-esmo/) - NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on DANYELZA® (naxitamab-gqgk) for the treatment of Refractory/Relapsed High-Risk Neuroblastoma was given at the ESMO Immuno-Oncology Virtual
- [LINK Medical acquires IRW, further expanding its clinical research services and expertise across the Nordic countries](http://danskbiotek.dk/news/link-medical-acquires-irw-further-expanding-its-clinical-research-services-and-expertise-across-the-nordic-countries/) - Press Release LINK Medical has today announced the acquisition of IRW Consulting AB (IRW), a Nordic CRO with more than 20 years of experience in clinical research outsourcing. With this acquisition LINK Medical will continue growing and strengthening its position in the Nordics while improving its already strong offerings and increasing its clinical operations capabilities
- [FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma](http://danskbiotek.dk/news/fda-approves-y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-neuroblastoma/) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of
- [Y-mAbs Announces Update on Omburtamab in DIPG](http://danskbiotek.dk/news/y-mabs-announces-update-on-omburtamab-in-dipg/) - Y-mAbs Therapeutics, Inc. today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“DIPG”). Data was presented at the Society for Neuro-Oncology (“SNO”) Virtual Annual Meeting held November 19 through November 21, 2020. The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine. In a poster presentation,
- [Damvad Analytics Report on Growth Opportunities for the Life Science Industry](http://danskbiotek.dk/news/damvad-analytics-report-on-growth-oipportunities-for-the-life-science-industry/) - As mentioned in a previous Newsletter, DANISH BIO – DANSK BIOTEK has joined the newly established Genstartsteam (Restart Teams) for Life Science & Biotech, headed by Novo Nordisk’s Lars Fruergaard. The initiative has a common goal of supporting the Danish export and get the country financially restarted as efficiently as possible. In connection with the
- [IO Biotech Announces First Patient Dosed in Phase 2 Trial in Head and Neck Cancer Conducted in a Collaboration with Cliniques Universitaires Saint-Luc in Belgium](http://danskbiotek.dk/news/io-biotech-announces-first-patient-dosed-in-phase-2-trial-in-head-and-neck-cancer-conducted-in-a-collaboration-with-cliniques-universitaires-saint-luc-in-belgium/) - IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced that the first patient has received the first dose in a Phase 2 study (HN1901) investigating activity and safety of peptide-based immunotherapy in the preoperative setting for in-patients with squamous cell carcinoma of the head and
- [Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020](http://danskbiotek.dk/news/y-mabs-to-announce-third-quarter-2020-financial-and-operating-results-on-november-5-2020/) - Y-mAbs Therapeutics, Inc. today announced that it will report its financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, November 6, 2020, at 9 a.m. ET. Participating on the call from
- [EATRIS SURVEY mapping patient stratification strategies currently undertaken by industry](http://danskbiotek.dk/news/survey-mapping-patient-stratification-strategies-currently-undertaken-by-industry-eatris/) - As a member of DANISH BIO – DANSK BIOTEK you are invited to participate in this survey mapping patient stratification strategies currently undertaken by industry developed by EATRIS, in the context of the PERsonalised MedicIne Trials (‘PERMIT’) project. The results of the survey will enable a better understanding of the challenges and opportunities in the translational development phase of personalised medicine
- [Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody for Adult Indications](http://danskbiotek.dk/news/y-mabs-announces-fda-clearance-of-ind-for-its-lutetium-177-labeled-omburtamab-antibody/) - Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer
- [Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma](http://danskbiotek.dk/news/y-mabs-announces-update-on-naxitamab-and-omburtamab-in-neuroblastoma/) - Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical updates on naxitamab for the treatment of relapsed/refractory high-risk neuroblastoma and omburtamab for CNS/leptomeningeal metastasis from neuroblastoma. Data was presented at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October
- [Berlingske insert on Biotech featuring DANISH BIO – DANSK BIOTEK (in Danish)](http://danskbiotek.dk/news/berlingske-insert-on-biotech-featuring-dansk-biotech-in-danish/) - Read the entire insert here and the article with Hans Shambye here.
- [Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted](http://danskbiotek.dk/news/y-mabs-nivatrotamab-for-the-treatment-of-patients-with-neuroblastoma-granted/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the FDA has granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation (“RPDD”) for its leading bispecific antibody program nivatrotamab for the treatment of neuroblastoma. Read full
- [Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma](http://danskbiotek.dk/news/y-mabs-provides-regulatory-update-on-omburtamab-for-the-treatment-of-patients-with-neuroblastoma/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Y-mAbs has received a Refusal to File letter from the U.S. Food and Drug Administration regarding the Biologics License Application for omburtamab for the treatment of pediatric patients
- [Danish Article: FREMTIDENS DANSKE EKSPORTEVENTYR KOMMER FRA BIOTEK](http://danskbiotek.dk/news/danish-article-fremtidens-danske-eksporteventyr-kommer-fra-biotek/) - For our Danish readers, please enjoy the Life Science section of Berlingske today 15th Sept 2020, where our Chairman Hans Schambye is featured in an article on page 14. https://issuu.com/partnermedier/docs/life_science
- [European start-ups selected as part of a joint initiative with J&J and the US government - join BLUE KNIGHT WEBINARS](http://danskbiotek.dk/news/european-start-ups-selected-as-part-of-a-joint-initiative-with-jj-and-the-us-government-join-blue-knight-webinars/) - European start-ups selected as part of a joint initiative with J&J and the US government Did you know European start-ups can work with BARDA (a part of the US Government in the US Department of Health and Human Services) too!? Johnson & Johnson Innovation announced the BLUE KNIGHT™ collaboration to stimulate innovation and incubation of
- [MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US](http://danskbiotek.dk/news/mc2-therapeutics-announces-collaboration-agreement-with-epi-health-on-commercialization-of-newly-approved-psoriasis-drug-wynzora-cream-in-the-us/) - MC2 Therapeutics, a commercial stage pharmaceutical company focused on innovative topical therapies for chronic inflammatory conditions, announced today its Collaboration Agreement with EPI Health, LLC on the commercialization of WYNZORA Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. WYNZORA Cream was approved by the U.S. Food and Drug Administration on July 20th, 2020
- [Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-announces-second-quarter-2020-financial-results-and-recent-corporate-developments/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020. Read the full press release here
- [Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA](http://danskbiotek.dk/news/y-mabs-announces-completion-of-submission-of-omburtamab-biologics-license-application-to-fda/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on August 5, 2020, the Company completed the submission of its Biologics License Application under the FDA’s Rolling Review process for omburtamab. Omburtamab is an investigational, monoclonal antibody
- [Commercializing products in the U.S. marketplace - Educational Web Series](http://danskbiotek.dk/news/commercializing-products-in-the-u-s-marketplace-educational-web-series/)
- [Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA](http://danskbiotek.dk/news/y-mabs-announces-initiation-of-submission-of-omburtamab-rolling-biologics-license-application-to-the-fda/)
- [Unilabs launches large-scale Covid-19 immunity study with Greater Copenhagen hospitals](http://danskbiotek.dk/news/unilabs-launches-large-scale-covid-19-immunity-study-with-greater-copenhagen-hospitals/)
- [Free book download for our members: Assembled Chaos: Accelerate your medical research career while changing the future of medicine...](http://danskbiotek.dk/news/free-download-for-our-members-assembled-chaos-accelerate-your-medical-research-career-while-changing-the-future-of-medicine/) - As you probably realise consortia are becoming an increasingly common way to conduct medical research and innovation. The book Assembled Chaos: Accelerate your medical research career while changing the future of medicine through highly interactive consortia by the founder of BioSci Consulting, Scott Wagers, is based upon experiences with a number of major consortium projects.
- [Dansk Standard: Invitation to participation in development of the future Biotech standards](http://danskbiotek.dk/news/dansk-standard-invitation-to-participation-in-development-of-the-future-biotech-standards/)
- [Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza™ (naxitamab) for the Treatment of Neuroblastoma for Priority Review](http://danskbiotek.dk/news/y-mabs-announces-u-s-fda-acceptance-of-biologics-license-application-for-danyelza-naxitamab-for-the-treatment-of-neuroblastoma-for-priority-review/)
- [Y-mAbs Announces First Quarter 2020 Financial Results and Recent Corporate Developments](http://danskbiotek.dk/news/y-mabs-announces-first-quarter-2020-financial-results-and-recent-corporate-developments/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter 2020. Read the full press release here
- [Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting](http://danskbiotek.dk/news/y-mabs-announces-data-to-be-presented-at-2020-asco-annual-meeting/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer is pleased to announce the acceptance of two poster presentations at the American Society of Clinical Oncology (“ASCO”) Virtual Annual Meeting, taking place virtually from May 29, 2020 to June 2,
- [Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020](http://danskbiotek.dk/news/y-mabs-to-announce-first-quarter-2020-financial-and-operating-results-on-may-7-2020/) - Y-mAbs Therapeutics, Inc. today announced that it will report its financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, May 8, 2020, at 9
- [Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors](http://danskbiotek.dk/news/y-mabs-announces-appointment-of-laura-j-hamill-to-its-board-of-directors/) - Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the Board of Directors nominates healthcare executive Laura J. Hamill to be elected as a Class II director at the Company’s 2020 annual meeting of stockholders. Read the full
- [Union Medico](http://danskbiotek.dk/news/union-medico/)
- [Article: Trial Subject GDPR Consent - A Do or a Don't?](http://danskbiotek.dk/news/article-trial-subject-gdpr-consent-a-do-or-a-dont/) - This article written by Jan Bjerrum Bach, Attorney-at-law, Jusmedico Law Firm / BioLawEurope will give you an insight to the Biotech Company GDPR Need-to-Knows. Quote from the article: "Considering the vast amount of GDPR advice available from a comprehensive number of sources, including the EU Data Protection Board and national data protection agencies, it should be
- [Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform](http://danskbiotek.dk/news/y-mabs-enters-into-worldwide-exclusive-license-agreement-for-sada-technology-a-novel-radioimmunotherapy-platform/) - Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology for a worldwide exclusive license and research collaboration to develop and
- [Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA](http://danskbiotek.dk/news/y-mabs-announces-submission-of-naxitamab-biologics-license-application-to-u-s-fda/) - On April 01, 2020, Y-mAbs announced that the Company has completed the submission of its Biologics License Application (“BLA”) under the FDA’s Rolling Review process for naxitamab after market close on March 31, 2020. Naxitamab is an investigational, monoclonal antibody that targets GD2. The naxitamab BLA is for the treatment of patients with relapsed/refractory high-risk
- [Servier signs a definitive agreement to acquire Symphogen to boost its antibody capabilities and leverage its R&D pipeline](http://danskbiotek.dk/news/servier-signs-a-definitive-agreement-to-acquire-symphogen-to-boost-its-antibody-capabilities-and-leverage-its-rd-pipeline/) - Servier, an independent international pharmaceutical company, announced today that it has entered into a definitive agreement with the owners of Symphogen A/S, a leader in therapeutic antibody discovery, to acquire 100% of Symphogen’s share capital. The acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities
- [NORGINE B.V. ACQUIRES AZANTA A/S](http://danskbiotek.dk/news/norgine-b-v-acquires-azanta-a-s/) - NORGINE B.V. ACQUIRES AZANTA A/S STRENGTHENING ITS POSITION AS A LEADING EUROPEAN SPECIALIST PHARMACEUTICAL COMPANY Amsterdam, The Netherlands, 24 March 2020 Norgine B.V. (“Norgine”) announces the acquisition of Azanta A/S, a specialty biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine. For the full press release click
- [Corona postpones all events in DANISH BIO – DANSK BIOTEK](http://danskbiotek.dk/news/corona-postpones-all-events/) - During the corona crisis, DANISH BIO – DANSK BIOTEK is of course following the advice provided by the Danish Government and Health Authorities. We are taking active measures to help limit the spread of the virus and consequently, events originally planned for March, April and May will be postponed until further notice. This affects also
- [The Life and Death of Startup Accelerators](http://danskbiotek.dk/news/the-life-and-death-of-startup-accelerators/) - In 2019, Accelerace celebrated its 10th anniversary. However, Accelerace was never supposed to become a startup, let alone grow into a company. Nonetheless, that is exactly what happened. In this month's insight story, Accelerace CEO Peter Torstensen reflects on what principles Accelerace was built on and what the purpose of the Accelerace project was. He
- [Y-mAbs’ GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation](http://danskbiotek.dk/news/y-mabs-gd2-gd3-vaccine-granted-rare-pediatric-disease-designation/) - NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based and immunotherapeutic products for the treatment of cancer, today announced that its GD2-GD3 Vaccine has been granted a Rare Pediatric Disease Designation (“RPDD”) by
- [MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis](http://danskbiotek.dk/news/mc2-therapeutics-announces-fda-acceptance-of-its-new-drug-application-for-wynzora-cream-for-treatment-of-plaque-psoriasis/) - COPENHAGEN, Denmark, November 21, 2019 / B3C newswire / -- MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Wynzora™ Cream. MC2 Therapeutics is seeking marketing approval
- [Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](http://danskbiotek.dk/news/24188/) - NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 5,134,750 shares of its common stock, at a
- [Y-mAbs Announces Proposed Public Offering of Common Stock](http://danskbiotek.dk/news/y-mabs-announces-proposed-public-offering-of-common-stock/) - NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the commencement of a registered underwritten public offering of up to $125 million in shares
- [Y-mAbs Announces Naxitamab Update](http://danskbiotek.dk/news/y-mabs-announces-naxitamab-update/) - NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on one of the Company’s lead products, naxitamab for the treatment
- [#EFIB2019 – EuropaBio hosts 12th annual Industrial Biotech and Bioeconomy Conference](http://danskbiotek.dk/news/efib2019-europabio-hosts-12th-annual-industrial-biotech-and-bioeconomy-conference/) - EuropaBio hosts 12th annual Industrial Biotech and Bioeconomy Conference - #EFIB2019 As the new European Institutions draw up political guidelines and goals to address climate and sustainability challenges, this year’s conference will highlight the sector’s latest achievements and the potential of a circular bioeconomy for Europe The European Forum for Industrial Biotechnology and the Bioeconomy
- [Mentor on the BRIDGE – Translational Excellence Programme?](http://danskbiotek.dk/news/mentor-on-the-bridge-translational-excellence-programme/) - The BRIDGE – Translational Excellence Programme is seeking mentor teams who wish to combine their research and perspectives from the clinical or Life Science Industry sector, and academic world to develop a two-year research project in collaboration with a young postdoctoral researcher. In the upcoming call opening on September 2, BRIDGE offers 11 new postdoc
- [Orphazyme appoints Kim Stratton as Chief Executive Officer](http://danskbiotek.dk/news/orphazyme-appoints-kim-stratton-as-chief-executive-officer/) - Kim Stratton to succeed Anders Hinsby, effective October 1, 2019 Copenhagen, July 15, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company’s Board of Directors has appointed Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby.
- [Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab](http://danskbiotek.dk/news/y-mabs-announces-successful-pre-bla-meeting-with-fda-for-naxitamab/) - NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has completed a successful Type B Pre-Biologics License Application (“Pre-BLA”) meeting with the
- [Resetting the ambition for biotechnology in the EU](http://danskbiotek.dk/news/resetting-the-ambition-for-biotechnology-in-the-eu/) - Brussels, 2 July 2019 Today, as the new European Parliament meets for its inaugural session in Strasbourg, EuropaBio publishes its Biotechnology Industry Manifesto 2019 The manifesto calls upon EU decision makers to reset the ambition for a healthier, more resource efficient, technology driven Europe. Biotechnology is already a transformative EU asset, significantly addressing unmet medical
- [Y-mAbs Announces Recruitment Status for Pivotal Trials](http://danskbiotek.dk/news/y-mabs-announces-recruitment-status-for-pivotal-trials/) - NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the status of patient recruitment for the Company’s two pivotal phase II trials, one for omburtamab for the treatment of
- [Y-mAbs Secures Commercial Radiolabeling Capacity](http://danskbiotek.dk/news/14570/) - NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has entered a development, manufacturing and supply agreement with SpectronRx in South Bend, Indiana, to secure access to
- [Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting](http://danskbiotek.dk/news/y-mabs-announces-data-to-be-presented-at-2019-asco-annual-meeting/) - NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of three poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting to be
- [Symphogen announces new capital raise and explores strategic options](http://danskbiotek.dk/news/symphogen-announces-new-capital-raise-and-explores-strategic-options/) - Today, Symphogen called for an ordinary shareholders meeting to be held on 29 May 2019. At the meeting, Symphogen’s Board of Directors will propose to raise new capital through a pre-emptive issue of new preferred shares and warrants to existing shareholders. A group of existing shareholders being: Novo Holdings, Essex Woodlands Healthcare, Sunstone and PKA
- [Y-mAbs Announces Development Update on Cancer Vaccine Program](http://danskbiotek.dk/news/y-mabs-announces-development-update-on-cancer-vaccine-program/) - NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce a development update on its cancer vaccine program, the GD2-GD3 Vaccine. At the Advances in Neuroblastoma Research (ANR) conference
- [DTU Biosustain joins new Global Biofoundries Alliance](http://danskbiotek.dk/news/dtu-biosustain-joins-new-global-biofoundries-alliance/) - The Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) joins the Global Biofoundries Alliance. This new initiative will strengthen international collaboration on efficient design and construction of cell factories. To enable global coordination and gain more visibility in the area of construction of cell factories, 16 non-commercial biofoundries from all across the world have formed
- [Danish biotech company announces the completion of a €5.5 M seed investment](http://danskbiotek.dk/news/danish-biotech-company-announces-the-completion-of-a-e5-5-m-seed-investment/) - The big Chinese fine chemical company Zhejiang NHU invest €5.5 M in the biotech start-up CysBio to develop new and affordable biochemicals. CysBio is making cost-effective and novel biochemicals via sustainable fermentation processes. Through advanced synthetic biology and metabolic engineering approaches microorganisms are engineered to convert simple sugars into desired biochemical products. This makes it
- [inVentiv Health](http://danskbiotek.dk/news/inventiv-health/)
- [Acesion Pharma receives 5M DKK from Innovation Fund Denmark to support human Proof-of-Concept study in Atrial Fibrillation (AF)](http://danskbiotek.dk/news/acesion-pharma-receives-5m-dkk-from-innovation-fund-denmark-to-support-human-proof-of-concept-study-in-atrial-fibrillation-af/) - COPENHAGEN, Denmark — 12 March 2019: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces that Innovation Fund Denmark has granted the Company 4,965,000 DKK from the Fund’s ‘Innobooster’ program. The Grant will support the conduction of Acesion’s first study in
- [Xenia Pharma](http://danskbiotek.dk/news/xenia-pharma/)
- [Zymenex A/S](http://danskbiotek.dk/news/zymenex-as/)
- [MethylDetect ApS](http://danskbiotek.dk/news/methyl-detect-aps/)
- [LBKPATENT ApS](http://danskbiotek.dk/news/lbkpatent-aps/)
- [Vaccibody announces collaboration to study VB10.16 and atezolizumab (Tecentriq®) in advanced cervical cancer](http://danskbiotek.dk/news/vaccibody-announces-collaboration-to-study-vb10-16-and-atezolizumab-tecentriq-in-advanced-cervical-cancer/) - Oslo, Norway, 13 February, 2019 Vaccibody AS, a clinical stage immuno-oncology company, announced today that it has entered into a collaboration with Roche to explore a combination of Vaccibody’s VB10.16 and the PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced cervical cancer. Vaccibody expects to start a phase II study with up to 50
- [Vaccibody AS – NOK 230 million (EUR 23.6 million) private placement successfully placed](http://danskbiotek.dk/news/vaccibody-as-nok-230-million-eur-23-6-million-private-placement-successfully-placed/) - Oslo, 14 February 2019 Reference is made to the press release by Vaccibody AS ("Vaccibody" or the "Company") on 13 February 2019 regarding a contemplated offer of new shares (the "Offer Shares") in a private placement to raise gross proceeds of approximately NOK 230 million (the "Private Placement"). The Company is pleased to announce that
- [Y-mAbs Therapeutics to Present at PEGS Boston](http://danskbiotek.dk/news/y-mabs-therapeutics-to-present-at-pegs-boston/) - NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that its Chief Scientific Officer, Mahiuddin Ahmed, PhD, will give a presentation titled “Past, Present and
- [ELIXIR Innovation and SME Forum: Genomics and Associated Data in National Healthcare Initiatives](http://danskbiotek.dk/news/elixir-innovation-and-sme-forum-genomics-and-associated-data-in-national-healthcare-initiatives/)
- [MinervaX Announces Award of 4.4 Million Euro in Investment from Novo Holdings REPAIR Impact Fund and Sunstone Capital for Further Clinical Development of the Company's Vaccine Against Group B Streptococcus (GBS)](http://danskbiotek.dk/news/minervax-announces-award-of-4-4-million-euro-in-investment-from-novo-holdings-repair-impact-fund-and-sunstone-capital-for-further-clinical-development-of-the-companys-vaccine-against-group-b-strepto/)
- [Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle](http://danskbiotek.dk/news/mabs-announces-appointment-of-gerard-ber-to-its-board-of-directors-and-planned-departure-of-michael-buschle/) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the appointment of the molecular nuclear medicine executive, Dr. Gérard Ber, PhD to its board of directors, and the planned departure of Dr.
- [Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody](http://danskbiotek.dk/news/y-mabs-therapeutics-announces-fda-clearance-of-ind-for-its-bispecific-gd2-antibody/) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Investigational New Drug (“IND”) application for a humanized bispecific GD2 antibody. It
- [Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development](http://danskbiotek.dk/news/galecto-biotech-raises-e79-million-in-series-c-financing-co-led-by-ysios-capital-and-orbimed-to-advance-galectin-inhibitor-to-late-stage-clinical-development/) - Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies Copenhagen, Denmark, 26 October 2018 – Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing
- [Naxitamab Receives Positive Opinion for Orphan Medicinal Product Designation Approval in the EU](http://danskbiotek.dk/news/naxitamab-receives-positive-opinion-for-orphan-medicinal-product-designation-approval-in-the-eu/) - NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) today announced that the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for naxitamab, one of the Company’s lead product candidates, for the treatment of relapsed or refractory
- [Nordic countries lead from the front with new bioeconomy action plan](http://danskbiotek.dk/news/nordic-countries-lead-from-the-front-with-new-bioeconomy-action-plan/) - The Nordic countries have launched an ambitious plan to fast-track the development of a sustainable bioeconomy in the region. The Nordic Bioeconomy Programme describes 15 action points that push for a boost in research and innovation, policies to accelerate the transition, and stronger collaboration to develop new bio-based products and new markets. This will fuel
- [Y-mAbs Therapeutics Announces Pricing of Initial Public Offering](http://danskbiotek.dk/news/y-mabs-therapeutics-announces-pricing-of-initial-public-offering/) - NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $16.00 per
- [Danish industrial biotech company BioPhero ApS completes a €3 million seed investment and appoints new chairman of the board](http://danskbiotek.dk/news/danish-industrial-biotech-company-biophero-aps-completes-a-e3-million-seed-investment-and-appoints-new-chairman-of-the-board/) - Press Release: 17th September 2018 Today, BioPhero ApS has announced the closing of a seed investment of €3 million by Novo Seeds, Syngenta Ventures and Syddansk Innovation. BioPhero is a pioneer in the production of insect pheromones that are used as highly sustainable and eco-friendly active ingredients in products for controlling insect pests in agriculture.
- [Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma](http://danskbiotek.dk/news/y-mabs-receives-breakthrough-therapy-designation-for-naxitamab-for-the-treatment-of-high-risk-neuroblastoma/) - The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF, for the treatment of high risk neuroblastoma NEW YORK, August 21, 2018 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that the Company has received a Breakthrough Therapy designation for
- [Life Science Survey by 'Biotech and Money'](http://danskbiotek.dk/news/life-science-survey-by-biotech-and-money/) - Biotech and Money is an influential community of senior life science decision makers conducting impactful events, powerful thought leadership content and unique networking opportunities to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. The organisation is now inviting members of DANISH BIO – DANSK BIOTEK to
- [Ja, GDPR er superkedeligt!](http://danskbiotek.dk/news/ja-gdpr-er-superkedeligt/) - Og denne mail er sikkert blot én i rækken af en endeløs mailstrøm, hvor du skal læse og tage stilling til, hvad afsenderen må eller ønsker at gøre med dine persondata. DANISH BIO – DANSK BIOTEK kommer heller ikke uden om det. Med de nye regler om Databeskyttelse har DANISH BIO – DANSK BIOTEK oplysningspligt
- [Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials](http://danskbiotek.dk/news/symphogen-further-strengthens-its-immuno-oncology-pipeline-by-advancing-into-two-additional-clinical-trials/) - Seventh Program to enter Clinical Development at Symphogen Symphogen’s antibody platform is now validated for Immuno-Oncology to deliver unique Monoclonal Antibody products Symphogen, a private clinical late-stage antibody oncology focused biopharmaceutical company with a novel and differentiated antibody mixture pipeline, announced today that it has enrolled the first patients into two separate Phase 1 clinical
- [Generalforsamling 9. maj 2018 og godkendt Årsregnskab 2017](http://danskbiotek.dk/news/generalforsamling-i-dansk-biotek-2018/) - DANISH BIO – DANSK BIOTEK afholdt i år ordinær generalforsamling den 9. maj hos Novo i forbindelse med Årsmødet. Læs referatet samt det godkendte Årsregnskab for 2017 her.
- [Generalforsamling i DANISH BIO – DANSK BIOTEK den 9. maj 2018](http://danskbiotek.dk/news/generalforsamling-i-dansk-biotek-den-9-maj-2018/) - Den 9. maj 2018 kl. 13.30 hos NOVO, Tuborg Havnevej 19, 2900 Hellerup Dagsorden c.f. vedtægterne: a. Valg af dirigent b. Formandens beretning c. Godkendelse af regnskab for 2017 d. Fastsættelse af kontingent for 2018. Bestyrelsen indstiller, at kontingentet er uændret 4.000 kr. for virksomheder med mindre end 10 ansatte, 10.000 kr. for virksomheder med 10
- [Formanden har ordet: Vækstplan for life science vil gøre en forskel](http://danskbiotek.dk/news/formanden-har-ordet-vaekstplan-for-life-science-vil-gore-en-forskel/) - For et par uger siden præsenterede regeringen sin længe ventede Vækstplan for life science. I DANISH BIO – DANSK BIOTEK er vi meget tilfredse med Vækstplanen, der med en række nyttige tiltag forbedrer life science branchens rammebetingelser og øger den politiske bevågenhed. Et af de initiativer, der virkelig vil gøre en forskel, er beslutningen om
- [Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation](http://danskbiotek.dk/news/acesion-pharma-receives-approval-for-phase-i-study-in-atrial-fibrillation/) - Appoints Internationally Renowned Scientific Advisors COPENHAGEN, Denmark— 8 February 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy
- [YmAbs Announces Closing of $30 Million Extension of Private Equity Placement](http://danskbiotek.dk/news/ymabs-announces-closing-of-30-million-extension-of-private-equity-placement/) - Common stock placement extended to a total of $80 million as Sofinnova Ventures and Scopia Capital Management are added to Y-mAbs’ list of institutional shareholders Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that, further to its press release dated October 24, 2017, the Company
- [Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease](http://danskbiotek.dk/news/symphogen-receives-milestone-payment-for-initiation-of-phase-1b-trial-in-infectious-disease/) - COPENHAGEN, Denmark (November 30, 2017) – Symphogen, a private clinical late-stage antibody oncology-focused company with a novel and differentiated antibody mixture pipeline, announced today that the company has received a $5 million milestone payment from Genentech, a member of the Roche Group, triggered by the initiation of a Phase 1b clinical trial evaluating DSTA4637S, an
- [Formanden har ordet: Godt gået Orphazyme!](http://danskbiotek.dk/news/formanden-har-ordet-godt-gaet-orphazyme/) - For knap to uger siden lykkedes det Orphazyme at gå på Børsen i København! Selskabet solgte 7,5 mio. nye aktier til højeste udbudspris og fik tilført hele 600 mio. kroner fra 3900 nye aktionær. Efterspørgslen på at købe aktier var så stor, at Orphazyme valgte at lukke udbudsrunden en dag før tid. Med den succesfulde
- [MonTa Biosciences indgår samarbejde med amerikansk universitet om ny, lovende](http://danskbiotek.dk/news/monta-biosciences-indgar-samarbejde-med-amerikansk-universitet-om-ny-lovende/) - Det danske biotekselskab MonTa Biosciences har netop tegnet en licensaftale med UC San Diego Universitet omkring deres lovende kræftbehandling, der aktivt uddanner kroppens immunforsvar til at genkende og nedkæmpe kræftceller. ”Den nye licensaftale giver os eksklusivret på verdensplan og er et stort skridt imod en kommercialisering af vores kræftbehandling ” siger Simon Skjøde Jensen, Ph.d.
- [Orphazyme publishes offering circular and the indicative offer price range for its IPO](http://danskbiotek.dk/news/orphazyme-publishes-offering-circular-and-the-indicative-offer-price-range-for-its-ipo/) - Orphazyme, a Danish biotech company with a late stage orphan drug pipeline, today published an offering circular and the indicative price range in connection with its intended initial public offering (“IPO” or the “Offering”) and subsequent admission to trading and official listing of its shares on Nasdaq Copenhagen. The indicative offer price range is DKK 64
- [Årsregnskab 2016](http://danskbiotek.dk/news/dansk-biotek-arsregnskab-2016/)
- [Orphazyme announces intention to launch an Initial Public Offering](http://danskbiotek.dk/news/orphazyme-announces-intention-to-launch-an-initial-public-offering/) - Orphazyme, a Danish biotech company with a late stage orphan drug pipeline, announces its intention to launch an Initial Public Offering (“IPO” or “Offering”) of its shares and to apply for admission to trading and official listing on Nasdaq Copenhagen. The intended IPO is expected to consist of an issue of new shares to raise
- [YmAbs Raises $50 Million in Equity Financing](http://danskbiotek.dk/news/ymabs-raises-50-million-in-equity-financing/) - Y-mAbs Therapeutics, Inc. closes $50 million in a private placement led by HBM Healthcare Investments (HBM) and supported by current shareholders NEW YORK, October 24, 2017 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that it has closed a private placement among HBM Healthcare
- [NOME Annual Meeting and Start-Up Competition 24 October](http://danskbiotek.dk/news/nome-annual-meeting-on-24-october/) - Pan-Nordic mentor network NOME provides Nordic life science start-ups with the opportunity to present their life science company to a selection of industry people at the NOME Annual meeting. The overall goal is to link Biotech, Medtech and E-Health start-ups with investors, serial entrepreneurs and high profile life science executives. DANISH BIO – DANSK BIOTEK
- [Formanden har ordet: Gode takter, men for små skridt](http://danskbiotek.dk/news/formanden-har-ordet-gode-takter-men-for-sma-skridt/) - For nogle uger siden præsenterede regeringen sit erhvervs- og iværksætterudspil med 22 initiativer til at styrke Danmarks små og mellemstore virksomheder. Som ’appetizer’ til Erhvervsministeriets kommende Vækstplan for Life Science, er det værd at notere sig, at flere af initiativerne i erhvervs- og iværksætterudspillet bidrager positivt til det danske biotekmiljø: Etablering af aktiesparekonto Lavere skat
- [Symphogen presents promising results from a randomized Phase 2 study with Sym004](http://danskbiotek.dk/news/symphogen-presents-promising-results-from-a-randomized-phase-2-study-with-sym004/) - Oral presentation of efficacy and safety data of Sym004 in refractory metastatic colorectal cancer Symphogen today announced that the promising data from its Phase 2 study with Sym004, a mAb mixture targeting EGFR, has been selected for oral presentation on 11 September 2017 at the European Society for Medical Oncology (ESMO) 2017 Congress, taking place
- [PERMIDES: Innovation Vouchers for Personalized Medicine](http://danskbiotek.dk/news/permides-innovation-vouchers-for-personalized-medicine/) - Interesting EU project PERMIDES provides innovation vouchers for biopharma SMEs valued up to 60,000 € for cooperation projects with IT companies. PERMIDES aims at bringing together SMEs from the biopharmaceutical and IT sector to advance precision medicine through the development of novel digital solutions along the biopharmaceutical value chain. Biopharma companies are e.g. active in the area of
- [Workshop om barrierer og muligheder for offentlig-privat forskningssamarbejde inden for Personlig Medicin](http://danskbiotek.dk/news/workshop-om-barrierer-og-muligheder-for-offentlig-privat-forskningssamarbejde-inden-for-personlig-medicin/) - Området for Personlig Medicin har potentialet til at blive et vigtigt dansk forskningsområde med lovende muligheder inden for offentlig-privat samarbejde om udvikling af bedre og nye diagnostik – og behandlingsformer til gavn for patienterne. Bestyrelsen for den nationale strategi for Personlig Medicin 2017-2020 afholder derfor en workshop tirsdag 29. august kl. 11-15 i København med
- [Det danske EMA kandidatur](http://danskbiotek.dk/news/4187/) - Mens sommerferien nu er i gang i det meste af Danmark er Udenrigsministeriet aktuelt ved at lægge sidste hånd på det officielle danske EMA-kandidatur. Jævnfør beslutningen på Det Europæiske Råd den 22. – 23. juni (for mere info klik her) vil ministeriet senest den 31. juli skulle indsende Danmarks officielle kandidatur. I mellemtiden har Udenrigsministeriet udarbejdet en
- [Precision NanoSystems to host nanomedicines symposium](http://danskbiotek.dk/news/precision-nanosystems-to-host-nanomedicines-symposium/) - Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15th of July in Boston, MA. Following the success of last year’s inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Society’s Annual Meeting
- [YmAbs Granted Rare Pediatric Disease Designation for hu3F8 Antibody](http://danskbiotek.dk/news/ymabs-granted-rare-pediatric-disease-designation-for-hu3f8-antibody/) - The FDA grants Y-mAbs Therapeutics, Inc. a Rare Pediatric Disease Designation for hu3F8 for the treatment of Neuroblastoma
- [Most Innovative European Biotech SME Awards](http://danskbiotek.dk/news/most-innovative-european-biotech-sme-awards/) - The Most Innovative European Biotech SME Award is a unique annual initiative recognizing biotech innovation and its contribution to society. Depending on their field of activity, SMEs can apply in 3 categories: healthcare, agricultural or industrial biotech. Applications must be submitted online by COB Monday 3 July 2017 (extension might be possible). Two companies will
- [European Biotech Week: Celebrating Innovation Sept 25 – Oct 1, 2017](http://danskbiotek.dk/news/european-biotech-week-celebrating-innovation-sept-25-oct-1-2017/) - The European Biotech Week aims to facilitate a genuine dialogue about the science, the people, the companies and other organizations that are working on or are interested in the various biotech sectors. Every year during the last week of September, those involved in biotechnology are offered a unique opportunity to engage with the general public
- [Artikel i Børsen om investeringsmiljøet i Danmark](http://danskbiotek.dk/news/artikel-i-borsen-om-investeringsmiljoet-i-danmark/) - Dansk Bioteks formand Martin Bonde vil hive større beløb ud af investorerne. Det skal sikre, at nye selskaber står bedre i konkurrencen med biotek fra USA
- [Analyse af perspektiver og vækstbarrierer for udvikling af dansk biotek](http://danskbiotek.dk/news/analyse-af-perspektiver-og-vaekstbarrierer-for-udvikling-af-dansk-biotek/) - Analyse af perspektiver og vækstbarrierer for udvikling af dansk biotek IRIS Group har netop publiceret en analyse, der foretager en benchmarking af Hovedstadsregionens biotekklynge mod seks udenlandske biotekklynger. Læs analysen her.
- [Langsigtet finansiering af biotekselskaber – ja tak!](http://danskbiotek.dk/news/langsigtet-finansiering-af-biotekselskaber-ja-tak/) - For nylig kom den gode nyhed, at det danske biotekselskab Dermtreat har rejst DKK 120 mio. (USD 17,7 mio.) fra et konsortium bestående af bl.a. amerikanske Sofinnova Ventures (hovedinvestor), Novo Seeds og Lundbeckfonden Emerge. Med pengene har Dermtreat finansiering nok til at gennemføre sine kommende fase 2 forsøg med mundplasteret Rivelin og samtidig eksplorere yderligere
- [Generalforsamling i DANISH BIO – DANSK BIOTEK 2017](http://danskbiotek.dk/news/generalforsamling-2017/) - DANISH BIO – DANSK BIOTEK afholdt i år ordinær generalforsamling den 4. maj hos Novo Nordisk i forbindelse med Årsmødet. Læs referatet her.
- [Y-mAbs releases important news: Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer](http://danskbiotek.dk/news/y-mabs-releases-important-news-burtomab-receives-breakthrough-therapy-designation-for-advanced-form-of-pediatric-cancer/) - Burtomab, a drug for metastatic neuroblastoma, created by Memorial Sloan Kettering Cancer Center (MSK) and licensed to Y-mAbs Therapeutics, Inc. (YmAbs), has been granted Breakthrough Therapy Designation by the FDA for the treatment of pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis.
- [Medicon Valley Alliance Microbiome Summit 2017](http://danskbiotek.dk/news/medicon-valley-alliance-microbiome-summit-2017/) - Is Microbiome Research part of the answer to the question “How do we build the most vital life science cluster in northern Europe?” Do I want to be part of a platform for academia and business within the field of Microbiome research? Do I have something to offer and/or gain from participating in a summit
- [EU GDPR by NNIT](http://danskbiotek.dk/news/eu-gdpr-by-nnit/) - In doubt about how GDPR affects Life Sciences processes and systems? Join upcoming webinar and learn more.
- [Translational Medicine 2017 Conference, 24-26 Sept](http://danskbiotek.dk/news/translational-medicines-2017-conference-24-26-september-prague/) - The theme of the Translational Medicine 2017 Conference organized by EATRIS (European infrastructure for translational medicine) is “Enhancing predictivity in medicines development”. Several key note speakers from the industry will be presenting at the event in Prague, i.e. Mark Schmidt, Janssen R&D, Phill Murphy, GSK and EMA, Isabelle Moulon. See the full program here.
- [Gymnasielærere fik overrakt priser af Novo Nordisk Fonden](http://danskbiotek.dk/news/gymnasielaerere-fik-overrakt-priser-af-novo-nordisk-fonden/) - Thomas Skadhede, Paderup Gymnasium og Mårten Flø Jørgensen, Bagsværd Kostskole og Gymnasium fik torsdag den 4/5 2017 officielt overrakt Novo Nordisk Fondens Gymnasielærerpris 2017. Prisen anerkender lærere, som har ydet et markant bidrag til den biologiske naturvidenskabelige undervisning og har til formål at sætte fokus på det høje faglige niveau i undervisning i gymnasierne Der uddeles årligt to
- [Bionedbrydelig kugle og mordgåder bag tildeling af Novo Nordisk Fondens Gymnasielærerpris 2017](http://danskbiotek.dk/news/bionedbrydelig-kugle-og-mordgader-bag-tildeling-af-novo-nordisk-fondens-gymnasielaererpris-2017/) - Gymnasielærere i Bagsværd i Nordsjælland og Paderum ved Randers modtager Novo Nordisk Fondens Gymnasielærerpris 2017. Kan der opfindes en bionedbrydelig kugle til brug ved jagt, så man undgår lidelser for dyr, der slæber rundt på hagl i kroppen efter et mislykket skud? Det er et af de spørgsmål, lektor Mårten Flø Jørgensen sammen med sine
- [Life science i verdensklasse](http://danskbiotek.dk/news/life-science-i-verdensklasse/) - Anbefalinger fra regeringens vækstteam for life science Marts 2017
- [YmAbs’ 131I-8H9 Receives EU Orphan Drug Designation](http://danskbiotek.dk/news/ymabs-131i-8h9-receives-eu-orphan-drug-designation/) - Y-mAbs Therapeutics, Inc. receives first European Orphan Drug Designation NEW YORK, March 1, 2017 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that 131I-8H9 for the treatment of Refractory Leptomeningeal Metastasis from Neuroblastoma has been designated an orphan drug by the European Medicines Agency
- [Gymnasielærerprisen 2017 fra DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden](http://danskbiotek.dk/news/gymnasielaererprisen-2017-fra-dansk-biotek-og-novo-nordisk-fonden-2/) - Indstillingsskema Novo Nordisk Fondens Gymnasielærerpris 2017 Opslag Novo Nordisk Fondens Gymnasielærerpris 2017 DANISH BIO – DANSK BIOTEK indkalder indstillinger til Novo Nordisk Fondens Gymnasielærerpris 2017. Novo Nordisk Fondens Gymnasielærerpris blev indstiftet i 2014 af DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden. Prisen har til formål at sætte fokus på det høje faglige niveau
- [DANISH BIO – DANSK BIOTEK støtter op om de syv grundprincipper for lige og åben adgang til sundhedsdata](http://danskbiotek.dk/news/dansk-biotek-stotter-op-om-de-syv-grundprincipper-for-lige-og-aben-adgang-til-sundhedsdata/) - 7 principper for sundhedsdata
- [Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen](http://danskbiotek.dk/news/forward-pharma-agrees-to-enter-into-settlement-and-license-agreement-with-biogen/) - Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory approvals Forward Pharma A/S (NASDAQ:FWP)
- [YmAbs Raises $12 Million in Equity Funding](http://danskbiotek.dk/news/ymabs-raises-12-million-in-equity-funding/) - Y-mAbs Therapeutics, Inc. closes $12 million in private placement among current shareholders NEW YORK, January 9, 2017 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing. innovative treatments for patients with cancer, today announced that it has closed a private placement predominantly among its current shareholders raising $12 million. No placement agent was
- [Dansk biotekfirma sigter mod ny fase](http://danskbiotek.dk/news/dansk-biotekfirma-sigter-mod-ny-fase/) - Det danske biotekselskab Minervax melder om positive resultater fra et fase 1-forsøg med dets vaccine mod livsfarlige infektioner hos nyfødte og er ivrig efter at udnytte momentum til at fortsætte ind i fase 2.
- [IO Biotech closes Series A Round including new investor Sunstone Capital to the investor syndicate](http://danskbiotek.dk/news/io-biotech-closes-series-a-round-including-new-investor-sunstone-capital-to-the-investor-syndicate/) - IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory targets to treat cancer. IO Biotech is focused on unlocking the full potential of the immune system to recognize and attack cancer cells. Check point vaccines have a unique dual mode of action leading to simultaneous activation of anti-cancer immune responses and direct
- [Save the Date for DKBIO' 17: Danish Science & the Citi](http://danskbiotek.dk/news/save-the-date-for-dkbio-17-danish-science-the-citi/) - Join us in New York to meet with top investors, pharma & partners hosted at Citi Headquarters. -Special track on entrepreneurial drive in medicine sponsored by NOVO SEEDS -Planing your financing strategy Start-up through Public -Deep dive into how the Trump Administration might affect industry regulations and hear about pricing direct from payers -Get the
- [Gymnasielærerprisen 2017 fra DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden](http://danskbiotek.dk/news/gymnasielaererprisen-2017-fra-dansk-biotek-og-novo-nordisk-fonden/)
- [Stenrig Novo-fond styrer uden om Danmark](http://danskbiotek.dk/news/stenrig-novo-fond-styrer-uden-om-danmark/) - Det stenrige investeringsselskab bag Novo Nordisk og Novozymes bruger sjældnere og sjældnere sine milliarder på at investere i nye iværksættervirksomheder herhjemme i Danmark. På trods af Novo-fondens danske rødder ender langt de fleste venturepenge i amerikanske firmaer.
- [Acesion Pharma er bedste Life Sciences-virksomhed](http://danskbiotek.dk/news/acesion-pharma-er-bedste-life-sciences-virksomhed/) - Prisen som EY Entrepreneur Of The Year i kategorien Life Sciences går i år til Acesion Pharma A/S, som med god entrepreneurånd leverer science med et stort markedspotentiale inden for behandling af akut og kronisk hjerteflimmer (atrial fibrillation).
- [Acesion Pharma recruits an experienced life science Chief Financial Officer](http://danskbiotek.dk/news/acesion-pharma-recruits-an-experienced-life-science-chief-financial-officer/) - Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), announced that it has recruited Jakob Dynnes Hansen as its Chief Financial Officer to succeed Herik Moltke, who will continue as CFO of Scandinavian Micro Biodevices that was recently acquired by Zoetis. Jakob joins Acesion from Evolva, a Swiss biotech company, where
- [Dansk medicoselskab modtager millioner fra kinesisk investor](http://danskbiotek.dk/news/dansk-medicoselskab-modtager-millioner-fra-kinesisk-investor/) - Det danske medicoselskab Acarix, der beskæftiger sig med medicinsk udstyr, har modtaget et tocifret millionbeløb fra det kinesiske selskab Puhua Jingxin. Det skriver selskabet i en pressemeddelelse: Selskabet, der i 2009 blev et såkaldt 'spin-out' fra medicoselskabet Coloplast, har siden 2010 haft investorerne SEED Capital og Sunstone life science Ventures som hovedinvestorer, men får altså
- [Dansk life science har overhalet Sverige](http://danskbiotek.dk/news/dansk-life-science-har-overhalet-sverige/) - Nu er det jo ikke fordi, at det skal udvikle sig til en konkurrence mellem den danske og den svenske life science-industri, men Danmark har alligevel lagt sig i spidsen på en række områder, viser en ny analyse fra Medicon Valley Alliance. Området Greater Copenhagen har over de sidste ti år udviklet sig til at
- [Dansk-ledet biotekfirma rejser tocifret millionbeløb](http://danskbiotek.dk/news/dansk-ledet-biotekfirma-rejser-tocifret-millionbelob/)
- [Nature: "Some suggestions for avoiding common mistakes made in life sciences startups"](http://danskbiotek.dk/news/nature-some-suggestions-for-avoiding-common-mistakes-made-in-life-sciences-startups/) - As members of a life sciences advisory and investment banking group, my partners and I have often noted that life sciences companies fall victim to the same mistakes and misconceptions, repeated again and again. These failures mostly hinge upon company management misunderstanding the fundamentals of market dynamics and failing to appreciate the importance of the

## Pages

- [Annual reports](http://danskbiotek.dk/about-us/annual-reports/) - DANISH BIO – DANSK BIOTEK prepares annual reports that give a retrospective of the organization's work in the past year. The annual reports are available for free use in PDF format on this page (in Danish).
- [Board of Directors](http://danskbiotek.dk/about-us/board-of-directors/)
- [Contact](http://danskbiotek.dk/contact/)
- [Report: Bridging the Gap - Transforming EU Biotech Policy](http://danskbiotek.dk/report-bridging-the-gap-transforming-eu-biotech-policy/) - It is finally here! We have been waiting to publish this report on the state of European biotech vs. US biotech which has been produced in cooperation with NovoFonden and ADC Consulting. Report_-Bridging-the-Gap-–-Transforming-EU-Biotech-Policy.pdf The outcome is concerning, however, not very surprising. The US takes a lead on almost every area, and most notably in terms
- [Membership](http://danskbiotek.dk/membership/) - DANISH BIO – DANSK BIOTEK is an organisation for: Biotech companies and their parent companies in Denmark that research, develop or produce pharmaceuticals or other products that are essentially based on biotechnology (registered as full members). Investment funds that actively own biotech companies (registered as full members). Private companies and organisations who significantly provide advice or other
- [Articles of Association](http://danskbiotek.dk/about-us/articles-of-association/) - ARTICLES OF ASSOCIATION DANISH BIO - DANSK BIOTEK (CVR no. 28 43 65 72) § 1 Name The name of the Association is DANISH BIO - DANSK BIOTEK – with the alias Foreningen af Bioteknologiske Industrier i Danmark. § 2 Object The object of the Association is to promote the conditions for biotechnological research,
- [Pictures from Biotech Spring Gala 2023](http://danskbiotek.dk/about-us/pictures-from-biotech-spring-gala-2023/) - Having started a new tradition only last year, we are proud to share the pictures of this year's very successful Biotech Spring Gala 2023.
- [About Us](http://danskbiotek.dk/about-us/) - DANISH BIO – DANSK BIOTEK is an active trade organisation which is in a continuous dialogue with the Danish authorities and who is recognised as an authority regarding biotechnology in the public debate. DANISH BIO – DANSK BIOTEK has furthermore taken steps to increase the public knowledge about modern biotechnology. The organisation publishes articles, participates
- [Privacy Policy](http://danskbiotek.dk/privacy-policy/) - This Privacy Policy sets out the steps that DANISH BIO – DANSK BIOTEK takes to ensure that any information provided to us is kept secure and confidential and is used only for the purposes for which it is provided. Please read the statement carefully in order to understand how we process, use and disclose your
- [Useful Links](http://danskbiotek.dk/useful-links/) - DANISH BIO – DANSK BIOTEK is located in the center of Medicon Valley, but has great cooperation with many different educational and member organisations that exist throughout the country. On this page are links to several of the related organisations' websites. DANISH BIO – DANSK BIOTEK is also a member of the European biotechnology organisation
- [Newsletters](http://danskbiotek.dk/chairmans-corner/newsletters/) - DANISH BIO – DANSK BIOTEK issues newsletters to members and other stakeholders approximately 3-4 times annually. The newsletters provide a status of current activities, including profiles of new members. The newsletters are distributed via email and uploaded here on the page as well.
- [DANISH BIO – DANSK BIOTEK in Brief](http://danskbiotek.dk/about-us/dansk-biotek-briefly/) - DANISH BIO – DANSK BIOTEK was established in 1987 as an industry association for Danish biotech companies with the aim of promoting the possibilities for biotechnological research, development and production in Denmark and taking care of corporate interests in this regard, both nationally and internationally. DANISH BIO – DANSK BIOTEK has offices in Copenhagen Bio Science
- [Partners](http://danskbiotek.dk/about-us/partners/) - DANISH BIO – DANSK BIOTEK has several useful collaboration partners. Please find below a short description of each of these as well as a link to their websites. Copenhagen Spin-outs Copenhagen Spin-outs is a collaboration between the academic research environment and industry with a focus on innovation and commercialisation of biotech research in the capital
- [FAQ](http://danskbiotek.dk/about-us/faq/) - Here are the most frequently asked questions to and answers from DANISH BIO – DANSK BIOTEK.
- [Vision and Mission](http://danskbiotek.dk/about-us/vision-and-mission/) - Vision DANISH BIO – DANSK BIOTEK's vision is to make Denmark the best country in the world to drive biotechnological research and production. Mission DANISH BIO – DANSK BIOTEK is working to ensure the best possible conditions for research, development, and production for the biotechnology companies in Denmark. Goals The ambition of DANISH BIO –
- [Members' List](http://danskbiotek.dk/members-list/)
- [The Biotech Industry](http://danskbiotek.dk/about-us/the-biotech-industry/) - A few facts The biotechnology industry emerged in the 1970s, based largely on the publication of a new recombinant DNA technique, which is a method of making proteins such as human insulin and other therapies in cultured cells under controlled manufacturing conditions. Since then biotechnology has created more than 200 new therapies and vaccines, including
- [Chairman's Corner](http://danskbiotek.dk/chairmans-corner/) - Hans Schambye, 2021-2023 CEO - Md, PhD Medical Sciences Galecto, Inc. Served as Chief Executive Officer of ReceptIcon from 2006 to 2009 and as CEO of Gastrotech Pharma A/S from 2004 to 2006 Served as Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company Hans has co-founded several biotech companies,
- [Cookies](http://danskbiotek.dk/cookies/) - Information about cookies A cookie is a small text file, which is placed on your computer or other device. It makes it possible for us to recognize your computer and gather information about which pages and functions are visited with your computer. Cookies contain only anonymous information. Cookies are used by most websites and are
- [Add new member](http://danskbiotek.dk/membership/add-new-member/)
- [Send news](http://danskbiotek.dk/send-news/)

## MailPoet Page

- [MailPoet Page](http://danskbiotek.dk/?mailpoet_page=captcha) - [mailpoet_page]
- [MailPoet Page](http://danskbiotek.dk/?mailpoet_page=subscriptions) - [mailpoet_page]

## Members

- [Orbis Medicines ApS](http://danskbiotek.dk/members/orbis-medicines-aps/)
- [Mazanti Andersen](http://danskbiotek.dk/members/mazanti-andersen-korso-jensen/)
- [NordicBlue ApS](http://danskbiotek.dk/members/nordicblue-aps/)
- [QuantumCell ApS](http://danskbiotek.dk/members/quantumcell-aps/)
- [Mastitia ApS](http://danskbiotek.dk/members/mastitia-aps/)
- [Lophora ApS](http://danskbiotek.dk/members/lophora-aps/)
- [Probmet](http://danskbiotek.dk/members/probmet/)
- [KLIFO A/S](http://danskbiotek.dk/members/klifo-as/)
- [World Courier A/S](http://danskbiotek.dk/members/world-courier-as/)
- [Neumirna Therapeutics](http://danskbiotek.dk/members/neumirna-therapeutics/)
- [Mediome Advisory](http://danskbiotek.dk/members/mediome-advisory/)
- [1stBiome ApS](http://danskbiotek.dk/members/1stbiome-aps/)
- [PreTT ApS](http://danskbiotek.dk/members/prett-aps/)
- [EJ Consulting](http://danskbiotek.dk/members/ej-consulting/)
- [TFS Health Science](http://danskbiotek.dk/members/hanna-karolina-stegared-pace-tfs-health-science/)
- [NEMERA](http://danskbiotek.dk/members/nemera/)
- [PharmaRelations](http://danskbiotek.dk/members/pharmarelations/)
- [Ozack](http://danskbiotek.dk/members/ozack/)
- [Amass technologies aps](http://danskbiotek.dk/members/amass-technologies-aps/)
- [Muna Therapeutics](http://danskbiotek.dk/members/muna-therapeutics/)
- [Adcendo ApS](http://danskbiotek.dk/members/adcendo-aps/)
- [MinervaX ApS](http://danskbiotek.dk/members/minervax-aps/)
- [Draupnir Bio](http://danskbiotek.dk/members/draupnir-bio/)
- [ELEVATE IP](http://danskbiotek.dk/members/elevate-ip/)
- [BOOST Pharma ApS](http://danskbiotek.dk/members/boost-pharma-aps/)
- [IQVIA Solutions Denmark A/S](http://danskbiotek.dk/members/iqvia-solutions-denmark-a-s/)
- [DTU: Centre for Diagnostics](http://danskbiotek.dk/members/dtu-centre-for-diagnostics/)
- [Vibraint ApS](http://danskbiotek.dk/members/vibraint-aps/)
- [Bech-Bruun](http://danskbiotek.dk/members/bech-bruun/)
- [BioColor Aps](http://danskbiotek.dk/members/biocolor-aps/)
- [de novo foundry ApS](http://danskbiotek.dk/members/biorigin-aps/)
- [Normik Advisors](http://danskbiotek.dk/members/normik-advisors/)
- [CMC Quality ApS](http://danskbiotek.dk/members/cmc-quality-aps/)
- [June Bio ApS](http://danskbiotek.dk/members/june-bio-aps/)
- [Breye Therapeutics ApS](http://danskbiotek.dk/members/breye-therapeutics/)
- [Nepsone Pharmaceuticals](http://danskbiotek.dk/members/nepsone-pharmaceuticals/)
- [Zevra Denmark A/S](http://danskbiotek.dk/members/zevra-denmark-a-s/)
- [AIMS International-Denmark](http://danskbiotek.dk/members/aims-international-denmark/)
- [Cell to Cure](http://danskbiotek.dk/members/cell-to-cure/)
- [aera A/S](http://danskbiotek.dk/members/aera-a-s/)
- [IDEA Pharma](http://danskbiotek.dk/members/idea-pharma/)
- [Imprint Medicine](http://danskbiotek.dk/members/imprint-medicine/)
- [Analona Therapeutics](http://danskbiotek.dk/members/analona-therapeutics/)
- [LYKKESFELDT ADVOKATFIRMA](http://danskbiotek.dk/members/lykkesfeldt-advokatfirma/)
- [SprayFleet ApS](http://danskbiotek.dk/members/sprayfleet-aps/)
- [Symphogen A/S](http://danskbiotek.dk/members/symphogen-as/)
- [Pephexia Therapeutics](http://danskbiotek.dk/members/pephexia-therapeutics/)
- [Proxi Biotech](http://danskbiotek.dk/members/proxi-biotech/)
- [EfficiencyTactics](http://danskbiotek.dk/members/efficiencytactics/)
- [Zyneyro](http://danskbiotek.dk/members/zyneyro/)
- [Gefjon Pharma ApS](http://danskbiotek.dk/members/gefjon-pharma-aps/)
- [LIFE SCIENCE PLUS Advokater](http://danskbiotek.dk/members/life-science-plus-advokater/)
- [Sunstone Life Science Ventures A/S](http://danskbiotek.dk/members/sunstone-capital-life-science-ventures/)
- [AFYX Therapeutics A/S](http://danskbiotek.dk/members/afyx-therapeutics-a-s/)
- [Hemab](http://danskbiotek.dk/members/hemab/)
- [Worldwide Clinical Trials](http://danskbiotek.dk/members/worldwide-clinical-trials/)
- [LEO Pharma A/S](http://danskbiotek.dk/members/leo-pharma-as/)
- [Fida Biosystems ApS](http://danskbiotek.dk/members/fida-tech-aps/)
- [AGC Biologics](http://danskbiotek.dk/members/agc-biologics/)
- [Ellegaard Göttingen Minipigs](http://danskbiotek.dk/members/ellegaard-gottingen-minipigs/)
- [Commit Biologics](http://danskbiotek.dk/members/commit-biologics/)
- [Labcorp Drug Development Laboratories Limited](http://danskbiotek.dk/members/labcorp-drug-development-laboratories-limited/)
- [Blue Cell Therapeutics Aps](http://danskbiotek.dk/members/blue-cell-therapeutics-aps/)
- [Løwenstein IP consulting ApS](http://danskbiotek.dk/members/lowenstein-ip-consulting-aps/)
- [Lonza](http://danskbiotek.dk/members/lonza/)
- [Herlev Pharma Service Aps](http://danskbiotek.dk/members/herlev-pharma-service-aps/)
- [Y-mAbs Therapeutics A/S](http://danskbiotek.dk/members/y-mabs-therapeutics-as/)
- [BioZeNergy Consulting](http://danskbiotek.dk/members/biozenergy-consulting/)
- [Midas Pharma Nordics](http://danskbiotek.dk/members/midas-pharma-nordics/)
- [Amplify Therapeutics ApS](http://danskbiotek.dk/members/amplify-therapeutics-aps/)
- [TFS Health Science](http://danskbiotek.dk/members/tfs-health-science/)
- [Dania Therapeutics ApS](http://danskbiotek.dk/members/dania-therapeutics-aps/)
- [Epoqe Pharma](http://danskbiotek.dk/members/epoqe-pharma/)
- [AnRes Clinical ApS](http://danskbiotek.dk/members/anres-clinical-aps/)
- [Sophion Bioscience A/S](http://danskbiotek.dk/members/sophion-bioscience-as-part-of-biolin-scientific/)
- [Biobridge Partners](http://danskbiotek.dk/members/biobridge-partners/)
- [Vesper Bio](http://danskbiotek.dk/members/vesper-bio/)
- [GLX Analytix](http://danskbiotek.dk/members/glx-analytix/)
- [Novonesis A/S](http://danskbiotek.dk/members/novozymes-as/)
- [Teitur Trophics](http://danskbiotek.dk/members/teitur-trophics/)
- [Kripthonite Therapeutics](http://danskbiotek.dk/members/kripthonite-therapeutics/)
- [InProTher](http://danskbiotek.dk/members/inprother/)
- [Raven biosciences](http://danskbiotek.dk/members/raven-biosciences/)
- [Sanos Group](http://danskbiotek.dk/members/sanos-group/)
- [XY Therapeutics](http://danskbiotek.dk/members/xy-therapeutics/)
- [ResoTher Pharma](http://danskbiotek.dk/members/resother-pharma/)
- [Hoba Therapeutics](http://danskbiotek.dk/members/hoba-therapeutics/)
- [ZBM Patents](http://danskbiotek.dk/members/zbm-patents/)
- [Nasdaq Copenhagen](http://danskbiotek.dk/members/nasdaq-copenhagen/)
- [Tetra Pharm Technologies](http://danskbiotek.dk/members/tetra-pharm-technologies/)
- [BioInnovation Institute Foundation](http://danskbiotek.dk/members/bioinnovation-institute-foundation/)
- [Curasight ApS](http://danskbiotek.dk/members/curasight-aps/)
- [Cessatech A/S](http://danskbiotek.dk/members/cessatech-a-s/)
- [Acesion Pharma ApS](http://danskbiotek.dk/members/acesion-pharma/) - Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events, and
- [Esrum Biotech Aps](http://danskbiotek.dk/members/esrum-biotech-aps/)
- [Fuse Vectors ApS](http://danskbiotek.dk/members/fuse-vectors-aps/)
- [MC2 Therapeutics](http://danskbiotek.dk/members/mc2-biotek-aps/)
- [PKF Munkebo Eriksen Funch](http://danskbiotek.dk/members/pkf-munkebo-vindelev/)
- [Loma Therapeutics](http://danskbiotek.dk/members/loma-therapeutics/)
- [Embark Laboratories ApS](http://danskbiotek.dk/members/embark-laboratories-aps/)
- [Aptol Pharma](http://danskbiotek.dk/members/aptol-pharma/)
- [Zealand Pharma A/S](http://danskbiotek.dk/members/zealand-pharma-as/)
- [LINK Medical ApS](http://danskbiotek.dk/members/link-medical-aps/)
- [Tailwind Biotech](http://danskbiotek.dk/members/tailwind-biotech/)
- [Kiox Pharmaceuticals](http://danskbiotek.dk/members/kiox-pharmaceuticals/)
- [Bristol Myers Squibb](http://danskbiotek.dk/members/bristol-myers-squibb/)
- [Synamics Therapeutics](http://danskbiotek.dk/members/synamics-therapeutics/)
- [Nykode Therapeutics Denmark A/S](http://danskbiotek.dk/members/nykode-therapeutics-denmark-a-s/)
- [Genmab A/S](http://danskbiotek.dk/members/genmab-as/)
- [Aida Oncology](http://danskbiotek.dk/members/aida-oncology/)
- [Black Swans Exist ApS](http://danskbiotek.dk/members/black-swans-exist-aps/)
- [BioSpringbok ApS](http://danskbiotek.dk/members/biospringbok-aps/)
- [BioPhenyx ApS](http://danskbiotek.dk/members/biophenyx-aps/)
- [Coulter Partners](http://danskbiotek.dk/members/coulter-partners/)
- [Ousia Pharma](http://danskbiotek.dk/members/ousia-pharma/)
- [Syneos Health](http://danskbiotek.dk/members/syneos-health/)
- [Plougmann Vingtoft A/S](http://danskbiotek.dk/members/plougmann-vingtoft-as/)
- [Plesner Advokatpartnerselskab](http://danskbiotek.dk/members/plesner/)
- [Pharma IT ApS](http://danskbiotek.dk/members/pharma-it-aps/)
- [Novo Nordisk Foundation](http://danskbiotek.dk/members/novo-nordisk-foundation/)
- [KU Research & Innovation](http://danskbiotek.dk/members/ku-research-innovation/)
- [Kromann Reumert](http://danskbiotek.dk/members/kromann-reumert/)
- [Inspicos P/S](http://danskbiotek.dk/members/inspicos-as/)
- [HØIBERG](http://danskbiotek.dk/members/hoiberg-as/)
- [Gorrissen Federspiel](http://danskbiotek.dk/members/gorrissen-federspiel/)
- [EY — Ernst & Young](http://danskbiotek.dk/members/ey-ernst-young/)
- [Devote Consulting](http://danskbiotek.dk/members/devote-consulting/)
- [Danske Bank](http://danskbiotek.dk/members/danske-bank/)
- [Copenhagen Capacity](http://danskbiotek.dk/members/copenhagen-capacity/)
- [Accura Advokataktieselskab](http://danskbiotek.dk/members/accura-advokataktieselskab/)
- [Novo Holdings A/S](http://danskbiotek.dk/members/novo-as/)
- [Lundbeckfonden BioCapital](http://danskbiotek.dk/members/lundbeckfond-ventures/)
- [Enduro](http://danskbiotek.dk/members/enduro/)
- [Biosyntia ApS](http://danskbiotek.dk/members/biosyntia-aps/)
- [ViroGates A/S](http://danskbiotek.dk/members/virogates-as/)
- [Unilabs A/S](http://danskbiotek.dk/members/unilabs-a-s/)
- [Synklino ApS](http://danskbiotek.dk/members/synklino-aps/)
- [Reapplix](http://danskbiotek.dk/members/reapplix/)
- [PanCryos](http://danskbiotek.dk/members/pancryos/)
- [Novo Nordisk A/S](http://danskbiotek.dk/members/novo-nordisk-as/)
- [NMD Pharma A/S](http://danskbiotek.dk/members/nmd-pharma-a-s/)
- [Niels Clauson-Kaas A/S](http://danskbiotek.dk/members/niels-clauson-kaas-as/)
- [Gubra](http://danskbiotek.dk/members/gubra/)
- [ExpreS2ion Biotechnologies](http://danskbiotek.dk/members/expres2ion-biotechnologies/)
- [Contera Pharma A/S](http://danskbiotek.dk/members/contera-pharma/)
- [Cirqle Biomedical](http://danskbiotek.dk/members/cirqle-biomedical/)
- [Bioneer A/S](http://danskbiotek.dk/members/bioneer-as/)
- [Avilex Pharma](http://danskbiotek.dk/members/avilex-pharma/)
- [Specific Pharma CTSM](http://danskbiotek.dk/members/nomeco-ctsm/)
- [PILA PHARMA](http://danskbiotek.dk/members/pila-pharma/)
- [FUJIFILM Diosynth Biotechnologies](http://danskbiotek.dk/members/biogen-manufacturing-aps/)
- [Initiator Pharma A/S](http://danskbiotek.dk/members/initiator-pharma-a-s/)
- [Eir Ventures](http://danskbiotek.dk/members/eir-ventures/)
- [KEMPEN & CO](http://danskbiotek.dk/members/kempen-co/)
- [Sound Bioventures Management ApS](http://danskbiotek.dk/members/sound-bioventures-management-aps/)
- [Henlez](http://danskbiotek.dk/members/henlez/)
- [Galecto, Inc.](http://danskbiotek.dk/members/galecto-biotech/)
- [PwC](http://danskbiotek.dk/members/pwc/)
- [Your Special Delivery Service](http://danskbiotek.dk/members/your-special-delivery-service/)
- [MonTa Biosciences](http://danskbiotek.dk/members/monta-biosciences/)
- [Antag Therapeutics ApS](http://danskbiotek.dk/members/antag-therapeutics-aps/)
- [The Novo Nordisk Foundation Center for Biosustainability](http://danskbiotek.dk/members/the-novo-nordisk-foundation-center-for-biosustainability/)
- [Xplico ApS](http://danskbiotek.dk/members/xplico-aps/)

## Events

- [Driving Decentralised Clinical Trials - BIG DISCOUNT FOR MEMBERS - Register before 26/6](http://danskbiotek.dk/events/driving-decentralised-clinical-trials-big-discount-for-members-register-before-26-6/) - This four-day course introduces you to the state of affairs in implementing digital solutions in clinical trials. It is invaluable to anyone involved with clinical research and trials. Professionals involved in clinical trials face numerous opportunities in these changing times. But to contribute and create value, it is necessary to understand how you can implement
- [Biotech Salon: You're Developing a Drug - So Why Does the Device Matter?](http://danskbiotek.dk/events/biotech-salon-yourre-developing-a-drug-so-why-does-the-device-matter/) - Practical insights for drug‑focused biotechs entering the world of combination products As biotech companies expand beyond drug-only development into combination products, new complexities emerge—particularly around device strategy, development timelines, and regulatory expectations. To support this transition, Nemera, in collaboration with Dansk Bio, invites you to a focused half-day salon exploring what it truly takes to
- [DANISH BIO-DANSK BIOTEK Annal General Meeting](http://danskbiotek.dk/events/danish-bio-dansk-biotek-general-meeting/) - Dear member, It is once again time for our General Meeting. Please see the agenda and power of attorney through these links: DANISH BIO - DANSK BIOTEK - Notice to convene annual general meeting on 27 May 2025 Power of attorney for the annual general meeting in DANISH BIO - DANSK BIOTEK 2025 and below:
- [ANNUAL GENERAL MEETING OF DANISH BIO-DANSK BIOTEK 2026](http://danskbiotek.dk/events/danish-bio-dansk-biotek-agm-2026/) - Dear member, It is again time for our Annual General Meeting, and this time, we will be convening in the office of Plesner, Amerika Plads 37, 2100 Copenhagen. This agenda is as follows, and please note the below link to PoA should you not be able to attend in person. Power of attorney for
- [Extraordinary General Meeting](http://danskbiotek.dk/events/extraordinary-general-meeting/) - Dear member, Due to insufficient number of votes participating in our Annual General Meeting Tuesday 28 May 2024, we hereby convene an Extraordinary General Meeting on 10 June 2024. Please find the documents of the Meeting below. DANISH BIO - DANSK BIOTEK - Notice to convene Extraordinary General Meeting Updated Articles of Association 28
- [Discount agreement with World Patient Safety Congress](http://danskbiotek.dk/events/discount-agreement-with-world-patient-safety-congress/) - We have entered a discount agreement with Terapinn on registration fees for World Patient Safety Congress. The discount is 50%, and you can get the code by contacting ps@danskbiotek.dk
- [Meeting in Legal Affairs Committee](http://danskbiotek.dk/events/meeting-in-legal-affairs-committee/)
- [HPS After Hours: Clinical Trial Insurance for Small Biotech](http://danskbiotek.dk/events/hps-after-hours-clinical-trial-insurance-for-small-biotech/) - Clinical development involves significant regulatory and financial risk. Ensuring that your clinical program is properly insured is essential for both regulatory compliance and protection of the company. Herlev Pharma Service, in collaboration with Danish Bio, invites founders, management teams and clinical development professionals from small biotech companies to an informal afternoon session focused on insurance
- [The New EU Pharma Legislation At A Glance - special discount for members of Danish Bio](http://danskbiotek.dk/events/the-new-eu-pharma-legislation-at-a-glance/) - Write in comment that you are a Danish Bio member, and you will obtain the discount.
- [Inspection readiness](http://danskbiotek.dk/events/inspection-readiness/)
- [Bevar oversigt i outsourcede kliniske forsøg](http://danskbiotek.dk/events/bevar-oversigt-i-outsourcede-kliniske-forsog/)
- [NAVIGATING THE GEOPOLITICAL REALITY IN LIFE SCIENCE](http://danskbiotek.dk/events/geopolitics-danish-life-science/) - As has become tradition, we are happy to be inviting you to our annual co-hosted meeting with our sister organisation, Women in Life Science Denmark, WiLD. The current business environment calls for a meeting shedding some light on how to navigate in this climate, and we hope you will participate and ask as many questions
- [The New EU Pharma legislation at a glance - get a 50% discount!](http://danskbiotek.dk/events/the-new-eu-pharma-legislation-at-a-glance-get-a-50-discount-🤩/) - Dear member, If this is of interest to you, please do not hesitate to email ps@danskbiotek.dk to get your members' discount code!
- [BioEquity Nordic 2026 - discount code for members of DANISH BIO!](http://danskbiotek.dk/events/bioequity-nordic-2026-discount-code-for-members-of-danish-bio/) - We've partnered with BioEquity Europe 2026. Please email ps@danskbiotek.dk to get your discount code 🥳
- [BIOTECH SPRING GALA 2026](http://danskbiotek.dk/events/biotech-spring-gala-2026/) - ARE YOU READY? We certainly are! To once again welcome you to our traditional BIOTECH SPRING GALA 2026 Registration is now open 💌 The Biotech Spring Gala 2026 is sponsored by: Black Swans Exist Fortrea Gorrissen Federspiel Kromann Reumert Nasdaq Worldwide Clinical Trials
- [Hot topic: EU Biotech Act – 50% discount for members](http://danskbiotek.dk/events/hot-topic-eu-biotech-act-50-discount-for-members/) - Skriv i kommentarfeltet: ”BiotekRabat”
- [LSX Nordic - Discount code for members!](http://danskbiotek.dk/events/lsx-nordic-discount-code-for-members/) - Please contact: ps@danskbiotek.dk for discount code Read more about the congress here:
- [BioFIT & MedFIT - disount code for members!](http://danskbiotek.dk/events/biofit-medfit-2/) - We are proud to support BioFIT and MedFIT as a partner! Meet us in Marseille on December 10th and 11th, 2026 for the joint edition of Europe’s leading partnering conventions dedicated to innovation in the Life Sciences and Healthtech sectors. Take advantage of an exclusive discount thanks to our partnership! Contact us or Marine Pentier
- [BIOSOLUTIONS on the Agenda](http://danskbiotek.dk/events/biosolutions-on-the-agenda/) - It is our great pleasure to be inviting you to an event focusing specifically on BIOSOLUTIONS. Our speakers are experts and more than worth listening to, and we are so very proud to have them. Book your ticket now!
- [State of the Union](http://danskbiotek.dk/events/state-of-union-save-the-date/)
- [LSX World Congress Europe - get a discount!](http://danskbiotek.dk/events/lsx-world-congress-europe-get-a-discount/) - We have once again partnered with LSX World Congress Europe to get our members a 10 % discount on the registration. Register here to get your discount: https://informaconnect.com/lsx-world-congress/purchase/select-package/?vip_code=DB10
- [Innovation for Health, March 2026 - discount code for members of DANISH BIO](http://danskbiotek.dk/events/innovation-for-health-march-2026-discount-code-for-members-of-danish-bio/) - We are partnering with Innovation for Health, which is held in Utrecht in Holland on 25-26 March 2026. This year’s theme, “Bridging the Gap - From Idea to Innovation & from Patent to Patient”, focuses on accelerating the development, funding, and adoption of impactful healthcare solutions. With over 800 high level participants, 70+ expert speakers,
- [ANNUAL MEETING: THE FUTURE OF BIOTECH](http://danskbiotek.dk/events/annual-meeting-biotech-in-europe/) - It is time for our traditional ANNUAL MEETING! We are thrilled to be inviting you to yet another event full of insights. The programme has been finalised and as you can see: It won't be boring! So sign up now!
- [Biotech Salon: Bought Not Sold: Exit Strategies in a Tough Market](http://danskbiotek.dk/events/biotech-salon-bought-not-sold/) - Come join us for an inspiring afternoon presented by IQVIA and DANISH BIO in cooperation. You can look forward to gaining valuable insights on exit strategies and the opportunity to ask the experts. Hoping to see you there!
- [Does your patent make your investors happy - or does it protect your future business?](http://danskbiotek.dk/events/does-your-patent-make-your-investors-happy-or-does-it-protect-your-future-business/) - Why not do both? Join us for an engaging and insightful seminar at Symbion Frederiksberg, where patent experts will tackle this question. Approaches to patent strategies depend highly on where your company is in the business cycle and who your competitors are. Many startups need to file so-called checkmark patents in order to show some
- [Er du på udkig efter finansiering og nye samarbejdspartnere ?](http://danskbiotek.dk/events/er-du-pa-udkig-efter-finansiering-og-nye-samarbejdspartnere/) - Mød 11 franske biotek- og sundhedsvirksomheder, der søger danske partnere til udvikling, test og forretning – med støtte fra Bpifrance, der kan gøre samarbejdet lettere at realisere. Netværksarrangementet finder sted den 16. oktober, hvor du kan møde de franske virksomheder og høre om deres løsninger. De er alle på udkig efter danske partnere, som de
- [Access to US Capital](http://danskbiotek.dk/events/access-to-us-capital/) - HUNGRY FOR INVESTMENTS? Then this is one event that you do not want to miss out on! In cooperation with William Hicks from the (US) lawfirm Mintz that services a number of biotech companies, we have the opportunity to invite you to this pop-up event focusing on how to get ACCESS TO US CAPITAL The
- [Åbn døren til Koreas erhvervsliv](http://danskbiotek.dk/events/abn-doren-til-koreas-erhvervsliv/) - DELTAG I VORES UNIKKE ERHVERVSEVENT Hvordan får din virksomhed succes på det sydkoreanske marked? Hvilke kulturelle og handelsmæssige barrierer kan du møde? Hvordan opbygger du stærke relationer med koreanske handelspartnere? BLIV KLÆDT PÅ TIL SUCCES Eventet er målrettet til erhvervsfolk, der ønsker at udvide deres forretning til Sydkorea eller importere fra Sydkorea. Du får et
- [Unlocking Opportunities in Korea's Biopharma Industry: Innovations in New Drug Development](http://danskbiotek.dk/events/unlocking-opportunities-in-koreas-biopharma-industry-innovations-in-new-drug-development/) - Background Invest KOREA, a division of KOTRA(Korea Trade-Investment Promotion Agency), has long been instrumental in attracting foreign direct investments to shape Korea's business landscape. By facilitating strategic partnerships and driving sustainable growth in emerging sectors, Invest KOREA plays a pivotal role in fostering fertile investment grounds for international players. Why Attend the Korea's Biopharma Industry
- [WORLD DRUG SAFETY CONGRESS EUROPE - get a discount!](http://danskbiotek.dk/events/world-drug-safety-congress-europe/) - We're once again partnering with World Drug Safety Congress Europe, which means a discount for our members. Please send an email to ps@danskbiotek.dk to get the discount code. www.terrapinn.com/dseu/dansk2025
- [BIO-EUROPE 2025 - get a 10% discount](http://danskbiotek.dk/events/bio-europe-2025/) - Once again, we are proud partners of BIO-EUROPE which means that our members ar able to obtain a 10% discount on registration fees. Please email ps@danskbiotek.dk to obtain the discount code.
- [TIME FOR CELEBRATION](http://danskbiotek.dk/events/time-for-celebration/)
- [Legal Affairs Committee Meeting](http://danskbiotek.dk/events/legal-affairs-committee-meeting/) - Dear member, We are thrilled to invite you to the first meeting in the Legal Affairs Committee. You can nominate one representative with relevant responsibility and decision-making authority to participate in the Committee by responding to Pernille Schmidt on ps@danskbiotek.dk. Invitation The legal digital landscape is evolving heavily these years as part of the
- [FREE EVENT: 3-Hour Morning Coffee Course - Clinical Data and Artificial Intelligence](http://danskbiotek.dk/events/free-event-3-hour-morning-coffee-course-clinical-data-and-artificial-intelligence/)
- [FREE EVENT: 3-Hour Morning Coffee Course - Fundamentals of Personalised Medicine](http://danskbiotek.dk/events/free-event-3-hour-morning-coffee-course-fundamentals-of-personalised-medicine/)
- [FREE EVENT: 3-Hour Morning Coffee Course - The EU Life Science Regulations At A Glance](http://danskbiotek.dk/events/free-event-3-hour-morning-coffee-course-the-eu-life-science-regulations-at-a-glance/)
- [FREE EVENT: 3-Hour Morning Coffee Course - Evidence That Shows Personalised Medicine Works](http://danskbiotek.dk/events/free-event-3-hour-morning-coffee-course-evidence-that-shows-personalised-medicine-works/)
- [Biotech Salary Survey](http://danskbiotek.dk/events/biotech-salary-survey/) - Get exclusive insights into Biotech pay: The most complete salary survey in Denmark. The Danish Biotech Salary Survey gives you hard-to-find data on all the most important biotech specific jobs. Danish Biotech Salary Survey in short: A salary survey specifically developed for the conditions in the biotech industry Tailor-made job catalogue for management and specialist
- [BIOTECH SPRING GALA](http://danskbiotek.dk/events/biotech-spring-gala-2/) - Dear member, We are very pleased to be inviting to you to our traditional BIOTECH SPRING GALA 2025 on 6 May 2025, 18:00-24:00 As in previous years, we will be celebrating our peers with the traditional awards ceremony: Company of the Year Rising Star CEO of the Year Life-Time Achievement Award In addition to celebrating
- [White House Executive Orders - what are the consequences?](http://danskbiotek.dk/events/36012/)
- [NLSDays 2025 - get a discount!](http://danskbiotek.dk/events/nlsdays-2025-get-a-discount/) - Once again, we're partnering with Sweden Bio to promote the NLSDays 2025. As a member of DANISH BIO-DANSK BIOTEK, you get a discount by emailing ps@danskbiotek.dk
- [JLABS | Road to first-in-human trials for small molecules](http://danskbiotek.dk/events/jlabs-road-to-first-in-human-trials-for-small-molecules/) - Do you know what it takes to start your first clinical trial? Submitting a Clinical Trial Application (CTA) is a critical early milestone for every biotech company. Johnson & Johnson Innovation – JLABS invites you for a program that takes an in-depth look into essential aspects of a CTA such as preclinical development, clinical trial
- [LSX World Congress - get 15% discount](http://danskbiotek.dk/events/lsx-world-congress-get-15-discount/) - Like in previous years, DANISH BIO-DANSK BIOTEK partners up with LSX World Congress to get a discount for our members on the registration fee. You will get a discount 15% as a member - all you need to do is email ps@danskbiotek.dk to get the code.
- [State of the Union](http://danskbiotek.dk/events/state-of-the-union-3/)
- [A special celebration ... our Chair turns 60](http://danskbiotek.dk/events/a-special-celebration-our-chair-turns-60/)
- [ANNUAL MEETING - programme revealed](http://danskbiotek.dk/events/annual-meeting/)
- [BIOTECH SALON: Two years with the Clinical Trials Regulation](http://danskbiotek.dk/events/biotech-salon-two-years-with-the-clinical-trials-regulation/)
- [BIOTECH SPRING GALA 2024](http://danskbiotek.dk/events/biotech-spring-gala-2024/) - It is finally time! Our traditional BIOTECH SPRING GALA is up for registration, and we hope you see you and enjoy a festive evening with you.
- [Annual General Meeting](http://danskbiotek.dk/events/placeholder-annual-general-meeting/) - Our Annual General Meeting is up! The agenda is inlcuded in the Notice to convene the meeting, and as you will see, we have some updates of our Articles of Association on the programme this year. Please register for the meeting no later than 27 May 2024. If you cannot attend the meeting yourself, you
- [EARLY CLINICAL RESEARCH meeting in Aarhus](http://danskbiotek.dk/events/early-clinical-research-meeting-in-aarhus/) - 13 June 2024 is your excellent opportunity to learn about early clinical research in Denmark from the perspectives of biotech, pharma, authorities, patients, and CROs. Please don't hesitate to sign up for the meeting and take the opportunity to also meet your peers Summer Meeting - Early Clinical Research in Denmark 13 June 2024
- [NLSDays Nordic Star Pitch Competition is NOW OPEN for applications](http://danskbiotek.dk/events/35337/) - As Dansk Biotek has been a supporter for NLSDays 2024 in Malmö, I’m happily sharing with you that the application for NLSDays Nordic Star Pitch Competition is NOW OPEN. Through Nordic Star Pitch Competition 2024, Dansk Biotek’s community members can showcase their ground-breaking ideas, impress a jury of pharmaceutical giants and savvy investors during NLSDays.
- [NLSDays 2024 - with a discount rate for members of DANISH BIO-DANSK BIOTEK](http://danskbiotek.dk/events/nlsdays-2024-with-a-discount-rate-for-members-of-danish-bio-dansk-biotek/) - Where Nordic life science meets the world Again this year, we have entered cooperation with NLSDays to secure our members a discounted rate for registration. You can read more on www.nlsdays.com Dates: 18-19 September 2024 Location: Malmö, Sweden Venue: Malmömässan, Måsgatan 6, 215 32 Malmö – Sweden Industry: Life sciences, biotechnology, pharmaceutical Please contact ps@danskbiotek.dk
- [BioFIT & MedFIT](http://danskbiotek.dk/events/biofit-medfit/) - We are happy to tell you that we have entered cooperation with BioFIT and MedFIT for the 2024 conference which is held in Lille, France. As a member of DANISH BIO-DANSK BIOTEK, you will obtain a discount of 20% on the regular rates. All you need to do is apply a discount code which you
- [Charles River & The Jackson Laboratory Seminar Series – Copenhagen](http://danskbiotek.dk/events/charles-river-the-jackson-laboratory-seminar-series-copenhagen/) - As the exclusive distributor and breeder of JAX® Mice in Europe, Charles River is pleased to welcome Dr. Katie Zyuzin from The Jackson Laboratory to our European seminar series. Secure your spot today to attend relevant talks by international experts on laboratory animal science and advanced research models and to discuss and network with your peers
- [What does it take to get Equity into the Danish Life Science Industry?](http://danskbiotek.dk/events/what-does-it-take-to-get-equity-into-the-danish-life-science-industry/)
- [State of the Union](http://danskbiotek.dk/events/state-of-the-union-2/)
- [BIOTECH SALON: Nonclinical Safety & Regulatory Strategy to reach your First in Human Trial](http://danskbiotek.dk/events/biotek-salon-nonclinical-regulatory-strategy-and-agency-interactions/)
- [Annual Meeting - DANISH BIO-DANSK BIOTEK](http://danskbiotek.dk/events/annual-meeting-danish-bio-dansk-biotek/) - Political insight, outlook and an excellent opportunity to network with your peers. 9 Oct. at Kromann Reumert. You don't want to miss this! See you there 😊
- [Calling Biotech startups! How can your biotech business benefit from partnering with Korea?](http://danskbiotek.dk/events/calling-biotech-startups-how-can-your-biotech-business-benefit-from-partnering-with-korea/) - The Danish embassy in Korea, DI and DTU are working on a joint project, which purpose is to secure more investments and partnering opportunities for Danish biotech startups and SMEs. The Korean government is going all in on biotech, and will create their own biotech cluster. Government and private investors are looking for the next
- [Life Science Forum 2023 – EU’s revision af lægemiddelreglerne](http://danskbiotek.dk/events/life-science-forum-2023-eus-revision-af-laegemiddelreglerne/) - Life Science Forum 2023 – EU’s revision af lægemiddelreglerne Hvilke udfordringer i forhold til lægemidler står patienter, industri og samfund over for i 2020erne? Og er EU's foreslåede revision af lægemiddelreglerne den længe ventede løsning? Vær med, når disse aktuelle spørgsmål diskuteres og debatteres til Bech-Bruun Life Science Forum. Patienter skal have hurtig adgang til
- [International Medical Device Regulators Forum (IMDRF)](http://danskbiotek.dk/events/international-medical-device-regulators-forum-imdrf/) - You are invited to join your fellow industry professionals and stakeholders from the medical device regulatory field at the EU-Chaired 24th session of the International Medical Device Regulators Forum (IMDRF) in Berlin, Germany, on 25-26 September 2023. This two-day event will provide a valuable opportunity for exchange between participating authorities, industry and clinical associations. What?
- [SUND INNOVATION DAY 2023 - Role models in innovation](http://danskbiotek.dk/events/sund-innovation-day-2023-role-models-in-innovation/) - Annual theme: Role models in innovation 23 October 13.00-17.00 Mærsk Tower, 15th floor The Pipeline Innovation team is pleased to invite you to the annual SUND Innovation Day at theFaculty of Health and Medical Sciences. The event is a celebration of the innovative mind and entrepreneurial spirit of researchers atUCPH. We bring together researchers, staff
- [Open Lecture with Nobel Laureate Professor William G. Kaelin: Insights into cancer and tumor suppression](http://danskbiotek.dk/events/open-lecture-with-nobel-laureate-professor-william-g-kaelin-insights-into-cancer-and-tumor-suppression/) - The Faculty of Health and Medical Sciences at the University of Copenhagen welcomes Nobel Laureate Professor William G. Kaelin for an open lecture in the Jerne Auditorium on 14 September 2023. Dr. Kaelin was recognized along with Peter J. Ratcliffe and Gregg Semenza with the 2019 Nobel Prize in Physiology or Medicine for their discoveries
- [JAPAN In Your Regulatory Strategy](http://danskbiotek.dk/events/japan-in-your-regulatory-strategy/)
- [Advanced imaging solutions together with Nikon BioImaging Lab, Ramcon, Mimetas and VitroScan](http://danskbiotek.dk/events/advanced-imaging-solutions-together-with-nikon-bioimaging-lab-ramcon-mimetas-and-vitroscan/) - Are you a life science startup with fixed capital that needs to collect mission critical microscopy data? Or perhaps you are a larger organization with a need for instrumentation and expertise, but the timing isn’t right for a big purchase? Join in and learn more about the options. Why should you join? Advanced imaging technologies
- [NLSDays in Copenhagen, 28-30 Nov. 2023 - 15% discount for DANISH BIO - DANSK BIOTEK members](http://danskbiotek.dk/events/nls-days-in-copenhagen-28-30-nov-2023-15-discount-for-danish-bio-dansk-biotek-members/) - Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. Most attendees express their delight in the informal atmosphere, combined with an organised approach to meeting
- [Clinical Innovation: A Futureproof Trial Strategy](http://danskbiotek.dk/events/clinical-innovation-a-futureproof-trial-strategy/) - JLABS Program | Clinical Innovation: A Futureproof Trial Strategy 13 June | 14:00 – 18:00 hours | Rotterdam, the Netherlands & virtual To get a product to patients fast, efficient clinical trial design has always been top-of-mind for drug developers. With new IP regulations and sustainability requirements being implemented, this will become more important than
- [Annual General Meeting](http://danskbiotek.dk/events/annual-general-meeting/) - NOTICE TO CONVENE THE ANNUAL GENERAL MEETING DANISH BIO - DANSK BIOTEK (CVR no. 28 43 65 72) Notice is hereby given to the Annual General Meeting of DANISH BIO - DANSK BIOTEK to be held on Thursday, 11 May 2023, at 16:30 (CEST) at Børsen, Slotsholmsgade, DK-1216 Copenhagen
- [Member's meeting on the revision of the Pharmaceutical legislation in the EU - May 4th](http://danskbiotek.dk/events/members-meeting-on-the-revision-of-the-pharmaceutical-legislation-in-the-eu-may-4th/) - Dear member of DANISH BIO - DANSK BIOTEK, I am writing to you regarding the recent policy proposal from the EU on the revision of the pharmaceutical legislation as part of the pharmaceutical strategy. The EU Commission presented its reform package earlier this week, and unfortunately, it contains a range of initiatives that we fear
- [Biotech Spring Gala](http://danskbiotek.dk/events/biotech-spring-gala/) - We are delighted to once again invite you to our Biotech Spring Gala, and again this year, we will be presenting the prestigous awards of our industry. We hope to see many of our members and colleagues of the industry.
- [17th Clinical Trials Nexus Conference Amsterdam 15-16 June 2023 - FREE for the members of DANSKBIOTEK](http://danskbiotek.dk/events/17th-clinical-trials-nexus-conference-amsterdam-15-16-june-2023-free-for-the-members-of-danskbiotek/) - Dear Representative, I am writing to invite you and your members to attend the 17th Clinical Trials Nexus Conference, which will take place in Amsterdam on 15-16 June 2023. The conference will provide insights into the latest trends in clinical operations, patient centricity, medical affairs, and outsourcing challenges. As a valued association, we would like
- [LINK Medical Summer Mingle](http://danskbiotek.dk/events/link-medical-summer-mingle/) - LINK Medical Summer Mingle – How to prepare for an inspection? Unique insight from two senior advisors experienced as GCP inspectors Join us on May 24th in Copenhagen at our free summer mingle event and attend a lecture with two senior advisors experienced as Good Clinical Practice (GCP) inspectors. Philip Lange Møller from Denmark and
- [BIOTEK SALON - How to navigate your liquidity in normal and uncertain times](http://danskbiotek.dk/events/biotek-salon/)
- [LIFE SCIENCE LEGAL](http://danskbiotek.dk/events/life-science-legal/) - NUVÆRENDE OG KOMMENDE REGULERING Inden for de sidste par år er Life Science industrien blevet pålagt en stor mængde ny lovgivning. Det er en udvikling der fortsætter, går stærkt og i stigende grad påvirker den strengt regulerede sektor, der vedvarende skal håndtere nye udfordringer i form af ændringer i internationale regler og retningslinjer. LIFE SCIENCE
- [Pharma Partnering Summit EU 2023](http://danskbiotek.dk/events/pharma-partnering-summit-eu-2023/) - The Pharma Partnering EU Summit 2023 is one of the most prestigious physical events of 2023 in the EU for life science professionals. This platform brings together senior executives from different parts of the world, focused on Licensing, R&D Collaborations, Commercialisation & Distribution deals, Fundraising, Investing, Digital Health Alliances, M&A, Going Public as well as
- [Introduction to The Danish Biotech Salary Survey 2023](http://danskbiotek.dk/events/introduction-to-the-danish-biotech-salary-survey-2023/) - Finding the right balance between salary costs and the ability to attract and retain key talent is crucial to company performance in our industry. For this you need market data. The upcoming Danish Biotech Salary Survey will give you unique insights in 20 biotech specific jobs such as Research Scientist, Laboratory Technician, Project Manager, Patent
- [Unique chance: Meet biotech Superstar Noubar Afeyan!](http://danskbiotek.dk/events/unique-chance-meet-biotech-superstar-noubar-afeyan/) - Dear members of DANISH BIO We’re really pleased to offer a unique opportunity to meet a truly global biotech SUPERSTAR! Vice Dean of Innovation and External Relations Trine Winterø is hosting co-founder of Moderna and founder and CEO of Flagship Pioneering mr. Noubar Afeyan who will give a talk at the Panum Institute. Please forward this
- [QPS Seminar: QPS Clinical Trial Partnerships to Accelerate Scientific Asset Development](http://danskbiotek.dk/events/qps-seminar-qps-clinical-trial-partnerships-to-accelerate-scientific-asset-development/) - The seminar is 1-hour sessions in which Maria Lundius and clinical pharmacologist Margreke Brill (QPS) will share QPS capabilities and experience in both conducting complex early phase clinical studies and supporting drug or asset development from the earliest phases of planning and development to later phase clinical trials and Regulatory submission. It is an opportunity
- [WiLD AND DANISH BIO: Preparing for the future – disruptive trends that will significantly affect your business](http://danskbiotek.dk/events/wild-women-in-life-science-denmark-and-danish-bio-dansk-biotek-co-hosting-meeting/)
- [World Drug Safety Congress Europe - discount for DANISH BIO - DANSK BIOTEK members](http://danskbiotek.dk/events/world-drug-safety-congress-europe-discount-for-danish-bio-dansk-biotek-members/) - The World Drug Safety Congress Europe will bring together 1500+ key thought leaders to explore key challenges in pharmacovigilance. From exploring the use of big data and AI in pharmacovigilance, examining benefit-risk management strategies and patient centric approaches, drug safety is at the forefront of innovative technologies that will have an impact on the lives
- [The Importance of Regulatory CMC Strategy During Early Development](http://danskbiotek.dk/events/the-importance-of-regulatory-cmc-strategy-during-early-development/) - Accelerate development using a Quality Target Product Profile Having the right Chemistry, Manufacturing, and Controls (CMC) documentation throughout drug development is essential for avoiding pitfalls, ensuring an efficient regulatory review process, and achieving the goals for your product. The key is an early development regulatory strategy that includes CMC. Join our regulatory CMC webinar to strengthen
- [State of the Union Members' meeting](http://danskbiotek.dk/events/state-of-the-union-members-meeting/) - We are happy to invite you to the 2023 edition of our State of the Union meeting, this time hosted by Novo Holdings. Registration is open, and we look forward to seeing you! Please register using the Register button on the left-hand side. Novo Holdings and DANISH BIO - DANSK BIOTEK will be serving
- [LSX World Congress - 15% discount for DANISH BIO members](http://danskbiotek.dk/events/lsx-world-congress/) - For nearly a decade, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science strategy, investment, partnering and deal-making. LSX World Congress gathers the founders and CEOs of innovative start-ups through to public healthcare giants, and everyone in between. It represents the breadth and depth
- [Meet Your Local CMO](http://danskbiotek.dk/events/meet-your-local-cmo/) - Join us for expert insights, meet leaders from other Medicon Valley biotech companies, and get exclusive details on AGC Biologics’ new mammalian manufacturing line that doubles our single-use technology capacity, ready in mid- 2023. Sign up for this unique chance to hear from industry leaders and executives, enjoy a lively discussion on biotech trends for
- [BIOSPAIN 2023](http://danskbiotek.dk/events/biospain-2023/) - BIOSPAIN 2023 will take place from 26-28 September 2023 in Barcelona, the main biotech cluster in Spain and one of the most dynamic cities in the world. Jointly organized in its 11th edition by AseBio, the Spanish Bioindustry Association, Biocat, the Government of Catalonia and Barcelona City Council, BIOSPAIN has become one of the leading biotech
- [Boosting product development of innovative wound healing therapies](http://danskbiotek.dk/events/boosting-product-development-of-innovative-wound-healing-therapies/) - Intro to EWMA Innovation Forum - Innovative technologies in wound healing 4-5 May 2023, Milan The webinar will introduce key topics of the EWMA Innovation Forum, which will feature at the EWMA congress, to be held 3-5 May 2023 in Milan, Italy. The EWMA Innovation Forum is meant for aspiring startups and spinouts, investors, and established
- [State of Denmark Life Science Campaign 2023](http://danskbiotek.dk/events/state-of-denmark-life-science-campaign-2023/) - LOOKING FOR LIFE-SCIENCE PROFESSIONALS? Copenhagen Capacity is now introducing the State of Denmark Life Science Campaign which is part of the Lighthouse Life Science project. It is a targeted digital campaign to create awareness of Copenhagen as a Global Capital for Health and attract experienced life science professionals from abroad to Denmark. Join the international talent
- [DANISH BIO Members’ Meeting: Human Resource Management in Biotech](http://danskbiotek.dk/events/danish-bio-members-meeting-human-resource-management-in-biotech/) - Human Resource Management with special emphasis on building international teams, recruitment, and how to tackle human resource management in the context of biotech Host of the day is: Devote Consulting, Langebrogade 3F, 1411 Copenhagen K Devote Consulting and DANISH BIO will be serving snacks and refreshments. The event is free of charge for members. Non-members
- [World of Microbiome Conference](http://danskbiotek.dk/events/world-of-microbiome-conference/) - The 4th edition of World of Microbiome Conference! The importance of understanding the human microbiome and its role for our health is gathering pace in recent years. This annual conference will offer you a unique chance to join colleagues across gastroenterology, obstetrics and gynecology, microbiology, immunology, endocrinology, neonatology, biotechnology, hepatology, dental medicine and members of
- [NOME Annual Meeting & Startup Competition](http://danskbiotek.dk/events/nome-annual-meeting-startup-competition-2/) - Nome is pleased to invite you to the 2022 Annual Meeting of the Nordic Mentor Network for Entrepreneurship, NOME (www.nome.nu). The program will be packed with startup pitches, talks, NOME prize, awards and great networking opportunities with Nordic and European life science professionals. About NOME The Nordic Mentor Network for Entrepreneurship (NOME) is an elite
- [Life Science Career Expo](http://danskbiotek.dk/events/life-science-career-expo/) - Copenhagen Capacity invites you to the Life Science International Career Expo hosted together with Copenhagen Science City on the top floor of the Maersk Tower with stunning views of Copenhagen. This is an exclusive event where Life Science companies' representatives and international talent in Denmark will meet to explore mutual career and networking opportunities in Denmark. Join
- [Invitation to Medical Innovation Day 2022, Aarhus University](http://danskbiotek.dk/events/invitation-to-medical-innovation-day-2022-aarhus-university/) - Medical Innovation Day is an annual event, which brings together students, researchers and business representatives to exchange ideas and think up solutions for health challenges of the future. In 2022, AU will zoom in on post-marketing surveillance in connection with drug development under the theme: "What are the implications of post-marketing studies on innovation and future
- [EU-Japan Biotech & Pharma Partnering Conference](http://danskbiotek.dk/events/eu-japan-biotech-pharma-partnering-conference/) - Since 2016, The EU-Japan Centre has been organizing a B2B Event in Biotech and Pharma sectors in Osaka, Japan. This year, the EU-Japan Biotech & Pharma Partnering Conference will be held with an hybrid format! Online Partnering Sessions: 26 - 30 September 2022 On-site Partnering Sessions: 11 October 2022, Osaka, Japan All meetings (should they
- [Biotek Salon #25 : Value creation in Life Sciences](http://danskbiotek.dk/events/value-creation-in-life-sciences/) - Two biotech companies A and B can have the same market cap/pre-money but very different price per share and it’s the latter that determines the value creation. Welcome to this session on Value creation in Life Sciences provided by Saurabh Mishra, Founder and Managing Partner of Farmantra. There are no black and white strategies for
- [LSX Nordic Congress - 15% discount for DANISH BIO members](http://danskbiotek.dk/events/lsx-nordic-congress-15-discount-for-danish-bio-members/) - In September 2022, leading Biotech, Medtech and HealthTech CEOs will be gathered for a 2-day executive conference, 1-2-1 in-person partnering and showcase opportunities at the 5th LSX Nordic Congress. After four years in Stockholm, and 2 years virtual, the LSX Nordic Congress is back in Copenhagen, Denmark! Join us and 400+ participants to meet your
- [BY WRITTEN PROCEDURE : NOTICE TO CONVENE AN EXTRAORDINARY GENERAL MEETING](http://danskbiotek.dk/events/egm/) - NOTICE TO CONVENE AN EXTRAORDINARY GENERAL MEETING DANISH BIO – DANSK BIOTEK (CVR no. 28 43 65 72) Notice is hereby given to an Extraordinary General Meeting of DANISH BIO – DANSK BIOTEK to be held on Monday, 27 June 2022, at 15.00 (CEST) by written procedure The agenda is as follows: a) Election
- [Pharmaceutical Social Media – the dos and don’ts from a Medical Compliance perspective](http://danskbiotek.dk/events/pharmaceutical-social-media-the-dos-and-donts-from-a-medical-compliance-perspective/) - Link Medical are gathering key Nordic authorities from ENLI, Lif, LMI and PIF to talk about Marketing Compliance for Pharmaceuticals. In the digital era, social media is increasingly becoming a bigger part of our lives. In this webinar, Link Medical want to take a closer look at the marketing compliance rules for Pharmaceuticals in Nordic countries. What do we need to
- [Lifs 25 års jubilæum](http://danskbiotek.dk/events/lifs-25-ars-jubilaeum/) - Life Science Meetup er tilbage! Den 17. august inviterer vi igen til fire inspirerende, spændende og tankevækkende timer med aktuelle debatter, talks og videndeling om life science-branchen, bæredygtighed, fremtidens sundhedsvæsen og alt derimellem - og derefter mingling med lidt godt til maven og til ganen. Alt sammen i Life Science Huset. Tilmeld dig allerede nu
- [ALGIECEL pilot plant opening ceremony at the Danish Technological Institute](http://danskbiotek.dk/events/algiecel-pilot-plant-opening-ceremony-at-the-danish-technological-insitute/) - NEW COMPACT MOBILE PHOTOBIOREACTOR TO FIGHT CO2 EMISSIONS To celebrate the opening of the mobile ALGIECEL pilot plant at the Danish Technological Institute in Taastrup, Denmark, ALGIECEL invite you to take part in the opening ceremony. Focus will be on the green transition and sustainability. ALGIECEL has developed a mobile photobioreactor with which photosynthesizing microalgae
- [Danish Standards - Life Science webinar](http://danskbiotek.dk/events/danish-standards-life-science-webinar/) - Danish Standards (DS) believes that Danish companies should participate in the process of shaping future market requirements for Life Science. Within this field, Denmark boasts some of the leading experts and companies, today accounting for 22 % of Denmark's total exports, which makes this a key business area in Denmark. The knowledge and experience of
- [Invitation for EU - Africa pharma and healthcare marketplace and matchmaking events](http://danskbiotek.dk/events/invitation-for-eu-africa-pharma-and-healthcare-marketplace-and-matchmaking-events/) - The European Commission is inviting to a series of online events to offer African and European organisations the opportunity to build-up and forge new ties within the pharma, biotech and medtech industries to address global health needs. The objectives of the series of events are to : Build-up and strengthen the existing relationship between EU
- [MVA Face to Face Morning Meeting: Surviving Early Biotech Pitfalls](http://danskbiotek.dk/events/mva-face-to-face-morning-meeting-surviving-early-biotech-pitfalls/) - MVA Face to Face Morning Meeting: Surviving Early Biotech Pitfalls - Overcoming challenges when moving from non-clinical to clinical. Join the LINK Medical Research breakfast meeting together with Medicon Village Alliance (MVA) in Copenhagen and meet their experts! Going from non-clinical to clinical is no easy step. That’s why LINK Medical Research gathered a few
- [The Danish Health Data Authority and the Ministry of Foreign Affairs of Denmark: AFTER-HOURS-EVENT ON ”DATA FOR LIFE”](http://danskbiotek.dk/events/the-danish-health-data-authority-and-the-ministry-of-foreign-affairs-of-denmark-after-hours-event-on-data-for-life/) - Join the pre-release of the new communication material on Danish health data and get news on the health data initiatives. Come along when The Danish Health Data Authority and the Ministry of Foreign Affairs of Denmark invite you to join their pre-release on the new communication material on the opportunities using Danish health data for
- [Biotek Salon #24: Biotech valuations as preparation for out-licensing and investment!](http://danskbiotek.dk/events/biotek-salon-24-biotech-valuations-as-preparation-for-out-licensing-and-investment/) - DANISH BIO – DANSK BIOTEK & MSC Nordics invite you to a workshop discussing financial models for biotech companies to guide business planning, portfolio management and negotiation. What is your valuation based on? This dreaded question most CEOs, with pre-commercial drugs in their pipelines, hate to answer. Investors and Big Pharma executives of course know
- [INVITATION BIO KOREA 2022](http://danskbiotek.dk/events/invitation-bio-korea-2022/) - BIO KOREA has been held every year since 2006 and serving as a business platform for international biohealth companies. Sponsored by the Ministry of Health and Welfare, BIO KOREA is a place of practical business correspondence as well as international information and technology exchange, invigorating the biohealth industry. In its 17th year of bringing together
- [DANISH BIO – DANSK BIOTEK ANNUAL GENERAL MEETING MAY 6, 2022](http://danskbiotek.dk/events/dansk-biotek-annual-general-meeting-may-6-2022/) - IMPORTANT! Please remember to register here stating also your e-mail as Safety at Børsen requires pre-registration in order to provide access to the building by QR-code sent to you by mail - o - NOTICE TO CONVENE THE ANNUAL GENERAL MEETING DANISH BIO – DANSK BIOTEK (CVR no. 28 43 65 72) Notice is hereby
- [Welcome to Biotech Spring Galla](http://danskbiotek.dk/events/biotech-spring-galla/) - Don’t miss the most exciting biotech event of the year. Come join the DANISH BIO Galla Party 6th May 6 pm at the beautiful Børsen building, and let’s all celebrate biotech and the many achievements that have been made. The entire Danish biotech sector will gather for a festive evening with dinner & jazz, entertainment,
- [Nordic Health Summit Tokyo](http://danskbiotek.dk/events/nordic-health-summit-tokyo/) - Connect with the 3rd Largest Healthcare Market in the World Japan is the 3rd largest economy and healthcare market in the world and it will continue to grow with a projected CAGR of 4% from 2018 to 2024. The Nordic Health Summit Japan is a partnering and investor conference aimed at connecting Nordic healthcare innovations
- [Webinar: Decentralised Clinical Trials from a Data Management Perspective](http://danskbiotek.dk/events/webinar-decentralised-clinical-trials-from-a-data-management-perspective/) - The Covid-19 pandemic has irreversibly changed the way clinical trials are conducted. The use of a wide range of technologies such as eConsent, teleconsultations, sensors, devices, and electronic patient diaries enables more patient-centric trials conducted to a larger population by conducting the clinical trial remotely in a participant’s home rather than at the clinic. A
- [DANISH BIO – DANSK BIOTEK ANNUAL MEMBERS’ MEETING 6 MAY 2022](http://danskbiotek.dk/events/dansk-biotek-annual-members-meeting-6-may-2022/)
- [Nordic Life Science Days 2022 - 15% discount for DANISH BIO – DANSK BIOTEK members](http://danskbiotek.dk/events/nordic-life-science-days-2022-15-discount-for-dansk-biotek-members/) - A welcome arena for business and people Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science and created a unique place to do business. Most attendees express their delight
- [LIVE Q&A on the New Veterinary Regulation 2019/6](http://danskbiotek.dk/events/live-qa-on-the-new-veterinary-regulation-2019-6/) - On March 29, members of the Regulatory team at LINK Medical will have a LIVE Q&A session to answer all questions regarding the new Veterinary Regulation. The team of experts goes over the New Veterinary Medicinal Products Regulation 2019/6, changes to MA applications, it also reviews the product information (label, package leaflet, and SPC), MAJOR
- [Pharma Partnering Summit in Brussels - In-Person & Virtual](http://danskbiotek.dk/events/pharma-partnering-summit-in-brussels/) - The Summit Conference for Collaborations in the Pharma and Biotech Sector Pharma Partnering Summit 2022 taking place during 12th & 13th May 2022 in Brussels, Belgium. It’s one of the most prestigious in-person event for life science industry professionals. The aim of the summit is to help companies to expand their network, identify products, partners
- [Johnson & Johnson Webinar: The ins and outs of outsourcing for startups](http://danskbiotek.dk/events/johnson-johnson-webinar-the-ins-and-outs-of-outsourcing-for-startups/) - To help ensure your innovation will eventually make a difference in peoples’ lives, you need the right team to make it happen. Startups may consider different models of gaining access to expertise and skills, while at the same time remaining lean and agile. With this webinar Johnson & Johnson Innovation aims to give life sciences
- [Johnson & Johnson Webinar: Recruitment - building your team as the foundation of success](http://danskbiotek.dk/events/johnson-johnson-webinar-recruitment-building-your-team-as-the-foundation-of-success/) - To bring your innovation to patients, you’ll need to build and retain a stellar team. While you can hire consultants and outsource many tasks, most life sciences companies are looking to expand beyond their founding team and recruit their own employees. With this webinar Johnson & Johnson Innovation aims to give life sciences entrepreneurs valuable
- [DANISH BIO – DANSK BIOTEK members’ meeting: State of the Union](http://danskbiotek.dk/events/dansk-biotek-members-meeting-state-of-the-union-2/)
- [World of Microbiome 2022 Congress](http://danskbiotek.dk/events/world-of-microbiome-2022-congress/) - Please be invited to the 3rd edition of the International World of Microbiome Conference, set to take place on 28-30 April, 2022 in Vienna – as a face to face event! ! At the 3rd edition of the World of Microbiome Conference a third Zone to the concept is being introduced – in addition to
- [Invitation - Life Science Matchmaking Day 2022](http://danskbiotek.dk/events/invitation-life-science-matchmaking-day-2022/) - DANISH BIO – DANSK BIOTEK is happy to share, that Aarhus University, the faculties of Natural Sciences, Technical Sciences and Health, invite you to Life Science Matchmaking Day 2022! Life Science Matchmaking Day is an annual matchmaking event. The event is a unique opportunity for companies to establish collaboration with students within all fields of life sciences. It is the
- [Biotek Salon #23 - EU Clinical Trials Regulation: On your marks, get set, go!](http://danskbiotek.dk/events/eu-clinical-trials-regulation-on-your-marks-get-set-go/) - DANISH BIO – DANSK BIOTEK & OZACK invite you to a workshop on the implications of the (not really) new EU Clinical Trials Regulation No 536/2014 (CTR) to smaller players in the world of pharma. The CTR will finally become applicable on January 31st, 2022 - even though it has been in force since 2014,
- [Biotek Salon #22 by PET: Is your company the next espionage target?](http://danskbiotek.dk/events/biotek-salon-22-is-your-company-the-next-espionage-target/) - DANISH BIO – DANSK BIOTEK & the Danish Security and Intelligence Service (PET) invite you to a briefing to raise awareness of the current threat landscape. Technology and research organizations are attractive targets for espionage and problematic knowledge transfer. PET will share insights on where the threat is coming from, who are potential targets, and
- [Invitation to Virtual Life Science Meeting](http://danskbiotek.dk/events/invitation-til-virtuelt-life-science-mode/) - Erhvervsministeriet, Dansk Erhverv, Lægemiddelindustriforeningen, Dansk Industri, Medicoindustrien and DANISH BIO – DANSK BIOTEK have the pleasure of inviting you to a virtual life science meeting on December 16, 2021. Together with the industry organizations, Minister of Business and Industry Simon Kollerup, will focus on the life science industry's significance for the Danish economy presenting this
- [Boardwork and Corporate Governance of Life Science Startups](http://danskbiotek.dk/events/boardwork-and-corporate-governance-of-life-science-startups/) - BOARDWORK AND CORPORATE GOVERNANCE FOR LIFE SCIENCE STARTUPS December 13 & 14, 2021 DAYS & DATES Boardwork and Corporate Governance of Life Science Startups takes place over 2 days: Day 1: Monday, December 13, 09.00-17.30 Welcome reception with snacks, 17.30-18.30 Day 2: Tuesday, December 14, 09.00-17.30 Certificate reception with tapas 17.30-18.30 Sign up here PRICE
- [DANISH BIO – DANSK BIOTEK members’ meeting 24 November 2021: Danish Biotech Anno 2030](http://danskbiotek.dk/events/dansk-biotek-members-meeting-24-november-2021-danish-biotech-anno-2030/) - Please join DANISH BIO – DANSK BIOTEK’s meeting on the visions for Danish biotech in 2030. Mads Krogsgaard Thomsen from the Novo Nordisk Foundation will be joined by Morten Mølgaard, COBIS, and Jens Nielsen, BII, as they present their ideas about how we maintain the strong momentum we have right now and how we make
- [Virtual Matchmaking event on the Development and production of COVID-19 therapeutics](http://danskbiotek.dk/events/virtual-matchmaking-event-on-the-development-and-production-of-covid-19-therapeutics/) - Second European Matchmaking event on the Development and production of COVID-19 therapeutics On the 29 and 30 November, the European Commission is organising the Second Virtual Matchmaking Event on COVID-19 Therapeutics in partnership with the Council of European BioRegions (CEBR), the European Cluster Alliance (ECA) and the ECCP. This event will aim to accelerate: The
- [Get GDPR done: Webinar #1 - The basic requirements](http://danskbiotek.dk/events/webinars-get-gdpr-done-nov-22nd-nov-29th-dec-6th/) - If you want to get GDPR done, this offer is for you You are probably in daily contact with more personal data than you think – and they all need to be handled correctly. GDPR is mandatory, and goes for both employees, customers and suppliers. The good news is that it is easier to get
- [Get GDPR done: Webinar #3 - Be prepared!](http://danskbiotek.dk/events/get-gdpr-done-webinar-3-be-prepared-dec-6th/) - If you want to get GDPR done, this offer is for you You are probably in daily contact with more personal data than you think – and they all need to be handled correctly. GDPR is mandatory, and goes for both employees, customers and suppliers. The good news is that it is easier to get
- [Get GDPR done: Webinar #2 - Cover the flanks](http://danskbiotek.dk/events/get-gdpr-done-webinar-2-cover-the-flanks-nov-29th/) - If you want to get GDPR done, this offer is for you You are probably in daily contact with more personal data than you think – and they all need to be handled correctly. GDPR is mandatory, and goes for both employees, customers and suppliers. The good news is that it is easier to get
- [OPEN INVITATION: EMBL ALUMNI & CAREER EVENT](http://danskbiotek.dk/events/open-invitation-embl-alumni-career-event/) - "EMBL in Denmark 2021: Enzymes of the future" – combined with DANEMO career event DANISH BIO – DANSK BIOTEK members are invited to join this free two-day event, which includes a diverse group of speakers from Denmark, recent Novozyme Prize winner Peer Bork and a keynote lecture from Bernard Henrissat. The event will focus on
- [PASSED DEADLINE: Korea-Denmark Health and Medical Cooperation Forum November 1st 2021 in Copenhagen](http://danskbiotek.dk/events/korea-denmark-health-and-medical-cooperation-forum-november-1st-2021-in-copenhagen/) - DANISH BIO – DANSK BIOTEK members are invited to join this Korea-Denmark Health and Medical Cooperation Forum organized by Embassy of the Republic of Korea to Denmark, Korea Ministry of Health and Welfare, Korea Health Industry Development Institute (KHIDI), Korea Trade Promotion Agency (KOTRA) and Healthcare Denmark. Please see attached agenda for further details and
- [Glögg Mingle in Solna or Malmö – Digital Clinical Trials – Possibilities and Challenges](http://danskbiotek.dk/events/glogg-mingle-in-solna-or-malmo-digital-clinical-trials-possibilities-and-challenges/) - The traditional LINK Medical Glögg Mingle is back! Save the date and join on November 30th at your closest location! Digital clinical trials are attracting a lot of attention right now. The pandemic has further raised questions and concerns on how we traditionally conduct clinical trials. There are many steps when conducting a clinical trial
- [Webinar: Making Clinical Trial Safety and Pharmacovigilance easy and affordable with HALOPV](http://danskbiotek.dk/events/webinar-making-clinical-trial-safety-and-pharmacovigilance-easy-and-affordable-with-halopv/) - LINK Medical & Insife have created a partnership to offer easy and affordable clinical trial safety and pharmacovigilance (PV) solutions In this webinar, you will learn how HALOPV, a sophisticated safety toolkit helps biotech and pharma companies manage their clinical trial safety and pharmacovigilance activities in a simple and cost-effective way. Modules are available to
- [Webinar: Fundamentals of USP Biologics](http://danskbiotek.dk/events/webinar-fundamentals-of-usp-biologics/) - Invitation to free webinar: Fundamentals of USP Biologics Safeguarding the quality of medication is fundamental to protecting the public's health, especially as ingredients and products come from all over the world. Biologics are growing faster than any other segment of medicine. Just as they do for chemical medicines, manufacturers must ensure the purity and quality
- [Webinar: Health Innovation and Research opportunities for Denmark with Israeli HMO - Leumit Health Services](http://danskbiotek.dk/events/webinar-health-innovation-and-research-opportunities-for-denmark-with-israeli-hmo-leumit-health-services/) - Invitation to a webinar on Health Innovation and Research Opportunities for Denmark with Israeli HMO - Leumit Health Services Leumit Health Services, a digital pioneer health fund from Israel, in partnership with the Embassy of Israel to Denmark, invites start-ups and innovation centers from Denmark to a webinar to introduce Leumit's innovation activity and the
- [2021 Europe K-Medical Partnering online medico event](http://danskbiotek.dk/events/2021-europe-k-medical-partnering-online-medico-event-from-2nd-to-5th-november-2021/) - Dear members of DANISH BIO – DANSK BIOTEK Please see attached invitation letter from Korea Business Center Copenhagen. In short, DANISH BIO – DANSK BIOTEK members are invited to the 2021 Europe K-Medical Partnering in the period between 2nd and 5th November, 2021 with the purpose of enabling Korean companies discover and understand European medical
- [Nordic Mentor Network for Entrepreneurship & Startup Competition - November 23rd 2021 in Copenhagen](http://danskbiotek.dk/events/nordic-mentor-network-for-entrepreneurship-startup-competition-november-23rd-2021-in-copenhagen/) - 2021 NOME Annual Meeting & Startup Competition November 23rd 14.30 – 19.30 at Industriens hus, Copenhagen Join this annual meeting on November 23 to network with leading life science experts and get to know promising life science startups before everyone else! Registrations are now open for the Annual Meeting of the Nordic Mentor Network for
- [Conference - AI & BIG DATA - LIFE SCIENCE, November 24th 2021](http://danskbiotek.dk/events/conference-ai-big-data-life-science-november-24th-2021/) - FORUM FOR AI & BIG DATA IN PRACTISE in COPENHAGEN November 24th 2021 AI & BIG DATA - LIFE SCIENCE is an annual conference on the practical experiences of the life science sector - a meeting place for the sector to network, share experiences and get updated. It's all about the practical challenges related to
- [Webinar: Next Wave of Immune Engagers in Hematological Malignancies](http://danskbiotek.dk/events/webinar-next-wave-of-immune-engagers-in-hematological-malignancies/) - Johnson & Johnson Innovation virtual event Next Wave of Immune Engagers in Hematological Malignancies 7 September 2021, 15:00 – 18:00 hours CEST The discovery and development of T-cell redirecting modalities, such as bispecific antibodies and CAR-Ts, holds great promise for patients with multiple myeloma and other hematological malignancies, such as lymphoma and acute myeloid leukemia.
- [Webinar: Antimicrobial Resistance - Breakthrough Innovation and Breaking Barriers](http://danskbiotek.dk/events/webinar-antimicrobial-resistance-breakthrough-innovation-and-breaking-barriers/) - Johnson & Johnson Innovation – JLABS webinar Antimicrobial Resistance - Breakthrough Innovation and Breaking Barriers 15 September 2021, 16:00 – 17:00 hours CEST Why aren’t (enough) new antibiotics being developed to address the AMR challenge? What other innovations might help without increasing antibiotic resistance? As multi-drug resistant bacteria become increasingly threatening to global public health
- [DANISH BIO – DANSK BIOTEK members' meeting 15 September 2021: New Government Strategy for Life Science](http://danskbiotek.dk/events/save-the-date-dansk-biotek-members-meeting-on-new-government-strategy-for-life-science/) - LUNDGRENS and DANISH BIO – DANSK BIOTEK will be serving snacks and refreshments. The event is free of charge for members; non-members will be charged a fee of 500 DKK.
- [Online event invitation August 24th 2021- Development of Orphan Drugs within Oncology](http://danskbiotek.dk/events/development-of-orphan-drugs-within-oncology-online-event-invitation-august-24th-2021/) - MVA ONCOLOGY NETWORK MEETING – DEVELOPMENT OF ORPHAN DRUGS WITHIN ONCOLOGY Medicon Valley Alliance together with Ascelia Pharma have the pleasure to invite DANISH BIO – DANSK BIOTEK members to the 11th meeting of the Medicon Valley Alliance Oncology Network on the 24th of August, 2021. In this MVA Oncology network webinar Ascelia Pharma will
- [Life Science Meetup August 19th 2021](http://danskbiotek.dk/events/life-science-meetup-august-19th-2021/) - Tre inspirerende og tankevækkende timer med aktuelle debatter og videndeling Life Science Huset kickstarter efteråret med en indholdsrig eftermiddag, når der for første gang inviteres til Life Science Meetup – et slags mini-folkemøde – den 19. august kl. 13.00 til 16.00. Det bliver tre inspirerende, overraskende og tankevækkende timer med aktuelle debatter, talks og videndeling.
- [Lifecycle Management in Pharma - Online Conference](http://danskbiotek.dk/events/lifecycle-management-in-pharma-online-conference/) - DANISH BIO – DANSK BIOTEK members are invited to join the upcoming "Lifecycle Management in Pharma", online conference which will take place on the 7th of July 2021 at 3:00pm CET. Main topics: Drug Delivery Devices as Consideration for LCM in Pharma Digital Health-connected Devices LCM aspects Benefits of LCM Approach in Pharma Strategies to
- [Pharmaceutical Nanotechnology Online Conference 2021](http://danskbiotek.dk/events/pharmaceutical-nanotechnology-online-conference-2021/) - DANISH BIO – DANSK BIOTEK members are invited to BCF Group's upcoming "Pharmaceutical Nanotechnology Online Conference 2021", which will take place on the 9th of June 2021 at 15:00 CET Among the speakers are Mr. Ricardo Flidor Totovao, Scientific Collaborator at Centre National de la Recherche Scientifique, Dr. Ankit Rochani, Research Fellow and Instructor at
- [Surviving early biotech pitfalls - Webinar](http://danskbiotek.dk/events/surviving-early-biotech-pitfalls-webinar/) - Webinar: Surviving early biotech pitfalls – Overcoming challenges when moving from non-clinical to clinical Going from non-clinical to clinical is no easy step. Join this free webinar on May 27th and listen to key experts from essential product development areas to talk about how to survive and minimize the early risks biotech companies face during
- [NOTICE TO CONVENE THE ANNUAL GENERAL MEETING OF DANISH BIO – DANSK BIOTEK 6 May 2021](http://danskbiotek.dk/events/notice-to-convene-the-annual-general-meeting/) - NOTICE TO CONVENE THE ANNUAL GENERAL MEETING DANISH BIO – DANSK BIOTEK (CVR no. 28 43 65 72) Notice is hereby given to the Annual General Meeting of DANISH BIO – DANSK BIOTEK to be held on Thursday, 6 May 2021, at 16:00 (CEST) Due to the COVID-19 pandemic, the Annual General Meeting will be
- [Virtual Members’ Meeting: The alternative listing - SPACs vs IPO vs reverse merger?](http://danskbiotek.dk/events/virtual-members-meeting-listing-strategies-stockholm-or-new-york/) - As the turbulent times of covid-19 affecting our private and business lives seem far from over, we will be continuing our series of short virtual meetings via Zoom. Over three consecutive weeks, we have invited experienced industry professionals from different parts of the biotech financing sphere to elaborate on the overall theme of Funding. Each
- [Webinar: Virtuelt morgenmøde om den nye life science-strategi](http://danskbiotek.dk/events/webinar-virtuelt-morgenmode-om-den-nye-life-science-strategi/) - Dansk Erhverv, Lif, Medicoindustrien, DANISH BIO – DANSK BIOTEK og DiaLab inviterer til virtuelt morgenmøde om den nye life science-strategi Kære medlem i DANISH BIO – DANSK BIOTEK Regeringen lancerer i morgen en ny life science-strategi, og på tirsdag præsenterer Erhvervsministeriet strategien frisk fra trykken, når vi inviterer til virtuelt morgenmøde: Tirsdag d. 20. april
- [Virtual Members’ Meeting: The alternative listing - SPACs vs IPO vs reverse merger?](http://danskbiotek.dk/events/virtual-members-meeting-the-alternative-listing-spacs-vs-ipo-vs-reverse-merger/) - As the turbulent times of covid-19 affecting our private and business lives seem far from over, we will be continuing our series of short virtual meetings via Zoom. Over three consecutive weeks, we have invited experienced industry professionals from different parts of the biotech financing sphere to elaborate on the overall theme of Funding. Each
- [Virtual Members’ Meeting: Funding strategies – VC or family office?](http://danskbiotek.dk/events/virtual-members-meeting-funding-strategies-vc-or-family-office/) - As the turbulent times of covid-19 affecting our private and business lives seem far from over, we will be continuing our series of short virtual meetings via Zoom. Over three consecutive weeks, we have invited experienced industry professionals from different parts of the biotech financing sphere to elaborate on the overall theme of Funding. Each
- [Invitation: Life Science Matchmaking Day 2021 - virtual](http://danskbiotek.dk/events/invitation-life-science-matchmaking-day-2021-virtual/) - Aarhus University, the faculties of Natural Sciences, Technical Sciences and Health, invites members of DANISH BIO – DANSK BIOTEK to Life Science Matchmaking Day 2021 Life Science Matchmaking Day is a unique opportunity for companies to establish collaborations with students within life science – ranging from collaborative projects or thesis to internships and student jobs.
- [Balancing interests in your IP approach Webinar](http://danskbiotek.dk/events/balancing-interests-in-your-ip-approach-webinar/) - Balancing interests in your IP approach Webinar 20 April 2021, 15:30 – 17:00 hours CET Whether innovators are looking for investments, research collaborations, services or potential partners, every step of the way start-ups and scale-ups need to have an Intellectual Property (IP) strategy in place. Join Johnson & Johnson Innovation - JLABS to hear from
- [Clinical Innovation Webinar: Making Patient Centricity a Reality](http://danskbiotek.dk/events/clinical-innovation-webinar-making-patient-centricity-a-reality/) - Clinical Innovation Webinar: Making Patient Centricity a Reality 12 April 2021, 15:30 – 17:00 hours CET Where do we stand on making clinical development more patient-centric? Are the emergence of platform trials, the use of real-world data, involving patient insights in clinical trial design, and decentralised care having an impact on how new potential healthcare
- [Early Stage Funding for Life Science Companies in Medicon Valley](http://danskbiotek.dk/events/early-stage-funding-for-life-science-companies-in-medicon-valley/) - Digital Meeting: Early Stage Funding for Life Science Companies in Medicon Valley The digital meeting is focusing on identifying and attracting funding for companies in the early stages of development. Attracting funds for early stage lifescience companies is challenging, however necessary, to ensure further development and growth. Funding can come from many different sources; public
- [Immunology Virtual Partnering Event: 9-12 March, 2021](http://danskbiotek.dk/events/immunology-virtual-partnering-event-9-12-march-2021/) - At Inova, the aim is to accelerate partnering by facilitating the bridge between science and business. From 9-12 March, Inova in collaboration with Biotechnology Innovation Organization (BIO), are organizing a 4-day virtual partnering event on immunology where participants will have the opportunity to network using the partnering platform and showcase their companies through short video
- [Oncology Virtual Partnering Event: 2-5 March, 2021](http://danskbiotek.dk/events/oncology-virtual-partnering-event-2-5-march-2021/) - At Inova, the aim is to accelerate partnering by facilitating the bridge between science and business. From 2 to 5 March, Inova in collaboration with BIO, are organizing a 4-day virtual partnering event on oncology, where researchers, biotech companies and business development executives from biopharmaceutical companies will be able to network in a virtual space.
- [FDA-EMA 4-part virtual seminar series - March 22, April 19, May 17 and June 14, 2021](http://danskbiotek.dk/events/fda-ema-4-part-virtual-seminar-series-march-22-april-19-may-17-and-june-14-2021/) - REGULATORY DEVELOPMENTS & TRENDS IN MEDICAL PRODUCTS REGULATION The Embassy of Denmark in Washington, DC and The Danish Medicines Agency are proud to present a 4-part virtual seminar series in collaboration with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Each session will focus on a specific theme addressing related
- [Online Medicon Valley Alliance Medtech Network meeting – Digital transformation in Medtech](http://danskbiotek.dk/events/online-medicon-valley-alliance-medtech-network-meeting-digital-transformation-in-medtech/) - Delivering patient centric care through digital transformation in Medtech Medicon Valley Alliance Medtech Network is hosting a digital network meeting on the theme of digital transformation in the Medtech industry with focus on patient centric care by highlighting some recent developments within the field in the Öresund region. Medicon Valley feature world class healthcare and
- [4th Annual Inhalation & Respiratory Drug Delivery Online Conference 25-26 February 2021](http://danskbiotek.dk/events/4-annual-inhalation-respiratory-drug-delivery-online-conference-25-26-february-2021/) - 4th Annual Inhalation & Respiratory Drug Delivery Online Conference will give you a unique opportunity to discuss last trends and innovations in inhalation technologies, the new challenges and approaches of the inhaler models on the market. The agenda also features digital future of effective respiratory devices, key studies on the latest trends in inhalation devices
- [Life Sciences Europe 26-28 January 2021 - Digital Conference](http://danskbiotek.dk/events/life-sciences-europe-26-28-january-2021-digital-conference/) - How Covid is Driving Life Sciences HR Leaders to Accelerate Radical Change in Engagement, Culture and Productivity To Boost Performance, Agility and Innovation Now LEAP HR forums provide industry-specific environments to challenge traditional thinking around how to build better companies. Their goal is to create a movement of bold, ambitious business leaders who want to
- [Nordic Life Science Days 20-23 April 2021 - digital format](http://danskbiotek.dk/events/nordic-life-science-days-20-23-april-2021-digital-format/) - Life Science Days - A welcome arena for business and peopleNordic The 8th Nordic Life Science Days Digital will be held on 20-23 April 2021 , with a full live educational program on 20-21 April and 4 days of 24/24 partnering on 20-23 April. Life Science Days is the largest Nordic partnering conference dedicated to
- [Virtual Members’ Meeting: Covid-19 - A Biotech Perspective](http://danskbiotek.dk/events/virtual-members-meeting-covid-19-a-biotech-perspective/) - Dear all, As touched upon in a previous newsletter, DANISH BIO – DANSK BIOTEK has been frustrated not to be able to arrange members meetings, biotek salons and other networking events due to the worldwide pandemic ! The situation has already made us decide to reduce the 2021 membership fee by 50% for current members
- [BioFIT 2020 Partnering Event, 9th Edition](http://danskbiotek.dk/events/biofit-2020-partnering-event-9th-edition/) - BioFIT 2020 - The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field With more than 1,300 international participants composed of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostics companies, and pre-seed / seed / Series A investors, BioFIT is the leading partnering
- [An Ocean of Opportunities](http://danskbiotek.dk/events/an-ocean-of-opportunities/) - How marine biotechnology provides much-needed solutions The Norwegian Embassy in Copenhagen and Biotech North invite DANISH BIO – DANSK BIOTEK's members to participate in a matchmaking webinar on marine life science and biotech. The COVID-19 crisis has shown how crucial the life science industry is. After the pandemic has brought the world to its knees,
- [WEBINAR: Realizing the Promise of Digital Health in the USA](http://danskbiotek.dk/events/webinar-realizing-the-promise-of-digital-health-in-the-usa/) - Invitation to Webinar: Realizing the Promise of Digital Health in the USA The Embassy of Denmark in the USA is pleased to invite DANISH BIO – DANSK BIOTEK members to an exciting webinar discussing the latest developments in the application of digital technologies in prevention, diagnosis, treatment, and management of health and disease. Sneak Peak
- [JLABS webinar - Meet with Optum Ventures](http://danskbiotek.dk/events/jlabs-webinar-meet-with-optum-ventures/) - JLABS webinar - Meet with Optum Ventures 3 December 2020 | 12:00 hours CET From Johnson & Johnson we have received this invitation for our members: Do you plan to launch your digital health concept in the US healthcare market? Are you ready to gain valuable insights and connect with a potential partner or collaborator?
- [JLABS webinar - Meet with BioGeneration Ventures](http://danskbiotek.dk/events/jlabs-webinar-meet-with-biogeneration-ventures/) - JLABS webinar - Meet with BioGeneration Ventures 13 November 2020 | 10:00 hours CET From Johnson & Johnson we have received this invitation for our members: Partnering with a Venture Capitalist (VC) may fast forward your innovation, because they could bring much more to the table than just funding. Virtually join JLABS, where Edward van
- [Virtual Partnering Event:  Meet with Johnson & Johnson Innovation in the Nordics](http://danskbiotek.dk/events/virtual-partnering-event-meet-with-johnson-johnson-innovation-in-the-nordics/) - Meet with Johnson & Johnson Innovation in the Nordics 24/25 November | Online From Johnson & Johnson we have received this invitation for our members: Are you a disruptive life science innovator from the Nordics? Are you working to revolutionize human health? If so, we would like to learn more. Apply before 27 October to
- [MVA ANNUAL MEETING 2020 - online event](http://danskbiotek.dk/events/mva-annual-meeting-2020-online-event/) - MVA ANNUAL MEETING 2020 Supporting research and innovation in the life science sector has been a long-standing strategic priority of both the Swedish and the Danish governments. In 2020 the COVID-19 pandemic has transformed people’s lives and impacted every industry. But the pandemic has not slowed innovation - it’s amplifying it to historic levels. The
- [A Virtual Shortcut to UK Life Science Investments](http://danskbiotek.dk/events/a-virtual-shortcut-to-uk-life-science-investments/) - Are you a biotech company looking to raise capital or build a network in the UK? You are invited to join a one-hour webinar followed by an interactive pitching session to UK investors! Click here to read the details of the FREE WEBINAR with the following speakers: H.E. Lars Thuesen, Ambassador of Denmark in the
- [DANISH BIO – DANSK BIOTEK EXTRAORDINARY GENERAL MEETING THURSDAY 8 OCTOBER 2020 & REDUCED MEMBERSHIP FEE](http://danskbiotek.dk/events/dansk-biotek-extraordinary-general-meeting-thursday-8-october-2020/) - Dear member, 2020 has been a very unusual year due to the covid-19 pandemic which is still affecting our day-to-day lives. Both in our private and in our business sphere, we have had to accept limited socializing, travel bans, virtual conferences, meetings etc. The situation has also deeply affected DANISH BIO – DANSK BIOTEK in
- [CANCELLED / POSTPONED: Biotek Salon #21: IP strategies for biotechs – Why is it important?](http://danskbiotek.dk/events/biotek-salon-21-ip-strategies-for-biotechs-why-is-it-important/) - As a consequence of covid-19 restrictions, it has been decided to cancel the planned the Biotek Salon #21 on Thursday 1 October 2020. DANISH BIO – DANSK BIOTEK and LUNDGREN’s Law firm are very sorry about this, as we had an exciting program lined up and had looked forward to meeting our members again. However, we will revisit
- [BIO-Europe® 2020 Digital - 26th Annual International Partnering Conference](http://danskbiotek.dk/events/bio-europe-2020-digital-26th-annual-international-partnering-conference/) - Partnerships that drive life science dealmaking For more than 25 years, BIO-Europe has played an instrumental role in bringing biopharma and investment leaders together to facilitate innovation and medical breakthroughs. The 26th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe, though in 2020 by necessity BIO-Europe has gone fully digital and
- [Marketing Material – A Nordic approach (Webinar)](http://danskbiotek.dk/events/marketing-material-a-nordic-approach-webinar/) - LINK Medical Research has gathered top authorities for ethical compliance within the Nordic countries. The aim of the webinar is to present the most important differences between the national Rules for Promotion of Medicinal Products in the Nordic countries. In addition, the webinar will focus on guidance regarding collaboration with healthcare during the corona pandemic.
- [Oncology Virtual Partnering Event](http://danskbiotek.dk/events/oncology-virtual-partnering-event/) - Where the best science comes to meet Oncology is one of the most challenging areas for research and development, but there are critical junctures where the right environment is crucial for success - and where partnering can help bring the best science forward. At Inova, the aim is to facilitate the bridge between science and
- [Online Global Cluster Partnering - Healthcare](http://danskbiotek.dk/events/online-global-cluster-partnering-healthcare/) - BECOME A PARTNER OF B2B MATCHMAKING EVENT - GLOBAL CLUSTER PARTNERING - HEALTHCARE Members of DANISH BIO – DANSK BIOTEK have the opportunity to become a partner of the online B2B matchmaking event Global Cluster Partnering - Healthcare taking place August 26-27, 2020. Partners of GCP-Healthcare get 100 tickets for free (please contact office@danskbiotek.dk to
- [Life Science Career Fair ‘20](http://danskbiotek.dk/events/life-science-career-fair-20/) - The Life Science Career Fair '20 is a one-of-a-kind opportunity for your company to engage with highly motivated and interested students in a unique networking setting and in an engaging way introduce your work to a new crowd. There is a small participation fee (see attachment) for companies to cover Synapse - Life Science Connect's
- [Let's work together at the LSX World Congress 2020](http://danskbiotek.dk/events/lets-work-together-at-the-lsx-world-congress-2020/) - STRATEGY, INVESTMENT, PARTNERING & DEAL MAKING FOR NORDIC LIFE SCIENCE EXECUTIVE LEADERS - The 3rd annual LSX Nordic Congress is going virtual! The decision to deliver the region's leading investment and partnering event as a virtual offering will ensure LSX Nordic can continue to help Nordic-based companies maintain business continuity through access to local and
- [3rd Annual Inhalation and Respiratory Drug Delivery Conference](http://danskbiotek.dk/events/3rd-annual-inhalation-and-respiratory-drug-delivery-conference/) - The BCF Group announces "3rd Annual Inhalation and Respiratory Drug Delivery" Conference, which will take place on the 1st – 2nd of October, 2020, in Prague, Czech Republic. Main topics of the conference: Micronization: of The API/Drug Environmental Friendliness of MDI & DPI Inhaler Regulation Status Of Drug Delivery Devices After Brexit Effective OINDPs Treatment
- [COVID-19: Risk Based Quality Management & Monitoring Webinar with Gunnar Danielsson](http://danskbiotek.dk/events/covid-19-risk-based-quality-management-monitoring-webinar-with-gunnar-danielsson/) - When it comes to the current COVID-19 situation, RBQM is a critical concept to master as it involves more remote work and centralized efforts, which will be essential to clinical trials moving forward. This requirement is an enhanced concept and requires a change in the mindset for the implementation of updated and new processes
- [DANISH BIO – DANSK BIOTEK ANNUAL GENERAL MEETING MAY 7, 2020](http://danskbiotek.dk/events/dansk-biotek-annual-general-meeting-may-7th-2020/) - Due to the outbreak of coronavirus/covid-19, all members are urged to give power of attorney to Plesner's Thomas Holst Laursen on thl@plesner.com, and not to attend the general meeting in person. NOTICE TO CONVENE THE ANNUAL GENERAL MEETING DANISH BIO – DANSK BIOTEK (CVR no. 28 43 65 72) Notice is hereby given to the
- [-P O S T P O N E D- Joint FDA-EMA Seminar](http://danskbiotek.dk/events/joint-fda-ema-seminar/) - -P O S T P O N E D- More information to follow when a new date is available. The Embassy of Denmark in Washington, DC is proud to present for the first time a seminar in collaboration
- [COVID19 Virtual Partnering Event](http://danskbiotek.dk/events/covid19-virtual-partnering-event/) - #PartneringAgainstCovid19 Do you want to find the perfect partner organisation to develop & deliver solutions to #COVID19? #PartneringAgainstCOVID19 is the unique virtual partnering event you have been looking for! Today’s COVID-19 crisis requires a previously unimaginable acceleration of output from the biopharmaceutical and life sciences industry. Now there is an opportunity for DANISH BIO –
- [-NEW DATE-  New Updates in Drug Formulation & Bioavailability](http://danskbiotek.dk/events/new-updates-in-drug-formulation-bioavailability-2/) - -NEW DATE- SEPTEMBER 30th 2020 EVENT LINK New updates in Drug Formulation & Bioavailability started in 2013 and is a platform based on the concept of synergies between "science" and "business". The presented content and topics will focus on advancements in formulations and cutting edge technologies that can allow cheaper, safer and effective drugs. Pharmaceutical
- [-NEW DATE-  The Future of Swedish & Danish Life Science](http://danskbiotek.dk/events/the-future-of-swedish-danish-life-science-2/) - -NEW DATE- SEPTEMBER 29th 2020 EVENT LINK Collaborations, directions and investments of the future Life Science in the Öresund region with its thriving ecosystem of cutting-edge science, hundreds of life science companies and investments in research infrastructure, major projects and product development is in a continuous growth mode. The 9th edition of our international partnering
- [-P O S T P O N E D- BIOROBOOST Round Table - Standards & Synbio, views of the BioTech Industry](http://danskbiotek.dk/events/bioroboost-round-table-standards-synbio-views-of-the-biotech-industry/) - -P O S T P O N E D- CHECK EVENT LINK FOR NEW DATE TO BE CONFIRMED The BIOROBOOST, a Horizon 2020 project assesses the convenience and opportunity to develop standards in synthetic biology.
- [MVA Microbiome Network webinar](http://danskbiotek.dk/events/mva-microbiome-network-webinar/) - WELCOME TO THE FIRST MVA MICROBIOME NETWORK WEBINAR! Keynote on EFSA regulatory perspectives on risk assessments and probiotics The microbiome community in the Medicon Valley region is vibrant and growing. Thanks to an overwhelming interest in the topic and keynote of the March 17 meeting of the network that needed to be postponed, MVA have
- [BIO-Europe Spring® 2020 - NOW DELIVERED DIGITALLY](http://danskbiotek.dk/events/bio-europe-spring-2020/) - ***IMPORTANT CHANGE: BIO-Europe Spring will be delivered as a full digital event which will take place over the entire week of March 23–27, 2020. In light of the increasing travel restrictions worldwide due to the ongoing COVID-19 outbreak, BIO-Europe Spring 2020 will now be delivered virtually Read more here. People who keep on doing business and
- [BIOLOGICS WORLD NORDICS 2020](http://danskbiotek.dk/events/biologics-world-nordics-2020/) - Biologics World Nordic is the only focused biologic drugs and vaccines conference in the Nordic region. It will bring together the complete network of the Nordic biologics industry including region’s smaller Biopharma, Big Pharma, International Biopharma, CMOs, CROs, Technocrats & Solution Providers. Partnership opportunities, scientific innovation, manufacturing best practices are at the centre stage waiting
- [MVA Microbiome Network Meeting](http://danskbiotek.dk/events/mva-microbiome-network-meeting/) - REGULATORY PERSPECTIVES ON PROBIOTICS AND THE COMMERCIALISATION OF MICROBIOME RESEARCH The microbiome community in the Medicon Valley region is vibrant and growing. Medicon Valley Alliance, together with one of it's members – McNeil AB – welcomes you to the 5th MVA Microbiome Network meeting. The topic for this meeting will be the regulatory framework for
- [Europe CEO - The Perfect Prelude to Partnering](http://danskbiotek.dk/events/europe-ceo-the-perfect-prelude-to-partnering/) - Europe CEO is an invitation-only, off-the-record forum that brings together industry leaders to network and share insights on the challenges and opportunities impacting the international biopharma community. The one-day event takes place just before BIO-Europe Spring, and includes a number of panel discussions, fireside chats, and plenty of networking opportunities during breakfast, lunch and the
- [LSX World Congress 2020 - 15% Discount for DANISH BIO – DANSK BIOTEK Members](http://danskbiotek.dk/events/lsx-world-congress-2020-15-discount-for-dansk-biotek-members/) - The 6th annual LSX World Congress is a high-calibre, senior executive, two-day conference, exhibition and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses. It is the leading event for attracting the C-suite of the global life science
- [DANISH BIO – DANSK BIOTEK Members’ Meeting 6 February 2020: State of the Union - Early Stage Financing](http://danskbiotek.dk/events/dansk-biotek-members-meeting-state-of-the-union-early-stage-financing/)
- [Biotek Salon #20: Toolbox for CAR-T cell development and gene therapy programs](http://danskbiotek.dk/events/biotek-salon-20-toolbox-for-car-t-cell-development-and-gene-therapy-programs/) - DANISH BIO – DANSK BIOTEK & Unilabs A/S invite you to a workshop on Epitope mapping, CAR-T cell therapy and gene therapy Agenda: 13:30 Registration and networking 13:50 Welcome by DANISH BIO – DANSK BIOTEK and Peder S. Andersen, Head of Business Development Unilabs A/S 14:00 Thomas Mørch Frøsig PhD, CEO and Founder at ImmuMap
- [IPO for early-stage life science companies](http://danskbiotek.dk/events/ipo-for-early-stage-life-science-companies/) - Pros and cons and how to do it SPEAKER: Morten Albrechtsen, CEO FluoGuide Early-stage life science companies are often struggling for cash. A common misconception is that small life science start-ups cannot be listed on the stock market, but this is not necessarily so. In spring 2019, the small Medicon Valley-based early-stage life science company
- [Entrepreneurial processes and Open Innovation in the Medtech Industry – why and how](http://danskbiotek.dk/events/entrepreneurial-processes-and-open-innovation-in-the-medtech-industry-why-and-how/) - The Medtech industry in the Greater Copenhagen area concists of everything from large and medium sized companies to startups. When the regulatory certifications are in place and the growth of the company is the main objective, how is it possible to stay in or stimulate the entrepreneurial mindset and work flow, to keep inventing new
- [DANISH BIO – DANSK BIOTEK members’ meeting: Biotech opportunities in China](http://danskbiotek.dk/events/dansk-dansk-biotek-members-meeting-biotech-opportunities-in-china/)
- [High Tea: How to deal with circular economy in the Danish life science sector](http://danskbiotek.dk/events/high-tea-how-to-deal-with-circular-economy-in-the-danish-life-science-sector/) - The life science industry must circulate ressources In spring 2019, the European Commission adapted a comprehensive report in the implementation of the Circular Economy Action Plan. The transition to a more circular economy in the EU, where the value of products, materials and resources is maintained in the economy for as long as possible, and
- [Registration is open for Bioagora 2019](http://danskbiotek.dk/events/registration-is-open-for-bioagora-2019-19-november-at-the-university-of-copenhagen/) - The main theme is autoimmune diseases, when Biopeople together with partners and sponsors invite you to attend Bioagora 2019 The theme is reflected by the two key-note speakers Magdalene Janina Laska, CSO at Aimvion and Thomas Vorup-Jensen, Professor at the Department of Biomedicine, Aarhus University. Everyone (researchers, students, companies, patient organisations and other stakeholders) interested
- [Workshop on Scientific Advice](http://danskbiotek.dk/events/workshop-on-scientific-advice/) - Informal Scientific Advice to Entrepreneurial “Newcomers” and Companies (SMEs) in the Development of Medicinal Products “What you need to know to understand” Abstract: The Danish Medicines Agency and Denmark’s Life Science Cluster, Biopeople, are pleased to announce this event. It is open to entrepreneurial researchers and employees in companies that are in need to know
- [GENESIS 2019 - London's Premier Life Science & Healthcare Networking Conference](http://danskbiotek.dk/events/genesis-2019-londons-premier-life-science-healthcare-networking-conference/) - New Horizons in Life Science and Healthcare Recent years have been transformational for the sector in many ways. Advances in science, technology inputs, communication strategies, patient engagement and health economics have influenced how innovative products may be funded, valued, adopted and ultimately benefit patients. Under the overarching theme of New Horizons in Life Science &
- [Medicon Valley Alliance Microbiome Network and its 4th meeting!](http://danskbiotek.dk/events/medicon-valley-alliance-microbiome-network-and-our-4th-meeting/) - Welcome to Medicon Valley Alliance Microbiome Network and the 4th meeting! Translational Microbiome Research in Medicon Valley The microbiome community in the Medicon Valley region is vibrant and growing. Medicon Valley Alliance, together with one of our members – University of Copenhagen – welcomes you to the 4th MVA Microbiome Network meeting. Hear about ongoing translational microbiome research and a newly initiated
- [Welcome to Medicon Valley Alliance R&D Network and its 4th meeting!](http://danskbiotek.dk/events/welcome-to-medicon-valley-alliance-rd-network-and-our-4th-meeting/) - Now is the time to get involved and take advantage of the four largest assets for life science research and innovation of our region: MAX IV, ESS, DESY and European XFEL! Welcome to Medicon Valley Alliance R&D Network and the 4th meeting! Medicon Valley Alliance (MVA), together with Hanseatic League of Science (HALOS), invites you
- [Save the Date! TMC Health Cluster Visit & Startup Pitch](http://danskbiotek.dk/events/save-the-date-tmc-health-cluster-visit-startup-pitch/) - The Consulate General of Denmark in Houston in collaboration with Texas Medical Center (TMC) are visiting Denmark to sign a formal BioBridge agreement between Denmark and TMC to collaborate on research, innovation and commercialization. At this event, Danish companies and startups have the opportunity to learn about TMC, the world's largest medical city, with more
- [Using a ‘virtual pharma model’ to attract targeted investors for biotech innovators](http://danskbiotek.dk/events/using-a-virtual-pharma-model-to-attract-targeted-investors-for-biotech-innovators/) - Welcome to Medicon Valley Alliance Good Morning Meeting with Syneos Health on: De-risk investment, de-risk operational delivery and maximize the return on investment (ROI) for all parties How to position your organization for fundraising using a virtual pharma partner model – Using the ‘two heads are better than one’ approach to investor outreach, coupled with
- [Event - How to prepare for an inspection?](http://danskbiotek.dk/events/event-how-to-prepare-for-an-inspection/) - Join us Oct. 1 in Copenhagen where we have gathered two former GCP Inspectors, Philip Lange Møller from Denmark and Gunnar Danielsson from Sweden, under one roof to share their knowledge and experiences. In this seminar, you will learn key things to expect when the GCP inspector is inevitably at the door. This is a rare and
- [Invitation: Business & Science Mission of Healthcare Sector Companies to Portugal](http://danskbiotek.dk/events/invitation-business-science-mission-of-healthcare-sector-companies-to-portugal/) - The Portuguese Trade & Investment Agency is organizing, in collaboration with Health Cluster Portugal, a Business & Science Mission of Danish and Swedish, Healthcare sector companies to Portugal, on October 2nd-3rd, 2019. The aim of this mission is the establishment of new business and scientific partnerships between Danish/Swedish companies and Portuguese R&D institutions, interface centres,
- [Medicon Valley Alliance Good Morning Meeting on Cancer immunotherapies - Preparing for a successful clinical program](http://danskbiotek.dk/events/medicon-valley-alliance-good-morning-meeting-on-cancer-immunotherapies-preparing-for-a-successful-clinical-program/) - Welcome to Medicon Valley Alliance Good Morning Meeting on Cancer immunotherapies - Preparing for a successful clinical program with KLIFO. Recent advances in immuno-oncology have shown great promise for effective and safer treatments. Best examples are the check point inhibitors which are moving towards first line treatment in various cancer types. Currently, numerous drug modalities within
- [BIO-Europe® 2019 - 25th Annual International Partnering Conference](http://danskbiotek.dk/events/bio-europe-2019-25th-annual-international-partnering-conference/) - Initiate new partnerships through life science partnering The 25th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,350 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an
- [Biotek Salon #19: How to implement foundations of success in the biotech development from the beginning](http://danskbiotek.dk/events/biotek-salon-19/) - DANISH BIO – DANSK BIOTEK and LINK Medical Research invite you to a discussion on “How to implement foundations of success in the biotech development from the beginning?" The Biotech & MedTech industry are increasingly complex from a commercial, regulatory, and clinical perspective. Join us to learn about essential development steps to take and get
- [DANISH BIO – DANSK BIOTEK members’ meeting: Antibiotic Resistance - Improving the Effectiveness of Antibiotics](http://danskbiotek.dk/events/dansk-biotek-members-meeting-antibiotic-resistance-improving-the-effectiveness-of-antibiotics/)
- [NOME Annual Meeting & Startup Competition](http://danskbiotek.dk/events/nome-annual-meeting-startup-competition/) - Join NOME at Industriens Hus in Copenhagen to celebrate the Nordic life science ecosystem. Network with leaders of the life science industry in the Nordic countries, including the NOME mentors, meet the NOME partners and ventures and catch up with old and new colleagues. NOME STARTUP COMPETITION At the startup competition, you can present your
- [Indkaldelse til ekstraordinær generalforsamling den 13. juni 2019 / Notice to convene the Extraordinary General Meeting 13 June 2019](http://danskbiotek.dk/events/indkaldelse-til-ordinaer-generalforsamling-den-13-juni-2019-notice-to-convene-the-annual-general-meeting-13-june-2019/) - INDKALDELSE TIL EKSTRAORDINÆR GENERALFORSAMLING I DANISH BIO – DANSK BIOTEK (CVR-nr. 28 43 65 72) Der indkaldes herved til ekstraordinær generalforsamling i DANISH BIO – DANSK BIOTEK til afholdelse Torsdag den 13. juni 2019, kl. 10.00 (CET) hos Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 København Ø Dagsordenen er som følger: a) VALG AF DIRIGENT b)
- [MVA Annual Meeting 2019 Ambitions and Visions – Regional life science and health care in a globalized world](http://danskbiotek.dk/events/mva-annual-meeting-2019-ambitions-and-visions-regional-life-science-and-health-care-in-a-globalized-world/) - One life science cluster, two national life science strategies and three regions To discuss how to ensure the competitiveness of our region in a globalized world, Medicon Valley Alliance has the pleasure of inviting you to an afternoon with inspirational regional, national and international speakers. The topics of this years Annual Meeting will be: How
- [MVA: Good Morning Meeting – Biomarkers analysis challenges in Clinical Trials](http://danskbiotek.dk/events/mva-good-morning-meeting-biomarkers-analysis-challenges-in-clinical-trials/) - Welcome to MVA’s Good Morning Meeting on “Biomarkers analysis challenges in Clinical Trials” with HalioDx. One of the biggest challenges in immunotherapy area is to find accurately which patients will benefit from a therapy or a combination of therapies. To help drug developers getting this information, the assessment of biomarkers through clinical research studies represent
- [DANISH BIO – DANSK BIOTEK Annual Members' Meeting 9 May 2019](http://danskbiotek.dk/events/dansk-biotek-annual-members-meeting-9-may-2019/)
- [3rd Medicon Valley Alliance Network Meeting](http://danskbiotek.dk/events/3rd-medicon-valley-alliance-network-meeting/) - Welcome to Medicon Valley Alliance R&D Network's 3rd meeting! What can R&D learn from orphan drug development: – The use of AI to find the right patients – Working closely with stakeholders Finding the right treatment for the right patient is one major challenge within R&D. The challenges inherent in drug development in rare diseases has enforced
- [6th Medicon Valley Medtech Network Meeting](http://danskbiotek.dk/events/6th-medicon-valley-medtech-network-meeting/) - Welcome to Medicon Valley Medtech Network's next meeting! Biological Implants, Bioprinting, and New Materials – The wonderful complexity of new technology in a biological context Medicon Valley Alliance, together with one of their members – Bioneer – also welcomes members of DANISH BIO – DANSK BIOTEK to the Medicon Valley Network and their 6th meeting. During this
- [Indkaldelse til ordinær generalforsamling den 9. maj 2019 / Notice to convene the Annual General Meeting 9 May 2019](http://danskbiotek.dk/events/indkaldelse-til-ordinaer-generalforsamling-den-9-maj-2019-notice-to-convene-the-annual-general-meeting-9-may-2019/) - INDKALDELSE TIL ORDINÆR GENERALFORSAMLING I DANISH BIO – DANSK BIOTEK (CVR-nr. 28 43 65 72) Der indkaldes herved til ordinær generalforsamling i DANISH BIO – DANSK BIOTEK til afholdelse Torsdag den 9. maj 2019, kl. 14.00 (CET) hos Lundbeck A/S, Ottiliavej 9, 2500 Valby Dagsordenen er som følger: a) VALG AF DIRIGENT b) FORMANDENS BERETNING
- [HealthTech Investor Day - 20% discount for DANISH BIO – DANSK BIOTEK members](http://danskbiotek.dk/events/healthtech-investor-day-20-discount-for-members-of-dansk-biotek/) - France Biotech, with the help of the European health innovation ecosystem, is organizing a HealthTech Investor Day in Paris (Peninsula Palace), on June 24th & 25th - www.htid-paris.com, under the high patronage of the French President. This international event has our support as well as of several European partners such as the European Biopharmaceutical Enterprises
- [New Updates in Drug Formulation & Bioavailability](http://danskbiotek.dk/events/new-updates-in-drug-formulation-bioavailability/) - New updates in Drug Formulation & Bioavailability started in 2013 and is a platform based on the concept of synergies between "science" and "business". The presented content and topics will focus on advancements in formulations and cutting edge technologies that can allow cheaper, safer and effective drugs. Pharmaceutical formulation can have a huge impact on
- [The Future of Swedish & Danish Life Science](http://danskbiotek.dk/events/the-future-of-swedish-danish-life-science/) - Theme for 2019: How can Swedish and Danish collaborations in R&D and innovation make the patient a winner? The international partnering-event The Future of Swedish & Danish Life Science started in 2012 and includes a combination of partnering (pre-bookable one-on-one meetings), presentations, exhibition and informal networking. These four core elements of the day run in
- [Biotek Salon #18: Novel Process Technology](http://danskbiotek.dk/events/biotek-salon-18-novel-process-technology/) - DANISH BIO – DANSK BIOTEK and BIOPRO invite you to an inspirational afternoon on novel process technology - approaches to biotech/biopharma research, upscaling and manufacturing Nine start-ups currently operate under the BIOPRO Umbrella. They are commercialising novel technologies for the bioprocessing industry. The technologies range from optic scanning of cell morphology to visualisation platform for
- [ENVIGO 3rd Biologics Symposium - Preclinical | Copenhagen](http://danskbiotek.dk/events/envigo-3rd-biologics-symposium-preclinical-copenhagen/) - ENVIGO is proud to announce the next event in its series of free scientific symposia in Scandinavia! This event is focused on the preclinical aspects of developing biologics and is being kindly hosted by Lundbeck in Valby. A panel of industry experts will cover a wide range of topics related to preclinical aspects of biologics
- [Lunch n' learn session on Drug-drug interaction (DDI) with ENVIGO](http://danskbiotek.dk/events/lunch-n-learn-session-on-drug-drug-interaction-ddi-with-envigo/) - DDI - Assessment of Drug-Drug Interaction potential The issue of DDI guidance(s) by worldwide Regulatory authorities (FDA/EMA/PMDA) during 2012/13 and more recently late 2017 by the FDA now form a solid framework for the assessment of small molecule drug-drug interactions (DDI), an increasingly important area of drug development. This presentation will review the various aspects
- [Nordic Life Science Days 2019 - 10% discount for DANISH BIO – DANSK BIOTEK members](http://danskbiotek.dk/events/nordic-life-science-days-2019-10-discount-for-dansk-biotek-members/) - A welcome space for business and people Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. Most attendees express their delight
- [Biotech Investors Day](http://danskbiotek.dk/events/biotech-investors-day/) - Biotech Investors Day - 8. April 2019 One day prior to the biggest national biotech event, the German Biotech Days in Würzburg, BIO DEUTSCHLAND will host the first Investors Day in Germany with a focus on biotech. The event aims to bring biotech executives together with investors from varying backgrounds, from VC to business angels.
- [Focus on: Cancer Collaboration](http://danskbiotek.dk/events/focus-on-cancer-collaboration-2/) - For the sixth year in a row you are invited to interact around research and innovation in the oncology area. How can new ideas be created by working cross borders? How can industry, academia and healthcare sector work together? Key note speaker of the 2019 meeting: Professor Joseph P. Schlessinger, Yale University, New Haven, Connecticut
- [Advanced Course - Trends in Enzymology & Biocatalysis](http://danskbiotek.dk/events/advanced-course-trends-in-enzymology-biocatalysis/) - The Advanced Course entitled Trends in Enzymology and Biocatalysis (Rome, 27-31 May 2019, https://teb2019.azuleon.org/ ) is now accepting applications from prospective participants. As detailed in the enclosed document and in the website, this course, which is being organized by Daniela De Biase (Rome) and Michael McLeish (Indianapolis), provides an opportunity for graduate students, post-docs and
- [Attend Swiss Biotech Day with 20 % MVA-member discount](http://danskbiotek.dk/events/attend-swiss-biotech-day-with-20-mva-member-discount/) - Attend Swiss Biotech Day with 20 % MVA-member discount - The place to be for entrepreneurs, investors, researchers, analysts, political decision-makers and industry stakeholders from across Europe The Swiss Biotech Day has become the must-attend annual get-together of the Swiss bio­pharmaceutical industry. It is the place to be for entrepreneurs, investors, researchers, analysts, political decision-makers
- [Meet British and European investors at the Anglo-Nordic Life Science Conference 2019 and register with your 20 % MVA discount](http://danskbiotek.dk/events/meet-british-and-european-investors-at-the-anglo-nordic-life-science-conference-2019-and-register-with-your-20-mva-discount/) - ANGLO-NORDIC LIFE SCIENCE CONFERENCE 2019 Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this 1-day London conference
- [7th MVA Oncology Network meeting](http://danskbiotek.dk/events/7th-mva-oncology-network-meeting/) - Welcome to MVA Oncology Network and our 7th meeting – Oncology Animal Models Oncology is one of the leading areas of research into new therapeutics. Due to the challenges inherent in researching and developing anticancer therapeutics, predictive and robust preclinical models and approaches are critical. Medicon Valley Alliance, together with one of our members –
- [Welcome to Medicon Valley Alliance Microbiome Network and our 3rd meeting!](http://danskbiotek.dk/events/welcome-to-medicon-valley-alliance-microbiome-network-and-our-3rd-meeting/) - Searching for Academic-Industrial collaborations: Microbiome workshop event Our ambition with the MVA Microbiome Network is to increase opportunities for microbiome researchers from industry and academia to meet and collaborate. In line with this network objective, Medicon Valley Alliance, together with one of our members – The Department of Food technology at LTH, Lund University –
- [Members' Meeting: State of the Union - Late Stage Financing – Crossover & IPOs](http://danskbiotek.dk/events/https-danskbiotek-dk-events-state-of-the-union-late-stage-financing-crossover-ipos/)
- [Boost Seminar - From Discovery to Clinic: Creating a Comprehensive and Efficient Development Operation](http://danskbiotek.dk/events/invitation-from-discovery-to-clinic-creating-a-comprehensive-and-efficient-development-operation/) - The pharmaceutical industry continues to experience decreasing productivity and high levels of attrition. Inflation of molecule physicochemical properties and complexities in clinical trial protocols stand among the main reasons for these trends. The most successful companies can leverage different expertise, manage risks, and follow logical sequences of operations in an integrated manner. This event will
- [2019 International Conference on Biotechnology and Bioengineering (9th ICBB)](http://danskbiotek.dk/events/2019-international-conference-on-biotechnology-and-bioengineering-9th-icbb/) - The 2019 International Conference on Biotechnology and Bioengineering (9th ICBB) will be held in Poznan, Poland during September 25-28, 2019. For more information please visit https://www.icbb.ibch.poznan.pl/ ICBB2019 is co-organized by Asia-Pacific Association of Science, Engineering and Technology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, and Chinese Journal of Biologicals , in collaboration with multiple academic affiliations.
- [Workshop for Life Science Business Executives 'The Term Sheet'](http://danskbiotek.dk/events/workshop-for-life-science-business-executives/) - Full day workshop for business developers and licensing professionals in life science. This interactive workshop course will focus on term sheets for transactions closed between universities and spin-outs/pharma/life science companies. The content of a term sheet will be addressed from the perspective of all parties – inventors, university, company(ies), and investors. COURSE CONTENT The term
- [DKBIO2019 meeting in NYC - Danish Science & the City](http://danskbiotek.dk/events/dkbio2019-meeting-in-nyc-danish-science-the-city/) - Join DKBIO in New York City and dive into "Functionalizing Data for Health" moderated by Wired Magazine, hear from "Our Patient Collaborators" about clinical trial experiences, learn about your financial "Tools in the Toolbelt" and so much more. Registration starting at 10.000 DKK.
- [BIO-Europe Spring & BIO-Europe 2019](http://danskbiotek.dk/events/bio-europe-spring-bio-europe-2019/) - DANISH BIO – DANSK BIOTEK is again collaborating with BIO-Europe to offer our members a special EUR 300 discount - in addition to the early bird discount - to the largest biotechnology partnering conferences held in Europe: BIO-Europe Spring® 2019 • March 25–27 • Vienna, Austria • www.ebdgroup.com/bes BIO-Europe 2019 • November 11-13 • Hamburg, Germany • www.ebdgroup.com/bioeurope
- [Next Health Cambridge 2019, World Innovation Forum](http://danskbiotek.dk/events/next-health-cambridge-2019-world-innovation-forum/) - Next Health, World Innovation Forum is a new healthcare conference organised in partnership with the Milner Therapeutics Institute at the University of Cambridge. The conference takes place in Cambridge, UK on the 26th - 27th June 2019. It is a new conference which aims to unite the leading stakeholders from across the entire healthcare ecosystem allowing
- [DANISH BIO – DANSK BIOTEK Members' Meeting: Clinical Phase Immuno-Oncology Projects](http://danskbiotek.dk/events/dansk-biotek-members-meeting-clinical-phase-immuno-oncology-projectson-early-stage-valuation-narratives-and-numbers/) - Clinical Phase Immuno-Oncology Projects How far are current development projects and what is the expected road to market? Host of the day is Y-mAbs.
- [Early stage value creation - Panel discussion](http://danskbiotek.dk/events/early-stage-value-creation-panel-discussion/) - DANISH BIO – DANSK BIOTEK recently held a very interesting and relevant Biotek Salon #17: Workshop on Early Stage Valuation: Narratives and Numbers. This was hosted by Farmantra and attendance to the event was very high. As a follow up, this Barcelona panel discussion hosted by Farmantra might be a good opportunity for companies intending
- [MVA R&D network meeting](http://danskbiotek.dk/events/mva-rd-network-meeting/) - Welcome to Medicon Valley Alliance R&D Network and our 2nd meeting! Enhancing collaboration – how to ensure the latest research is implemented in the health care sector faster How can we promote collaboration between preclinical and clinical researchers to make sure that excellent research goes the whole way and turns into successful innovations for the benefit of patients and
- [Commercialization of technology and IP](http://danskbiotek.dk/events/commercialization-of-technology-and-ip/) - Welcome to MVA’s Good Morning Meeting on commercialization of technology and IP with Plougmann Vingtoft The IP and commercialization experts from Plougmann Vingtoft, Katja Sørensen and Jon Wulff Petersen will walk you through aspects of: the importance of aligning technology development, IP development and business development how IP developed outside your core business may be of
- [BIO-Europe - Join an exclusive side event on Neuroscience](http://danskbiotek.dk/events/bio-europe-join-an-exclusive-side-event-on-neuroscience/) - Grasp the opportunity to get unique insights and discuss exciting innovations in the field of Neuroscience with the international and regional biotech and pharma industry as well as preclinical and clinical researchers. Selected regional academic and industrial organizations are given the opportunity to pitch their projects/products/business concept. In addition, we have plenty of networking time
- [Serialisation seminar – how to implement serialisation solutions in the production line](http://danskbiotek.dk/events/serialisation-seminar-how-to-implement-serialisation-solutions-in-the-production-line/) - Mandatory serialisation is here! Are you in the early or late process of integrating solutions to meet the EU directive 2011/62/EU? Join our seminar and get valuable tips and tricks on how to implement serialisation solutions successfully. The seminar provides you with a unique opportunity to get key tips and insights about the topic of
- [BIO-Europe side event – MVA Microbiome network meeting](http://danskbiotek.dk/events/bio-europe-side-event-mva-microbiome-network-meeting/) - Welcome to BIO-Europe side event – Microbiome – in collaboration with Medicon Valley Alliance Microbiome Network BIO-Europe is coming to Copenhagen 5th – 7th of November this year. This is a unique opportunity to showcase regional life science strongholds and reach out to the many international guests before they travel back. In order to seize this
- [Understanding Biocompatibility of Medical Devices](http://danskbiotek.dk/events/9076/) - Understanding Biocompatibility of Medical Devices – biological evaluation and biocompatibility testing according to ISO 10993 Medical device manufacturers must conduct biological safety (biocompatibility) evaluations for their medical devices to meet regulatory obligations and receive approval to market medical devices. The complexity of this process is increasing due to new regulatory requirements. Do you have an updated strategy for the
- [NDA HTA SEMINAR – THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE](http://danskbiotek.dk/events/nda-hta-seminar-the-future-of-health-technology-assessment-in-europe/) - On the 24th October NDA Group invites you and your colleagues in the market access department/HEOR to a complimentary seminar on the future of HTA. The market access environment is getting increasingly challenging. The ability to develop plans and strategies for access, for today as well as tomorrow, is critical to bring new medicines to
- [Biotek Salon #17: Workshop on Early Stage Valuation: Narratives and Numbers](http://danskbiotek.dk/events/biotek-salon-17/) - Most of the time, valuation is considered a numbers' game or building complex models. Does creating complex models lead to a good valuation? In this workshop, we will explore how a good early stage valuation is actually a mix of building right narratives backed by numbers. We will also bust a few myths such as
- [MVA Oncology Network meeting – an investor pitch evening](http://danskbiotek.dk/events/mva-oncology-network-meeting-an-investor-pitch-evening/) - Welcome to MVA Oncology Network and MVA's 6th oncology meeting – an investor pitch evening! Medicon Valley Alliance Oncology Network set up by prof. and entrepreneur Nils Brünner (University of Copenhagen) and prof. and entrepreneur Carl Borrebaeck, (Lund University) has now been up and running for two years. To celebrate these succesful years, Medicon Valley
- [Early Development Workshop](http://danskbiotek.dk/events/early-development-workshop/) - Efficient early clinical drug development Innovative and adaptive approaches built out from mechanism-of-action Meet the experts: Ewoud-Jan van Hoogdalem, PRA Health Sciences; Mads Almose Røpke, Leo Pharma; Martin Bonde, Vaccibody; Iftekhar Khan, MHRA; Suzanne Pihl, Ascendis; Nils Piwon, and Jo Hulbert, PRA Health Sciences as we share perspectives in deciding the best early clinical development
- [INVITATION TO BIOJAPAN 2018](http://danskbiotek.dk/events/invitation-to-biojapan-2018/) - WITH SCANDINAVIAN PAVILION: A SWEDEN-DENMARK JOINT EXHIBITION BOOTH BIOJAPAN 2018 DELEGATION ANNOUNCEMENT The Trade Council in the Royal Danish Embassy in Tokyo together with Copenhagen Capacity is delighted to invite DANISH BIO – DANSK BIOTEK's members to join its Scandinavian Life Science delegation to BioJapan 2018 organized in close collaboration with its Swedish partners Business Sweden, Business
- [Pharmaceutical raw materials regulation - latest updates](http://danskbiotek.dk/events/pharmaceutical-raw-materials-regulation-latest-updates/) - Regulations relative to pharmaceutical raw materials are ever evolving. Meet with industry leaders to better understand these regulations and share experiences on their implementation.
- [Academic Drug Discovery - how to secure that preclinical findings reach the patients](http://danskbiotek.dk/events/academic-drug-discovery/) - University of Copenhagen, Lund University, and Medicon Valley Alliance invite you to Academic Drug Discovery – how to secure preclinical findings reach the patients: The Medicon Valley universities have many research activities within early drug discovery and they offer a wide range of know-how and research within new therapeutic goals and new and innovative methods to develop drugs.
- [NOME Annual Meeting & Start-up Competition](http://danskbiotek.dk/events/nome-annual-meeting-start-up-competition/) - Join the Annual Meeting at the Maersk Tower in Copenhagen to celebrate the Nordic life science ecosystem. Network with leaders of the life science industry in the Nordic countries, including the NOME mentors, meet the NOME partners and catch up with old and new colleagues. The afternoon will bring the opportunity to network with key
- [DANISH BIO – DANSK BIOTEK på folkemødet](http://danskbiotek.dk/events/dansk-biotek-pa-folkemodet/) - Kære medlemmer, Folkemødet i Allinge begynder næste uge, og DANISH BIO – DANSK BIOTEK er medarrangører på arrangementet "På talentjagt i life science", der afholdes med Dansk Erhverv, Lif, Medicondustrien og Dialab. Arrangørerne stiller spørgsmålet: Hvordan sikrer vi, at flere unge tør springe ud som iværksættere i life science-branchen? Og hvad skal der til for,
- [Nordic Private Equity Summit 2018](http://danskbiotek.dk/events/nordic-private-equity-summit-2018/) - Den 21. juni 2017 løber Nordic Private Equity Summit (NPES) af stablen – NPES er Nordens største kapitalfondskonference og tiltrækker årligt ca. 300 deltagere. DANISH BIO – DANSK BIOTEK har indgået en aftale med DVCA, der arrangerer konferencen, om at du kan komme med til samme pris som DVCAs medlemmer. Årets tema er digitalisering og digital virksomhedstransformation.
- [BIO-Europe® 2018 - Additional Discount !](http://danskbiotek.dk/events/bio-europe-2018/) - Initiate new partnerships through life science partnering The 24th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an
- [Medicon Valley Medtech Network meeting](http://danskbiotek.dk/events/medicon-valley-medtech-network-meeting-2/) - Required steps to get your medical device on the market Over the coming years new medtech regulations – Medical Device Regulations (MDR 2017/745) and in-vitro Diagnostic Regulations (IVDR 2017/746) – come into effect and everyone that wish to have a medical device or an in-vitro diagnostic device on the market needs to relate to these
- [MVA Annual Meeting 2018](http://danskbiotek.dk/events/mva-annual-meeting-2018/) - For the last 20 years, life science in Medicon Valley has been the most innovative, fastest growing and most job creating sector in the Greater Copenhagen region and we have been growing together! To sustain and develop the region’s momentum, we need to effectively remove barriers to the scale-up of our innovative life science companies,
- [Medicon Valley Alliance Summer Reception 2018](http://danskbiotek.dk/events/medicon-valley-alliance-summer-reception-2018/) - Meet with your network before the summer and celebrate the accreditation of Malmö university as a full research university! MVA hopes to see existing and future MVA members, DANISH BIO – DANSK BIOTEK members, decision makers and everybody else with an interest in the future of Medicon Valley at the MVA Summer Reception. This year
- [Biotek Salon#16: Immunogenicity Testing in a Regulated Environment](http://danskbiotek.dk/events/biotek-salon16-immunogenicity-testing-in-a-regulated-environment/)
- [Invitation to Life Sciences Baltics Forum 2018](http://danskbiotek.dk/events/invitation-life-sciences-baltics-forum-2018/) - Life Sciences Baltics is one of the largest international life sciences event in the Nordic region and the only one in the Baltic State for the world-class experts in biotechnology, pharmaceutical and medical devices. The 4th Life Sciences Baltics Forum is being organized under the patronage of the President of the Republic of Lithuania H.E.
- [Biotek Salon#15: Rare Disease Workshop](http://danskbiotek.dk/events/biotek-salon15-rare-disease-workshop/) - DANISH BIO – DANSK BIOTEK & Syneos Health invite you to a Rare Disease Workshop See the full program here
- [Biotek Salon#14: Moving to the Next Generation of Clinical Development](http://danskbiotek.dk/events/biotek-salon14-moving-to-the-next-generation-of-clinical-development/) - DANISH BIO – DANSK BIOTEK invites you to a meeting with IQVIA (formerly QuintilesIMS) to learn more about what is called the next generation of clinical development. Join this workshop to learn more about this highly innovative clinical trial planning and execution approach. A few recent case studies will be used to introduce novel data-driven
- [Pitch your company to British and European investors - attend The Anglo-Nordic Life Science Conference with a 20% discount](http://danskbiotek.dk/events/the-anglonordic-life-science-conference/) - Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this 1-day London conference provides exceptional value. Discount: Members
- [Generalforsamling i DANISH BIO – DANSK BIOTEK den 9. maj 2018](http://danskbiotek.dk/events/generalforsamling-i-dansk-biotek-den-9-maj-2018/) - Den 9. maj 2018 kl. 13.30 hos NOVO, Tuborg Havnevej 19, 2900 Hellerup Dagsorden c.f. vedtægterne: a. Valg af dirigent b. Formandens beretning c. Godkendelse af regnskab for 2017 d. Fastsættelse af kontingent for 2018. Bestyrelsen indstiller, at kontingentet er uændret 4.000 kr. for virksomheder med mindre end 10 ansatte, 10.000 kr. for virksomheder med
- [DANISH BIO – DANSK BIOTEK Annual Member Meeting 9 May 2018](http://danskbiotek.dk/events/dansk-biotek-annuel-meeting-9-may-2018/)
- [2nd Biologics Symposium - Preclinical](http://danskbiotek.dk/events/2nd-biologics-symposium-preclinical/) - ENVIGO is proud to announce the next event in a series of free scientific symposia in Scandinavia! This event is focussed on the preclinical aspects of biologics and is being kindly hosted by Lundbeck in Valby. A panel of industry experts will cover a wide range of topics related to preclinical aspects of biologics such
- [Swiss Biotech Day 2018 – 20% MVA & DANISH BIO – DANSK BIOTEK Discount](http://danskbiotek.dk/events/swiss-biotech-day-2018-20-mvadansk-biotek-discount/) - The Swiss Biotech Day in Basel has long become the standard annual get-together for the Swiss biopharmaceutical industry. There are only a few spaces in the world where so many life sciences jobs are concentrated in one place with the density seen in Basel. From world-leading research groups, biotech entrepreneurs, start-ups and patent specialists –
- [Biotek Salon#13: Japan as a target market – to do or not to do?](http://danskbiotek.dk/events/biotek-salon13-japan-as-a-target-market-to-do-or-not-to-do/) - Masami Tamura (President & CEO, CoreMed) and Ann Christine Korsgaard (Regulatory Affairs Executive & Mg. Director, Biotrack) on the Japanese environment for small pharmaceutical/biotech companies – foreign and domestic. The world is getting smaller and Japan is getting closer. Join an opportunity to open your mind towards Japan and get some tips and tricks for
- [Human Biotech & Animal Health Business Partnering Summit - member discount!](http://danskbiotek.dk/events/human-biotech-animal-health-business-partnering-summit/) - This conference brings together C-Level members of the human biotech industry with Directors of External Innovation from leading animal health pharmaceutical companies and is the 2nd conference of its type. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation
- [Nordic Life Science Days 2018 - 10% discount for DANISH BIO – DANSK BIOTEK members](http://danskbiotek.dk/events/nordic-life-science-days-2018-10-discount-for-dansk-biotek-members/) - A welcome space for business and people Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. NLSDays is a space for meaningful
- [Biomarker AGORA 2018](http://danskbiotek.dk/events/biomarker-agora-2018/) - Exhibition booths are free of charge, but registration is mandatory - selection of exhibitions will occur on ongoing basis Keep an eye at bioagora.dk for updates.
- [Biotek Salon#12: New EU General Data Protection Regulation (GDPR) - What does it mean for biotech?](http://danskbiotek.dk/events/biotek-salon-12-new-eu-general-data-protection-regulation-gdpr-what-does-it-mean-for-biotech/) - The new EU General Data Protection Regulation will take direct effect in all Member States from 25 May 2018. The purpose of the GDPR is to harmonize personal data protection rules across the EU as well as strengthening the right of individuals. Many biotech companies are processing special categories of personal data (sensitive data) on
- [Biotek Salon#1: COMBINATION TRIALS IN ONCOLOGY](http://danskbiotek.dk/events/combination-trials-in-oncology/) - Combination Trials in Oncology: Do’s and Don’ts in Oncology Combination Trials How to best ENSURE SUCCESS How TO make a difference
- [HØRING: På vej mod en vækstplan for life science](http://danskbiotek.dk/events/horing-pa-vej-mod-en-vaekstplan-for-life-science/) - ”På vej mod en vækstplan for life science”. Under denne overskrift inviterer Lægemiddelindustriforeningen, Medicoindustrien, DANISH BIO – DANSK BIOTEK, Pharmadanmark, Dansk Erhverv og Dansk Industri til life science høring i Børssalen, Slotsholmsgade 1 i København den 3. april kl. 9.00-12.00.
- [Good Morning Meetings: Introduction to Health Hotspot Helsinki and upgraded Life Festival](http://danskbiotek.dk/events/good-morning-meetings-introduction-to-health-hotspot-helsinki-and-upgraded-life-festival/) - O/B/O Medicon Valley Alliance: Join us at the upcoming Good Morning Meeting and learn about Health Capital Helsinki and its collaboration possibilities. Health Capital Helsinki is also looking for new partners. In the event you will hear about the biggest health startup and innovations event in the Nordics, Upgraded Life Festival which will be held 25-26
- [Good Morning Meetings: Home Healthcare- The Future of Clinical Trials](http://danskbiotek.dk/events/good-morning-meetings-home-healthcare-the-future-of-clinical-trials/) - O/B/O Medicon Valley Alliance: For most Sponsors & Physicians running clinical trials, patient recruitment and retention is a major challenge; in order to participate, patients must often be willing to travel long distances at inconvenient times to undergo treatment and vital procedures, a situation that is certain to lead to headaches and frustration all round.
- [How can your R&D benefit from ESS?](http://danskbiotek.dk/events/how-can-your-rd-benefit-from-ess/) - In our region there is a construction going on for the world’s most powerful pulsed neutron source. It is currently being build in Lund, Sweden. The European Spallation Source (ESS) is a multi-disciplinary research facility enabling new opportunities for researchersacross the spectrum of scientific discovery, including life sciences, energy, environmental technology, cultural heritage and fundamental physics.
- [7th Annual Biologics Symposium](http://danskbiotek.dk/events/7th-annual-biologics-symposium/) - Join us for two days of presentations discussing the latest advances in the biologics field Our agenda has been designed to encourage thought-provoking and insightful debate from the industry’s leading experts. Our 2017 series also benefits from an EU Continuing Professional Development (CPD) accredited agenda. Attend ABS 2017 and take a proactive approach to enhancing
- [Can Medicine be printed?](http://danskbiotek.dk/events/can-medicine-be-printed/) - Danish Pharmaceutical Society- The Biopharmaceutical Section invites to the event: Can medicine be printed? February 7th 2017, 14:00-17:15, Auditorium 4 It will soon be possible to apply 3D-printing of medicine. Consider what it would be like to be able to print drugs at the point of need and to utilize software apps for drug formulation
- [Precision Medicine- 2017 Kickoff by REBBLS](http://danskbiotek.dk/events/precision-medicine-2017-kickoff-by-rebbls/) - This year's kickoff will focus on the future of Precision Medicine with a keynote speaker Thomas Wilkens. Precision medicine is a medical model that uses better diagnostics, tailored gene therapies (Combigene, Roche) and other customizable healthcare practices. This model holds potential to improve the old broken R&D paradigm to make the next medicines safer, more effective and
- [Nordic Life Science Days 2017](http://danskbiotek.dk/events/nordic-life-science-days-2017/) - A welcome space for business and people! Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. DANISH BIO – DANSK BIOTEK
- [DKBIO'17 Danish Science & The City: New York City](http://danskbiotek.dk/events/dkbio17-danish-science-the-city-new-york-city/) - -Special track on entrepreneurial drive in medicine sponsored by NOVO SEEDS -Planning your financing strategy Start-Up through Public -Deep drive into how the Trump Administration might affect industry regulations and hear about pricing direct from payers -Get the inside scoop from top Pharma BD executives in what they are looking for -Private 1x1 meetings with
- [Seminar: Other test event](http://danskbiotek.dk/events/seminar-other-test-event/) - In the pharmaceutical industry there is no guidance which states that you must use data-driven analytics, yet this is the only effective way to meet the requirements imposed by regulatory agencies. Andrew Lawton, CEO of Risk Based Approach Ltd, will examine and interpret forthcoming regulations and guidance changes and the use of big data and
- [JMP for Space Help, Copenhagen at Medicon Valley Alliance](http://danskbiotek.dk/events/jmp-for-space-help-copenhagen-at-medicon-valley-alliance/) - In the pharmaceutical industry there is no guidance which states that you must use data-driven analytics, yet this is the only effective way to meet the requirements imposed by regulatory agencies. Andrew Lawton, CEO of Risk Based Approach Ltd, will examine and interpret forthcoming regulations and guidance changes and the use of big data and
- [DANISH BIO – DANSK BIOTEK ANNUAL MEETING, 4th May 2017](http://danskbiotek.dk/events/dansk-biotek-annual-meeting/) - DANISH BIO – DANSK BIOTEK Annual Meeting 4th May 2017 Host of the day is Novo Nordisk Novo Allé, 2880 Bagsværd Programme: 14.30 Registration and networking 15:00 Welcome Martin Bonde, Chairman DANISH BIO – DANSK BIOTEK 15.10 ”Progress of the Vækstteam Project” Brian Mikkelsen – Ministry of Economic and Business Affairs 15.30 “Novo Nordisk towards
- [Nordic Precision Medicine Forum 2017](http://danskbiotek.dk/events/nordic-precision-medicine-forum-2017/) - Nordic Precision Medicine Forum will bring together those at the very forefront of precision medicine from biologists, physicians and technology developers to data scientists, patient groups, governments and more. The forum will cover a whole plethora of topics uncovering what the most pressing issues are. Hear Government talk about their vision for healthcare in the
- [BIO-EUROPE SPRING 2017: 11th International Partnering Conference](http://danskbiotek.dk/events/bio-europe-spring-2017-11th-international-partnering-conference/) - The eleventh annual BIO-Europe Spring® conference is the premier springtime partnering conference for the biotechnology industry. For its 2017 edition, BIO-Europe Spring comes to Barcelona, Spain on March 20–22, 2017. The conference annually attracts the international “who’s who” from biotech, pharma and finance for three days of high caliber networking. BIO-Europe Spring’s world-class workshops, panels
- [Seminar in Copenhagen at Medicon Valley Alliance](http://danskbiotek.dk/events/seminare-in-copenhagen-at-medicon-valley-alliance/) - In the pharmaceutical industry there is no guidance which states that you must use data-driven analytics, yet this is the only effective way to meet the requirements imposed by regulatory agencies. Andrew Lawton, CEO of Risk Based Approach Ltd, will examine and interpret forthcoming regulations and guidance changes and the use of big data and
- [STATE of the UNION, 9th February 2017](http://danskbiotek.dk/events/state-of-the-union/) - participation list Members’ Meeting 2017: State of the Union 9th February 2017 Host of the day is Danske Bank Kuppelsalen, Laksegade 8 1063 Copenhagen Programme: 14.30 Registration and networking 15:00 Welcome Martin Bonde, Chairman DANISH BIO – DANSK BIOTEK 15.10 “Big Picture” Søren Møller-Rasmussen – Managing Director, Goldman Sachs. 15.45 ”Market for small and
- [SUMONDO: workshop 25th April at COBIS](http://danskbiotek.dk/events/sumondo-workshop-25th-april-at-cobis/) - On behalf of Sumondo’s CEO Mr. Vishal Sisodia, we invite you for the workshop on April, the 25th at 13:00 in COBIS. About the company: Sumondo, is a healthcare company, that provides a medically approved app, which helps people around the world to monitor and relieve their day-to-day stress. If you want to know more about
- [Medicon Valley Alliance Microbiome Summit 2017](http://danskbiotek.dk/events/medicon-valley-alliance-autumn-events/) - Medicon Valley Alliance is inviting DANISH BIO – DANSK BIOTEK's members to attend the Microbiome Summit 2017: MEDICON VALLEY ALLIANCE MICROBIOME SUMMIT 2017 The emerging field of microbiome research is a potential future stronghold of Medicon Valley and national and regional research activities are already blooming in the region. It is the explicit ambition of Medicon Valley
- [DANISH BIO – DANSK BIOTEK members’ meeting: New Therapeutic Modalities](http://danskbiotek.dk/events/dansk-biotek-members-meeting-new-therapeutic-modalities/) - Gorrissen Federspiel and DANISH BIO – DANSK BIOTEK will be serving snacks and refreshments
- [Børsen M&A-konference 2017 - rabat for DANISH BIO – DANSK BIOTEK medlemmer](http://danskbiotek.dk/events/borsen-ma-konference-2017-rabat-for-dansk-biotek-medlemmer/) - Børsen afholder den 28. september M&A-konference, hvor der med baggrund i cases diskuteres nye vilkår og muligheder på M&A-markedet og udfordringer i at gennemføre succesfulde virksomhedshandler. Konferencen byder på gode råd til at overkomme kulturforskelle, løse praktiske problemer og skabe synergier ved M&A´s og belyser mulighederne på et glohedt M&A-marked. Der vil desuden være rig lejlighed til at netværke.
- [Life Sciences Seminar at Gorrissen Federspiel](http://danskbiotek.dk/events/life-sciences-seminar-at-gorrissen-federspiel/) - Back Bay Life Science Advisors and Gorrissen Federspiel jointly invites to a seminar for the Nordic biotech community. Participating in the seminar will give you an opportunity to discuss: Ideas and insights into successful cross-border M&A Ingredients for increasing sustainability of the Nordic ecosystem Best practices for growing and sustaining thriving biotechs in the Nordic
- [SCIENCE & INDUSTRY: Boosting COOPERATION by improving COMMUNICATION](http://danskbiotek.dk/events/science-industry-boosting-cooperation-by-improving-communication/) - Innovation Forum, BioNet and REBBLS are proud to invite you to a free seminar at Copenhagen University, 5 October 2017, 17:00 at the Lundbeck Auditorium, Ole Maaløes Vej 5, København N. Two tribes: academia & industry. One common goal: to bring benefit to society. How do we create a common language and develop a joint
- [Meet researchers from BIO-UCPH](http://danskbiotek.dk/events/meet-researchers-from-bio-ucph/) - Meet Denmark’s leading bioscience researchers at BIO-UCPH Experience what the biosciences research environment at the Department of Biology has to offer Get input for your R&D-demanding projects and explore collaborative opportunities Program highlights 2018 Innovation Fund Denmark information by vice president Tore Duvold Research frontiers & technology pitches Partnering sessions & knowledge input Collaboration opportunities
- [International Conference on Perspectives in Precision Medicine](http://danskbiotek.dk/events/•international-conference-on-perspectives-in-precision-medicine/) - BioPeople invites members of DANISH BIO – DANSK BIOTEK to the International Conference on Perspectives in Precision Medicine 28 Februar 2018 - 1 March 2018, Maersk Tower, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. The conference especially targets SMEs, researchers and anyone else who are looking into new insight and knowledge on
- [DANISH BIO – DANSK BIOTEK members' meeting: State of the Union](http://danskbiotek.dk/events/dansk-biotek-members-meeting-state-of-the-union/)
- [Real world integrated pathways for the US Medtech market](http://danskbiotek.dk/events/real-world-integrated-pathways-for-the-us-medtech-market/) - Are you an SME or medtech startup developing a new medical device or optimizing an existing technology? Have you developed and integrated a US strategy inclusive of regulatory, clinical research and reimbursement? Are you are faced with challenges harmonizing strategies for both the European and US markets? Perhaps you need the right tools and specific
- [Listing on Nasdaq First North](http://danskbiotek.dk/events/listing-on-nasdaq-first-north/) - In the past several years the market for smaller listings in Denmark has been stagnant, but this changed in 2017 where, among others, BDO advised Conferize on its listing on Nasdaq First North by which Conferize raised new capital of DKK 28 million. BDO and Poul Schmith invite you to an event regarding listing on
- [BIO-EUROPE SPRING 2018: 12th International Partnering Conference](http://danskbiotek.dk/events/bio-europe-spring-2017-12th-international-partnering-conference/) - The twelfth annual BIO-Europe Spring® conference is the premier springtime partnering conference for the biotechnology industry. For its 2018 edition, BIO-Europe Spring comes to Amsterdam, The Netherlands on March 12–14, 2018. The conference annually attracts the international “who’s who” from biotech, pharma and finance for three days of high caliber networking. BIO-Europe Spring’s world-class workshops,
- [Medicon Valley Alliance Microbiome Network Meeting](http://danskbiotek.dk/events/medicon-valley-alliance-microbiome-network-meeting/) - Join Medicon Valley Alliance Microbiome Network and 1st meeting! The growing interest in microbiome science identified at the Medicon Valley Alliance Microbiome Summit 2017, convinced MVA that microbiome research will be a science of the future Medicon Valley region. As a result, MVA, together with the Technical University of Denmark, Lund University and Novo Nordisk,
- [Medicon Valley Medtech Network Meeting](http://danskbiotek.dk/events/medicon-valley-medtech-network-meeting/) - Join Medicon Valley Medtech Network and their next meeting! The road to success is becoming longer, costlier and more complex as commercial and regulatory requirements increase. What does it take to be successful in the Medtech industry? If you are looking for a clear, straightforward, cost-efficient and structured process, this event offers an overview of a
- [What’s next in digital customer engagement?](http://danskbiotek.dk/events/whats-next-in-digital-customer-engagement/) - Medicon Valley Alliance invites you to a 'Good Morning Meeting' in Copenhagen. An opportunity to get inspired and learn how new digital advancements such as virtual engagement technologies can enable you to meet new customer demands. Experience what other companies within and beyond pharma are doing right now to provide a more holistic customer experience. Key
- [Publicly Listing a Life Sciences Company in Copenhagen, New York and Stockholm](http://danskbiotek.dk/events/publicly-listing-a-life-sciences-company-in-copenhagen-new-york-and-stockholm/) - ...and how best to partner and collaborate with Big Pharma to get there How to navigate the listing process The past few years have witnessed a growing number of Nordic life sciences companies tap the capital markets of Copenhagen, New York and Stockholm. The paradigm for how Nordic life sciences companies have traditionally achieved financial
- [IP strategy – why do I need it?](http://danskbiotek.dk/events/test/) - Good Morning Meeting... Join MVA when HØIBERG Patent Attorneys, Pernille Winding Gojkovic and Jens Viktor Nørgaard, elaborate on why you need a patent strategy that is aligned with your business plan. They will encourage you to get value for money and maximize your ROI
- [New update in Drug Formulation & Bioavailability](http://danskbiotek.dk/events/new-update-in-drug-formulation-bioavailability/) - MORE NEW MEDICINES! Formulation and bioavailability are critical steps in the development process of new effective drugs. One reason for failure in clinical trials might be explained by poor formulation and bioavailability properties of the drug. Meet R&D people, the pharma industry, increase your awareness and gain more knowledge about these topics at this meeting
- [MVA Oncology Network Meeting](http://danskbiotek.dk/events/mva-oncology-network-meeting/) - Biomarkers – opportunities and challenges in oncology drug development Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. What does it take to get a biomarker from discovery to translation to commercialization? Are we making the most out of the biomarker expertise we have in the Medicon Valley
- [Focus on: Cancer Collaboration](http://danskbiotek.dk/events/focus-on-cancer-collaboration/) - For the fifth year in a row MVA invites DANISH BIO – DANSK BIOTEK's members to interact around research and innovation in the oncology area. How can new ideas be created by working cross borders? How can industry, academia and the healthcare sector work together? MVA is continuing last year’s successful speed-networking and dialogue forums in
- [LSX Nordic Congress - more effective investment, business planning and partnering in life science](http://danskbiotek.dk/events/lsx-nordic-congress-more-effective-investment-business-planning-and-partnering-in-life-science/) - The LSX Nordic Congress is a high-calibre, senior executive conference and partnering event providing the education, strategies, solutions, and contacts that life science companies need to enable more effective investment, business planning and partnering within their businesses. The Nordic region has long produced world-leading science and innovation and Nasdaq Nordic is one of the leading
- [DANISH BIO – DANSK BIOTEK members' meeting: Nonalcoholic Steatohepatitis (NASH) - the new black!](http://danskbiotek.dk/events/dansk-biotek-members-meeting-nash-the-new-black/) - Gubra and DANISH BIO – DANSK BIOTEK will be serving snacks and refreshments
- [MVA Boost Seminar – Navigating the Shifting Currents of U.S. Biotech and Pharmaceutical Patent Law](http://danskbiotek.dk/events/mva-boost-seminar-navigating-the-shifting-currents-of-u-s-biotech-and-pharmaceutical-patent-law/) - Hosted by Medicon Valley Alliance, law firm King & Spalding will elaborate on the development and implementation of patent strategies at a time where United States patent law is in flux. They will focus on their impact on creating effective patent portfolios, conducting due diligence or participating in IP transactions, and participating in interparty disputes.
- [MVA Oncology Network – a pitch evening with Alligator Bioscience!](http://danskbiotek.dk/events/mva-oncology-network-a-pitch-evening-with-alligator-bioscience/) - Medicon Valley Alliance Oncology Network set up by prof. and entrepreneur Nils Brünner (University of Copenhagen) and prof. and entrepreneur Carl Borrebaeck, (Lund University) has now been up and running for one year. To celebrate this first succesful year, Medicon Valley Alliance, together with one of its members – Alligator Bioscience, are happy to invite you to the
- [Innovation Forum Annual Leaders Conference](http://danskbiotek.dk/events/innovation-forum-annual-leaders-conference/) - Supporting early stage ventures and industry-academia collaborations in the healthcare space the Innovation Forum – Leaders Conference is centered on innovation in deep science industries, with a particular focus on pharmaceutical, biotechnology and healthcare sectors. The event is a C-level conference gathering top leaders from industry, academia and government and mixing them with early stage ventures investors
- [Join the Medicon Valley Alliance Annual Meeting 2017](http://danskbiotek.dk/events/join-the-medicon-valley-alliance-annual-meeting-2017/) - Members of DANISH BIO – DANSK BIOTEK are invited to join the Medicon Valley Alliance Annual Meeting: ANNUAL MEETING 2017 – HEALTH, WEALTH AND WORLDCLASS Medicon Valley Alliance’s Annual Meeting 2017 is inspired by the Danish life science growth team´s recommendation published in March, which emphasized better health, more wealth and growth and more world
- [Gymnasielærerprisen 2017 fra DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden](http://danskbiotek.dk/events/gymnasielaererprisen-2017-fra-dansk-biotek-og-novo-nordisk-fonden-2/) - DANISH BIO – DANSK BIOTEK indkalder indstillinger til Novo Nordisk Fondens Gymnasielærerpris 2017. Novo Nordisk Fondens Gymnasielærerpris blev indstiftet i 2014 af DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden. Prisen har til formål at sætte fokus på det høje faglige niveau i den biologiske naturvidenskabelige undervisning og anerkende de gymnasielærere, som yder et
- [Gymnasielærerprisen 2017 fra DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden](http://danskbiotek.dk/events/gymnasielaererprisen-2017-fra-dansk-biotek-og-novo-nordisk-fonden-3/) - Indstillingsskema Novo Nordisk Fondens Gymnasielærerpris 2017 Opslag Novo Nordisk Fondens Gymnasielærerpris 2017 DANISH BIO – DANSK BIOTEK indkalder indstillinger til Novo Nordisk Fondens Gymnasielærerpris 2017. Novo Nordisk Fondens Gymnasielærerpris blev indstiftet i 2014 af DANISH BIO – DANSK BIOTEK og Novo Nordisk Fonden. Prisen har til formål at sætte fokus på det høje faglige niveau
- [DANISH BIO – DANSK BIOTEK members’ meeting](http://danskbiotek.dk/events/dansk-biotek-members-meeting/) - Members’ Meeting 2016 TFS Denmark and DANISH BIO – DANSK BIOTEK serve snacks and refreshments.

## Categories

- [News](http://danskbiotek.dk/news/)

## Members Categories

- [Medical Biotech](http://danskbiotek.dk/member-category/medical-biotech/)
- [Industrial Biotech](http://danskbiotek.dk/member-category/industrial-biotech/)
- [Investors](http://danskbiotek.dk/member-category/investors/)
- [Associated to the biotech industry](http://danskbiotek.dk/member-category/associated-to-the-biotech-industry/)

## Events categories

- [Upcoming Events](http://danskbiotek.dk/event-category/upcoming-events/)
- [Past Events](http://danskbiotek.dk/event-category/past-events/)